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Abstract
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease resulting from deficiency of the enzyme
α-L-iduronidase (IDUA). Accumulation of the IDUA substrates heparan and dermatan sulfate causes
widespread organ pathology. While many of the somatic manifestations of MPS I can be treated with
intravenous enzyme replacement, the devastating CNS sequelae—cognitive impairment, spinal cord
compression, and hydrocephalus—do not respond to treatment. Partial preservation of cognitive function is
possible with early hematopoietic stem cell transplantation, although transplant is associated with substantial
morbidity and mortality. Gene transfer using adeno-associated virus (AAV) vectors offers a potential
alternative approach to deliver the IDUA enzyme to the CNS. Introducing a functional IDUA gene to a subset
of quiescent cells could provide a permanent source of secreted enzyme beyond the blood-brain barrier.
However, preclinical studies evaluating direct injection of AAV vectors into the brain have shown that
transduction is limited to small regions surrounding the injection site, and that injection can be associated
with a localized inflammatory response and immune-mediated killing of transduced cells. In order to
overcome these limitations, we evaluated delivery of an AAV serotype 9 vector into the cerebrospinal fluid as a
less invasive method to achieve widespread brain transduction. Studies in nonhuman primates demonstrated
that intrathecal AAV9 delivery results in transduction of cells throughout the brain and spinal cord without
eliciting destructive immune responses to the transgene product. Intrathecal injection of AAV9 vectors
expressing IDUA in canine and feline models of MPS I replicated the widespread transduction observed in
primate studies, and demonstrated resolution of storage lesions throughout the CNS. Antibodies against the
enzyme were detected in the CSF of some animals, which coincided with lower CSF IDUA activity and less
efficient correction of storage lesions. We found that immunological tolerance could be induced to IDUA by
exposing newborn MPS I dogs to the enzyme, which enhanced the efficacy of subsequent gene transfer. These
results were replicated in rhesus macaques, supporting the potential to translate neonatal tolerance induction
to clinical applications. Intrathecal AAV delivery offers the potential for widespread gene transfer in the CNS
with a single minimally invasive vector injection, which could prove transformative for the field of gene
therapy for inherited neurological disorders.
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ABSTRACT 
INTRATHECAL ADENO-ASSOCIATED VIRUS VECTOR DELIVERY FOR 
MUCOPOLYSACCHARIDOSIS TYPE I 
Christian Hinderer 
James M Wilson, MD PhD 
 
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease resulting from 
deficiency of the enzyme α-L-iduronidase (IDUA).  Accumulation of the IDUA substrates 
heparan and dermatan sulfate causes widespread organ pathology.  While many of the 
somatic manifestations of MPS I can be treated with intravenous enzyme replacement, 
the devastating CNS sequelae—cognitive impairment, spinal cord compression, and 
hydrocephalus—do not respond to treatment.  Partial preservation of cognitive function 
is possible with early hematopoietic stem cell transplantation, although transplant is 
associated with substantial morbidity and mortality.  Gene transfer using adeno-
associated virus (AAV) vectors offers a potential alternative approach to deliver the 
IDUA enzyme to the CNS.  Introducing a functional IDUA gene to a subset of quiescent 
cells could provide a permanent source of secreted enzyme beyond the blood-brain 
barrier.  However, preclinical studies evaluating direct injection of AAV vectors into the 
brain have shown that transduction is limited to small regions surrounding the injection 
site, and that injection can be associated with a localized inflammatory response and 
immune-mediated killing of transduced cells. In order to overcome these limitations, we 
evaluated delivery of an AAV serotype 9 vector into the cerebrospinal fluid as a less 
invasive method to achieve widespread brain transduction.  Studies in nonhuman 
primates demonstrated that intrathecal AAV9 delivery results in transduction of cells 
throughout the brain and spinal cord without eliciting destructive immune responses to 
the transgene product.  Intrathecal injection of AAV9 vectors expressing IDUA in canine 
and feline models of MPS I replicated the widespread transduction observed in primate 
studies, and demonstrated resolution of storage lesions throughout the CNS.  Antibodies 
against the enzyme were detected in the CSF of some animals, which coincided with 
lower CSF IDUA activity and less efficient correction of storage lesions.  We found that 
immunological tolerance could be induced to IDUA by exposing newborn MPS I dogs to 
the enzyme, which enhanced the efficacy of subsequent gene transfer.  These results 
were replicated in rhesus macaques, supporting the potential to translate neonatal 
tolerance induction to clinical applications.  Intrathecal AAV delivery offers the potential 
for widespread gene transfer in the CNS with a single minimally invasive vector injection, 
which could prove transformative for the field of gene therapy for inherited neurological 
disorders. 
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CHAPTER 1: Introduction  
Mucopolysaccharidosis type I 
 
Mucopolysaccharidosis type I (MPS I) is a rare genetic disease affecting 
approximately 1 in 100,000 newborns worldwide (Moore et al. 2008).  Children with MPS 
I typically appear normal at birth, although umbilical hernias or spinal deformities are 
sometimes present (Beck et al. 2014).  Often after one to two years of normal 
development, patients rapidly develop a constellation of devastating disease 
manifestations—chronic upper respiratory infections, joint pain and immobility, bone 
deformities, coarsened facial features, hepatomegaly, carpal tunnel syndrome, 
communicating hydrocephalus, spinal cord compression, hearing impairment, corneal 
clouding, obstructive sleep apnea, and cardiac disease (Beck et al. 2014, Aldenboven, 
Boelens, and de Koning 2008, Boelens et al. 2007, Souillet et al. 2003, Whitley et al. 
1993).  Most patients also begin to show signs of developmental delay by 2 years of 
age, which progresses to profound intellectual impairment in early childhood.  Without 
treatment most patients do not survive beyond the first decade (Aldenboven, Boelens, 
and de Koning 2008, Boelens et al. 2007, Fleming et al. 1998, Souillet et al. 2003, Staba 
et al. 2004, Whitley et al. 1993). 
MPS I is caused by mutations in the IDUA gene encoding the lysosomal enzyme 
α-L-iduronidase (IDUA).  IDUA catalyzes the hydrolysis of iduronic acid linkages in 
heparan and dermatan sulfate, two ubiquitous glycosaminoglycans (GAG).  In the setting 
of deficient IDUA activity, undegraded GAGs accumulate in nearly every tissue, leading 
to diverse clinical manifestations.  GAG storage in the cornea causes characteristic 
clouding and visual impairment, airway abnormalities caused by GAG infiltration 
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contribute to obstructive sleep apnea and chronic upper respiratory infections, and 
storage lesions in the cardiac valves cause the valves to thicken and shorten, leading to 
mitral and aortic regurgitation.  Both spinal cord compression and communicating 
hydrocephalus have been linked to GAG storage in the meninges—the thickened dura 
mater directly compresses the spinal cord, and leptomeningeal GAG storage is thought 
to block perivascular channels and arachnoid granulations through which CSF is 
resorbed, leading to increased CSF pressure (Dickson, Hanson, et al. 2010, Kakkis, 
McEntee, et al. 2004, Munoz-Rojas et al. 2008, Kachur and Del Maestro 2000, Taccone 
et al. 1993).  The mechanism by which IDUA deficiency leads to cognitive dysfunction is 
less clear; neurons exhibit GAG storage, but this does not appear to correlate with 
disease onset or severity. Neurons do, however, exhibit marked abnormalities.  Ectopic 
neurite growth, axonal spheroids, and storage of gangliosides are pronounced in cortical 
neurons, and these features correlate with cognitive phenotype in MPS I as well as in 
related lysosomal storage disorders (Constantopoulos, Iqbal, and Dekaban 1980, Shull 
et al. 1984, Walkley and Vanier 2009). It is not clear how the primary biochemical defect 
leads to these downstream consequences in the brain. 
MPS I patients present across a spectrum of severity, ranging from the most 
common and severe presentation of early somatic involvement and rapid cognitive 
decline, to onset after the first decade of life with attenuated somatic disease and normal 
intelligence (Beck et al. 2014).  The disease phenotype is related to residual enzyme 
activity—patients with the attenuated form of MPS I typically have missense mutations, 
whereas patients with severe disease have nonsense mutations, deletions or insertions 
(Terlato and Cox 2003).  In the US the most frequent mutations are W402X and Q70X, 
both of which cause the severe form of the disease in homozygotes or compound 
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heterozygotes.  The disease causing mutations that result in an attenuated phenotype 
produce less than 1% of normal IDUA activity, demonstrating that very low levels of 
enzyme can modify the course of the disease (Terlato and Cox 2003). 
The first therapy developed for MPS I was hematopoietic stem cell 
transplantation (HSCT). HSCT can impact systemic storage pathology through the 
principle of cross correction: upon successful engraftment of HSCs, donor derived cells 
secrete small amounts of IDUA, which is taken up by host cells from the systemic 
circulation through receptor-mediated binding of terminal mannose-6 phosphate 
residues present on glycosylated IDUA (Dahms, Lobel, and Kornfeld 1989, Sando and 
Neufeld 1977, Aldenboven, Boelens, and de Koning 2008). Uptake of IDUA through this 
pathway results in trafficking to the lysosome, where the enzyme catalyzes the 
degradation of stored polysaccharides. HSCT has demonstrated improvements in 
survival, growth, cardiac and respiratory function, mobility, and intellect. The effect of 
HSCT on the CNS is attributed to migration of bone marrow derived precursors across 
the blood-brain barrier, where they differentiate into microglia and serve as a source of 
secreted IDUA in the brain (Aldenboven, Boelens, and de Koning 2008). 
Despite the impact of HSCT on the clinical course of MPS I, there are important 
limitations of the procedure. HSCT for MPS I is associated with substantial morbidity and 
up to 20% mortality (Aldenboven, Boelens, and de Koning 2008). Accordingly, the 
procedure is now reserved only for patients with severe disease. HSCT is also generally 
only performed in patients identified before two years of age, as the risk-benefit ratio is 
thought to be more favorable in younger patients who are more likely to derive greater 
cognitive benefit (de Ru et al. 2011). A second critical limitation of HSCT is the 
incomplete treatment of CNS symptoms.  Among successfully engrafted patients, 
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cognitive decline continues for up to a year after transplant before stabilizing, leaving 
permanent developmental deficits (Fleming et al. 1998, Staba et al. 2004). This delayed 
effect of HSCT is believed to be due to the time required for bone marrow-derived 
microglia to migrate into the CNS. Studies in animal models suggest that only 30% of 
microglial engraftment occurs by one year after transplant, with most of these engrafted 
cells occupying perivascular spaces rather than the brain parenchyma (Kennedy and 
Abkowitz 1997). There is therefore little improvement in neuronal storage lesions within 
the first year after transplantation (Ellinwood et al. 2007). 
More recently, a recombinant form of human IDUA has been approved for the 
treatment of MPS I. Given as a weekly intravenous infusion, enzyme replacement 
therapy (ERT) has demonstrated many of the same benefits as HSCT, including 
improvement in hepatomegaly, growth, mobility and respiratory function (de Ru et al. 
2011, Sifuentes et al. 2007, Wraith et al. 2007, Wraith et al. 2004). However, as the 
enzyme cannot cross the blood-brain barrier, ERT does not treat the CNS 
manifestations of MPS I.  Several studies have investigated the direct delivery of 
recombinant IDUA to the CNS by intrathecal (IT) injection (Dickson, Naylor, Mlikotic, 
Victoroff, Chen, Passage, and Le 2008, Dickson, Naylor, Mlikotic, Victoroff, Chen, 
Passage, Le, et al. 2008, Munoz-Rojas et al. 2008, Vera et al. 2013). Monthly IT 
infusions of IDUA demonstrated minimal adverse effects, and have shown evidence for 
improvement in spinal cord compression. However, IT ERT has limited potential for the 
treatment of CNS disease in MPS I due to the need for repeated access to the 
cerebrospinal fluid (CSF) for the life of the patient. Further, the efficacy of this approach 
is likely limited by the extremely short half-life of the enzyme in the CSF and the long 
intervals between injections (Vite et al. 2011). 
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Adeno-associated virus mediated gene therapy for MPS I 
 
The limitations of HSCT and ERT leave a significant unmet need for a method to 
safely achieve long term IDUA reconstitution in the CNS. Delivery of the gene encoding 
the enzyme to cells within the CNS could provide a permanent source of secreted IDUA 
beyond the blood-brain barrier, allowing for long term cross-correction of cells 
throughout the CNS. This strategy could also provide rapid IDUA delivery to the brain, 
potentially preventing the progression of developmental deficits that otherwise occurs in 
Hurler patients during the slow process of donor cell migration into the CNS following 
HSCT. 
Adeno-associated virus (AAV) vectors have demonstrated the potential for safe, 
long term transgene expression in vivo. The wild type AAV from which these vectors are 
derived is a small non-enveloped parvovirus that is ubiquitous in humans and other 
species (Samulski and Muzyczka 2014).  AAV is nonpathogenic and has limited 
replicative capacity in the absence of a helper virus.  AAV is composed of a 20 nm 
icosahedral capsid containing a 4.7 kb single-stranded DNA genome.  The genome 
contains three protein coding genes—Rep, Cap, and AAP—flanked by short double-
stranded inverted terminal repeats.  The Rep gene encodes four proteins required for 
the replication and packaging of the genome.  Cap encodes three proteins—VP1, VP2 
and VP3—that form the viral capsid.  AAP (assembly activator protein) is expressed 
from an alternate reading frame overlapping Cap, and appears to have a role in capsid 
assembly (Sonntag, Schmidt, and Kleinschmidt 2010).  Only the inverted repeats are 
essential for DNA packaging in AAV; the other essential proteins can be provided in 
trans (Samulski, Chang, and Shenk 1989, 1987). Completely replacing the viral coding 
sequences of AAV has yielded vectors capable of in vivo gene transfer. Upon entering a 
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host cell, the vector genome persists as an episome, allowing for stable expression for at 
least ten years in quiescent tissues (Buchlis et al. 2012). However, early clinical trials 
utilizing AAV vectors showed limited gene transfer and poor efficacy.  Over the past 
decade, a second generation of AAV vectors discovered as latent viruses in human and 
macaque tissues has demonstrated vastly improved gene transfer efficiency over that 
achieved with the original vectors based on AAV serotype 2 (AAV2) (Gao et al. 2004, 
Gao et al. 2002, Xiao et al. 1999). Using these new vectors, clinical trials of gene 
transfer to both liver and muscle have demonstrated efficacy in diseases such as 
hemophilia B and lipoprotein lipase deficiency, the latter leading to the first approved 
gene therapy product in Europe (Nathwani et al. 2011, Bryant et al. 2013).  
AAV vectors have been tested extensively for gene transfer to the brain.  One of 
the most heavily pursued CNS targets for early AAV trials was Parkinson’s disease (PD).  
Preclinical studies in a nonhuman a primate model of drug induced degeneration of the 
substantia nigra demonstrated the efficacy of several gene therapy strategies 
(Bankiewicz et al. 2006, Bartus et al. 2011, Björklund et al. 2000, Bohn et al. 1999, 
Burns et al. 1983, Emborg et al. 2007, Hadaczek et al. 2010, Jarraya et al. 2009, 
Muramatsu et al. 2002, Nagahara et al. 2009).  Some were based on expression of 
enzymes involved in neurotransmitter synthesis, aiming to augment dopamine 
production in the substantia nigra in order to increase responsiveness to the dopamine 
precursor L-dopa, or to increase GABA production in the subthalamic nucleus to restore 
inhibitory signals to the basal ganglia that are disrupted in PD.  Other strategies were 
based on delivery of genes encoding neurotrophic factors, aiming to preserve remaining 
dopaminergic neurons.  The efficacy of these approaches in the primate model led to a 
series of human trials.  However, after more than 100 patients have been treated, there 
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has been little evidence of efficacy (Bartus, Weinberg, and Samulski 2014).  While these 
studies called into question the relevance of the drug-induced primate model of PD, 
these early human studies provided important evidence for the safety of AAV delivery to 
the brain.  Further, PET imaging studies carried out in a trial for a vector expressing 
aromatic amino acid decarboxylase (AADC) demonstrated transgene expression in the 
brain for several years after treatment (Mittermeyer et al. 2012).  Thus while gene 
therapy has not shown promise for the treatment of PD, the failed PD trials paved the 
way for a variety of CNS gene therapy studies.  Many of these were for rare genetic 
diseases, and to date these are some of the only indications for which there has been 
evidence of efficacy.  In trials for Canavan disease and aromatic amino acid 
decarboxylase deficiency, treated patients have shown evidence of modestly attenuated 
disease progression after intracranial AAV delivery (Janson et al. 2002, Leone et al. 
2012, Hwu et al. 2012). 
Intrathecal AAV Delivery 
 
All trials of AAV-mediated CNS gene transfer to date have utilized multiple 
intraparenchymal brain injections.  While this delivery method demonstrated efficacy in 
mouse models of many genetic disorders, there are two potential problems with 
translating this approach to humans—scaling to the larger human brain (for diseases 
that require whole-brain targeting), and the potential inflammatory response caused by 
localized brain damage at the injection site.  The issue of scaling is derived from the 
distribution of transduction after intraparenchymal brain injection.  Transgene expression 
is generally limited to the cells immediately surrounding the injection site, although some 
transduction can occur at more distal sites due to vector transport along axonal 
projections (Vite et al. 2005, Castle et al. 2014).  Some investigators have attempted to 
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increase vector distribution using convection-enhanced delivery, which employs 
pressure gradients to drive the vector deeper into the brain parenchyma, although 
improvements have been modest (Bankiewicz et al. 2000).  In mouse models, even the 
limited distribution that occurs after intraparenchymal injection results in transduction of 
a significant portion of the brain.  The problem with applying this approach to diseases in 
which the entire CNS is affected has become apparent in studies of canine and feline 
models of lysosomal storage diseases.  Even with the potential cross correction of 
neighboring cells due to transgene secretion, these studies typically required at least 6 
injections to correct storage pathology in a significant portion of the brain (Vite et al. 
2005, Ciron et al. 2006).  Scaling this method from the 30-70 g brain of a cat or dog to a 
1.4 kg human brain would require more than 100 injections for equivalent distribution.  
Since this is not feasible in humans, trials have instead pursued much more limited 
injection strategies that cannot replicate the extent of brain transduction that has been 
required for efficacy in animal models. 
 A second obstacle to translation of intraparenchymal vector injection to humans 
is the potential local inflammation caused by the injection, and the resulting impact on 
immune responses to the transgene product.  Initiation of an adaptive immune response 
requires an inflammatory “danger” signal to activate antigen presenting cells and recruit 
lymphocytes, including CD8 T cells that can kill host cells presenting the target antigen, 
as well as CD4 T cells which can activate B cells to produce antibodies against the 
antigen.  In the absence of inflammatory signals, reactive lymphocytes enter a default 
pathway of anergy or tolerance to the foreign antigen.  In the setting of gene therapy, it is 
critical to avoid inflammatory signals at the time of vector delivery, as the newly 
expressed non-self antigen could be a target for circulating B and T cells, and providing 
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a danger signal can initiate this response.  This has been demonstrated in studies with 
adenoviral vectors, in which the vector capsid provides an inflammatory signal so that 
immunity is elicited against the transgene (Liu and Muruve 2003).  With AAV vectors, 
tolerance typically develops to the transgene product, apparently due to expression in 
the absence of an inflammatory signal from the viral capsid or genome.  However, 
providing the inflammatory signal by other means—such as local tissue destruction at 
the time of injection—could result in transgene-specific immunity. This seems to have 
occurred in early preclinical studies of AAV-mediated CNS gene therapy for two 
lysosomal storage diseases.  In dog models of these diseases, direct brain injection of 
AAV vectors resulted in localized tissue damage followed by lymphocyte recruitment and 
elimination of transduced cells (Ciron et al. 2006, Ellinwood et al. 2011). 
Intrathecal injection presents a clear alternative to multiple direct brain injections.  
CSF is produced by the choroid plexus in the ventricles and flows through the ventricular 
system to the cisterna magna, then around the length of the spinal cord and the surface 
of the brain.  Thus vector injection into CSF could allow for widespread distribution in the 
CNS with a single injection.  However, intrathecal injection has not been widely pursued 
as a method for delivery of biologics to the brain due to the belief that CSF is primarily 
confined between the pia and arachnoid membranes, with little interaction with the brain 
parenchyma (Papisov, Belov, and Gannon 2013).  More recent studies have revealed 
that in fact CSF flows deep into the brain via perivascular channels, and that even large 
molecules can directly diffuse from these channels into the brain interstitial fluid (Iliff et 
al. 2013, Iliff et al. 2012).  This new view of CSF flow is supported by studies of 
intrathecal enzyme replacement therapy in animal models, which demonstrate that 
enzyme delivered into CSF is readily taken up by the brain (Dickson, Ellinwood, et al. 
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2010, Dickson et al. 2009, Dickson, Hanson, et al. 2010, Dickson, Naylor, Mlikotic, 
Victoroff, Chen, Passage, Le, et al. 2008, Kakkis, McEntee, et al. 2004, Vite et al. 2011). 
These findings opened up the possibility of widespread delivery of proteins, or even viral 
vectors, to the entire CNS with a single injection.  This approach could potentially solve 
the issue of scaling intraparenchymal injections to the human brain, and could have a 
more favorable immunological profile by avoiding tissue damage and inflammation at the 
time of injection. 
Large animal models of MPS I 
 
Evaluating intrathecal AAV delivery for MPS I requires animal models that 
accurately reflect disease pathophysiology while also having the necessary size and 
CNS anatomy to reasonably replicate intrathecal vector delivery and distribution in 
humans.  Mutations in the gene encoding IDUA resulting in a phenotype mimicking MPS 
I have been described in transgenic mice, the Plott Hound dog, and the domestic 
shorthair cat (Menon, Tieu, and Neufeld 1992, Shull et al. 1984, Haskins, Desnick, et al. 
1979, Haskins, Jezyk, et al. 1979, He et al. 1999). MPS I mice have been generated 
both as traditional knockouts and by targeting a common human mutation (W402X) to 
the endogenous gene. The MPS I cat carries a 3 base pair in-frame deletion in the IDUA 
gene, resulting in production of a protein missing a single aspartate residue that is 
critical for substrate binding (He et al. 1999, Maita et al. 2013). The MPS I dog carries a 
splice site mutation that results in the inclusion of the first intron in the mature mRNA, 
creating an immediate stop codon (Menon, Tieu, and Neufeld 1992). All three animal 
models exhibit the biochemical and histological abnormalities characteristic of MPS I, 
including extensive storage lesions in the CNS. The neuropathology in the dog has been 
the best characterized, and shows remarkably similarity to humans, with ectopic neurite 
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growth, axonal spheroids, and extensive ganglioside storage, providing strong evidence 
for similar pathophysiology to the human disease.   
The canine and feline models were used for all studies, as these species 
appeared to much more closely recapitulate critical characteristics of MPS I patients. 
Foremost among these is the sheer scale of the brain and CSF compartment.  Delivery 
of enzyme to cells throughout the brain is an essential obstacle for CNS directed gene 
therapy for MPS I, which is dependent on both the diffusion of the vector in the CSF and 
penetration into the brain parenchyma, as well as diffusion of the secreted enzyme from 
transduced cells. In the small mouse brain (0.4 g) even very limited enzyme diffusion 
from transduced cells near the injection site could result in significant correction of 
storage lesions; however, in the 80 to 200-fold larger feline or canine brain, widespread 
correction would depend on the same process of distribution through CSF that would be 
essential for efficacy in humans.  These considerations of vector distribution and 
similarities in brain pathology made the MPS I dog and cat appealing models for 
evaluation of intrathecal AAV delivery for MPS I. 
Goals of this dissertation 
 
 The following studies were carried out based on the central hypothesis that IT 
AAV could achieve widespread targeting of cells in the CNS, and through cross-
correction, globally resolve storage pathology. Chapter 2 outlines the development of the 
intrathecal approach for AAV delivery in nonhuman primates and initial findings 
supporting the capacity of this method to achieve widespread transduction and evade 
immune activation.  These studies also delineate the critical importance of the site of 
intrathecal injection for the distribution of vector in the CNS.  Chapter 3 describes the 
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application of this approach to MPS I in the feline model, including the impact on brain 
pathology and the importance of humoral immune responses to the transgene.  In 
Chapter 4 intrathecal AAV delivery was evaluated in MPS I dogs, which resulted in 
strong antibody responses to IDUA.  To circumvent the antibody response, a method 
was developed to induce persistent antigen specific tolerance to IDUA.  Subsequent 
studies helped to define the impact of antibodies on CSF enzyme levels and disease 
correction.  This study also presented a potential method for preventing immune 
responses to gene and protein therapies for recessive diseases, an approach that was 
confirmed in nonhuman primates.  Finally in Chapter 5 this approach was utilized to 
induce tolerance to the human IDUA enzyme in MPS I dogs to allow for evaluation of 
intrathecal injection of a clinical candidate vector as a prelude to first in human trials. 
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Chapter 2: Widespread Gene Transfer in the Central Nervous 
System of Cynomolgus Macaques Following Delivery of AAV9 
into the Cisterna Magna 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 is adapted from: C. Hinderer, P. Bell, C. H. Vite, J.-P. Louboutin, R. Grant, E. 
Bote, H. Yu, B. Pukenas, R. Hurst, J. M. Wilson, Molecular Therapy — Methods & 
Clinical Development (2014). 
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Abstract 
Adeno-associated virus serotype 9 (AAV9) vectors have recently been shown to 
transduce cells throughout the central nervous system of nonhuman primates when 
injected into the cerebrospinal fluid (CSF), a finding which could lead to a minimally 
invasive approach to treat genetic and acquired diseases affecting the entire CNS.  We 
characterized the transduction efficiency of two routes of vector administration into the 
CSF of cynomolgus macaques— lumbar puncture, which is typically used in clinical 
practice, and suboccipital puncture, which is more commonly used in veterinary 
medicine. We found that delivery of vector into the cisterna magna via suboccipital 
puncture is up to 100-fold more efficient for achieving gene transfer to the brain.  In 
addition, we evaluated the inflammatory response to AAV9-mediated GFP expression in 
the nonhuman primate CNS.  We found that while CSF lymphocyte counts increased 
following gene transfer, there were no clinical or histological signs of immune toxicity.  
Together these data indicate that delivery of AAV9 into the cisterna magna is an 
effective method for achieving gene transfer in the CNS, and suggest that adapting this 
uncommon injection method for human trials could vastly increase the efficiency of gene 
delivery. 
 
Introduction 
 
Gene therapy using AAV vectors has enormous potential to treat acquired and 
congenital diseases affecting the central nervous system (CNS).  Numerous studies in 
murine disease models have demonstrated the efficacy of AAV-mediated gene transfer 
in the brain, and initial human studies have shown an excellent safety profile (Haurigot et 
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al. 2013, Wolf et al. 2011, Tardieu et al. 2013, Kaplitt et al. 2007, McPhee et al. 2006).  
These pioneering clinical trials were carried out using multiple direct injections of the 
vector into the brain parenchyma, a strategy which has been shown in preclinical studies 
to achieve efficient gene transfer to cells surrounding the injection site (Vite et al. 2005).  
However, treatment of diseases affecting cells throughout the CNS will ultimately 
necessitate a delivery strategy capable of widespread transduction.  Simply increasing 
the number of intra-parenchymal injections is not feasible, as even the most promising 
large animal studies have required at least 4 injection sites, which would translate to 
more than 100 injections in an adult human (Vite et al. 2005, McCurdy et al. 2014).  
Intravascular (IV) delivery of AAV serotype 9, which can traverse the blood-brain barrier, 
has been proposed as an alternative approach to achieve widespread transduction in 
the CNS (Bevan et al. 2011).  While IV delivery is extremely effective in mice, in larger 
animals transduction in the CNS has been much more restricted (Gray et al. 2011, 
Samaranch et al. 2012).  This approach is further limited by the extremely large doses 
required to achieve transduction in the brain and the resulting high off-target 
transduction of peripheral organs (Bevan et al. 2011, Gray et al. 2011). 
Several groups have recently reported that delivery of AAV serotypes 7 and 9 
into the cerebrospinal fluid (CSF) of nonhuman primates can effect transduction of both 
neurons and glia throughout the brain and spinal cord (Samaranch et al. 2012, 
Samaranch, Salegio, et al. 2013, Gray et al. 2013).  This represents a critical advance in 
the field of CNS gene therapy.  It may now be possible not only to achieve gene transfer 
throughout the CNS in humans, but to do so with a single minimally invasive injection.  
Access to the subarachnoid CSF is routinely achieved by lumbar puncture in clinical 
practice for diagnostic purposes and for administration of medications.  Although less 
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common, access can also be achieved at the level of the cisterna magna by sub-
occipital puncture.  Intrathecal AAV delivery therefore represents a relatively low-risk 
delivery strategy that could be readily translated to the clinic. 
In order to advance this approach toward clinical trials, we performed nonhuman 
primate studies to evaluate the efficiency of two minimally invasive delivery 
approaches—lumbar puncture and suboccipital puncture—for achieving vector 
distribution throughout the brain and spinal cord. One previous study reported that both 
strategies result in transgene expression in the brain, but did not quantitatively compare 
vector distribution (Gray et al. 2013). Based on our findings we estimate that sub-
occipital puncture is 10 to 100-fold more efficient for brain transduction, making this 
approach far more promising for clinical use. 
In addition, we performed detailed evaluation of histological markers of 
inflammation in the CNS of treated animals.  Several studies have found intrathecal 
delivery of AAV9 to be safe in nonhuman primates and other species, although one 
group has reported that macaques treated with a vector carrying a GFP transgene 
experienced neurological deficits associated with histological evidence of an 
inflammatory response (Samaranch et al. 2014).  We found that treated animals 
exhibited no clinical or histological abnormalities, although CSF lymphocytes were 
elevated in some animals.  Overall our data suggest that intrathecal AAV injection by 
suboccipital puncture could serve as a useful gene transfer method for the treatment of 
neurological disease. 
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Materials and Methods 
Animals: All study protocols were approved by the institutional animal care and use 
committee of the University of Pennsylvania.  Six adult female cynomolgus macaques 
were used in this study.  These animals were not pre-screened for AAV9 neutralizing 
antibodies.  An additional female rhesus macaque was used for the intravenous delivery 
experiment.  This animal was prescreened for AAV9 neutralizing antibodies as 
previously described(Wang et al. 2011). 
Lumbar vector injection: Animals were anesthetized using IM 
ketamine/dexmedetomidine. The hair over the lumbar spine was shaved and the skin 
sterilely prepped. To widen the intervertebral space the spine is flexed slightly, drawing 
the animal’s hind limbs forward toward the umbilicus. A spinal needle was inserted into 
the center of the L3-L4 intervertebral space just behind the anterior vertebral spinous 
process. Needle placement was confirmed by CSF return.  CSF (1 mL) was collected, 
then a syringe containing vector (1 mL diluted in PBS) was attached to the spinal needle 
through a flexible linker.  Vector was slowly injected by hand over one minute. After 
injection placement was again confirmed by CSF return.  The needle was removed and 
direct pressure applied to the puncture site. 
Intracisternal vector injection: Animals were anesthetized using IM 
ketamine/dexmedetomidine. The hair over the back of the head and neck was shaved 
and the skin sterilely prepped. The occipital protuberance at the back of the skull and the 
wings of the atlas (C1) were palpated, and a needle was inserted midway between them. 
Needle placement was confirmed by CSF return.  CSF (1 mL) was collected, then a 
syringe containing vector (1 mL diluted in PBS) was attached to the needle through a 
flexible linker.  Vector was slowly injected by hand over one minute. After injection 
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placement was again confirmed by CSF return.  The needle was removed and direct 
pressure applied to the puncture site. 
Vector Production:  Single-stranded AAV9 vectors were produced by triple transfection 
of 293 cells and purified by iodixanol gradient centrifugation as previously 
described(Wang et al. 2011). 
Quantitative PCR: Vector genomes were quantified in tissue samples by Taqman PCR 
as previously described(Wang et al. 2011). 
Histology:  Brains were divided into left and right hemisphere. The right half was sliced, 
fixed in formalin overnight, and embedded in paraffin for the preparation of H&E stained 
sections and for immunostaining. Slices from the left half were formalin-fixed and 
processed for GFP detection as described below. PCR samples for vector biodistribution 
studies were also retrieved from the left brain half prior to fixation. Tissues from spinal 
cord was collected from cervical, thoracic, and lumbar regions and processed for paraffin 
and cryosections as described for the brain. 
Hematoxylin and eosin staining (H&E): H&E staining was performed on 6 µm paraffin 
sections according to standard protocols. 
GFP fluorescence: Brain slices were fixed overnight in formalin, equilibrated sequentially 
in 15% and 30% sucrose in PBS, and frozen in OCT embedding medium for the 
preparation of cryosections for visualization of direct GFP fluorescence. Sections were 
mounted in Vectashield containing DAPI (Vector Laboratories, Burlingame, CA) as 
nuclear counterstain. 
Immunohistochemistry for GFP: Sections were deparaffinized through an ethanol and 
xylene series, boiled in a microwave for 6 min in 10mM citrate buffer (pH 6.0) for antigen 
retrieval, treated sequentially with 2% H2O2 (15 min), avidin/biotin blocking reagents (15 
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min each; Vector Laboratories), and blocking buffer (1% donkey serum in PBS + 0.2% 
Triton for 10 min) followed by incubation with primary (1h) and biotinylated secondary 
antibodies (45 min; Jackson Immunoresearch, West Grove, PA) diluted in blocking 
buffer. As primary antibodies served a rabbit serum or a chicken antibody against GFP 
(both from Abcam, Cambridge, MA; diluted 1:1000) which both yielded similar results. A 
Vectastain Elite ABC kit (Vector Laboratories) was used according to the manufacturer's 
instructions with DAB as substrate to visualize bound antibodies as brown precipitate. 
Sections were slightly counterstained with hematoxylin to show nuclei. In some 
experiments hematoxylin counterstaining or antibodies were omitted as described in the 
text. 
Immunofluorescence: Immunostaining was performed on sections from formalin-fixed 
paraffin-embedded tissue samples. Sections were deparaffinized and treated for antigen 
retrieval as described above, then blocked with 1% donkey serum in PBS + 0.2% Triton 
for 15 min followed by sequential incubation with primary (1 h) and fluorescence-labeled 
secondary antibodies (45 min) diluted in blocking buffer. Primary antibodies used were 
goat antibodies against GFAP (Novus Biologicals, Littleton, CO; 5µg/ml working 
concentration) and Iba1 (Abcam, 1:200), and TRITC-labeled donkey anti-goat (Jackson 
Immunoresearch, 1:100) served as secondary antibody. 
Morphometric analyses: To quantify astrocytes (GFAP-positive cells) and microglia 
(Iba1-positive cells), 15 images were taken from immunostained brain sections per 
animal with a 20x objective showing the area directly below the cerebral cortex surface. 
Positive cells were counted manually and averaged for each animal. Brain tissues from 
two cynomolgus macaques from an unrelated study that had received AAV2.TGB.EPO 
intravenously and showed negligible vector genome copy numbers in the brain (below 
1x10-4 gc/cell) served as controls (Gao et al. 2006).  
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For the quantification of transduced motor neurons, spinal cord sections were stained 
with Neurotrace red fluorescent Nissl stain (Life Technologies, Grand Island, NY) 
according to the manufacturer's instructions and images were taken at low magnification 
(4x objective) showing GFP expression and Neurotrace staining. Between three to five 
images were taken from the ventral area of each spinal cord region (cervical, thoracic, 
lumbar) to cover several sections per animal. ImageJ software (Rasband W. S., National 
Institutes of Health, USA; http://rsb.info.nih.gov/ij/) was used to first threshold and then 
select all Neurotrace-positive cells with a minimum pixel number of 175 reflecting a 
threshold diameter of approximately 25 µm. To determine the percentage of size-
selected neurons that were GFP-positive, all selected neurons and those that were GFP-
positive were counted for each image. 
Results 
Intracisternal delivery achieves broader vector distribution in the CNS 
 We treated six cynomolgus macaques with an intrathecal injection of a single-
stranded AAV9 vector expressing GFP from either the cytomegalovirus (CMV) or 
chicken beta-actin (CB) promoter (Table 2-1).  Four of the animals were injected via sub-
occipital puncture; two were treated via lumbar puncture.  There were no adverse clinical 
events during the course of the study.  All animals were sacrificed 14 days after injection 
for histological analysis.   
 Vector distribution was evaluated in CNS and peripheral tissues by quantitative 
PCR (Figure 2-1).  All animals treated by sub-occipital puncture exhibited substantial 
vector deposition in the brain and spinal cord, with up to one vector genome per cell in 
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most regions.  Animals treated by lumbar puncture had approximately 10-fold lower 
gene transfer throughout the spinal cord, and up to 100-fold less in the brain.  In 
contrast, both groups had similar distribution to peripheral organs. Vector copy numbers 
were quite high in liver and spleen, indicating significant vector escape to the peripheral 
circulation. 
 As previous studies have demonstrated the ability of AAV9 to transduce cells 
within the CNS following intravascular injection, we treated one rhesus macaque 
intravenously to compare the efficiency of this approach to intrathecal injection (Figure 2-
1).  Despite the use of a high vector dose (2 x 1013 GC/kg) and the absence of 
detectable neutralizing antibodies to AAV9 in this animal, vector distribution to the CNS 
was substantially lower than that achieved at 4-8 fold lower doses via cisternal injection.   
Due to the low CNS gene transfer efficiency observed in this animal we did not explore 
this route of administration further. 
GFP false positives complicate assessment of transgene expression in the CNS 
 We initially attempted to quantify GFP expressing cells in the CNS by 
immunohistochemistry (IHC), as other groups have previously utilized this method to 
measure GFP expression in the nonhuman primate CNS (Gray et al. 2013, Samaranch, 
Salegio, et al. 2013).  We identified what appeared to be a large number of GFP positive 
cells throughout the CNS of treated macaques (Figure 2-7, A and C). However, we also 
detected a similar staining pattern in some negative control brain tissues from animals 
that had not received a GFP expressing vector (Figure 2-7, B and D).  The false-positive 
neurons appeared dark on H&E sections, a property consistent with the “dark neuron” 
artifact that has long been described in brain tissue, particularly when prepared by 
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immersion fixation (Jortner 2006).  The high affinity of these cells for H&E did not explain 
their dark color in IHC sections, as the cells still appeared to stain positive when the 
hematoxylin counterstain was omitted from IHC sections (Figure 2-7 E, G). Omission of 
the primary antibody and both primary and secondary antibodies in combination 
demonstrated that the false-positive neurons did not exhibit endogenous peroxidase 
activity, but instead nonspecifically bound antibodies used for IHC (Figure 2-7 F, H).  
Because these false positive neurons were detected sporadically in various negative 
control tissues, we determined that IHC could not be used to reliably detect GFP 
expression in brain samples. 
  In order to overcome the problem of GFP false positive cells, we instead used 
direct GFP fluorescence to measure expression.  We initially avoided this method 
because many cells in the CNS exhibit auto-fluorescence.  We found that we could 
account for these fluorescence false positives by overlaying images captured in a red 
fluorescence channel, as GFP is detectable only in the green channel whereas auto-
fluorescent material appears across several channels (Figure 2-8).  We therefore used 
direct GFP fluorescence verified by overlay with a red channel image to identify GFP 
positive cells.  Using this method, GFP expressing cells were detected in treated animals 
but not in any control tissues.  All subsequent analyses were carried out using this 
approach, and red channel images are shown for all cases in which auto-fluorescence 
was observed. 
Intracisternal AAV9 transduces cells throughout the brain and spinal cord 
 Consistent with the high vector distribution to the brain in animals treated by 
intra-cisternal injection, GFP expression was observed in clusters of cells throughout 
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most regions of the brain, which were interspersed with untransduced regions (Figure 2-
3).  Costaining with a fluorescent Nissl stain (NeuroTrace) and antibodies against 
astrocyte and microglial markers (GFAP and Iba1) revealed that virtually all GFP positive 
cells were neurons (Figure 2-3) although rare transduced astrocytes were also detected 
(Figure 2-3, l).  Virtually no GFP positive cells were detected in the cerebrum of animals 
treated by lumbar puncture.  In the spinal cord, GFP expression was prominent in the 
ventral horns of animals treated by intracisternal injection (Figure 2-4a).  High 
magnification images show that these transduced cells were primarily the large lower 
motor neurons (Figure 2-4b).  These cells were heavily transduced in the thoracic and 
lumbar segments of animals treated by intracisternal injection (Figure 2-4, Table 2-2). 
There were also a small number of transduced motor neurons in the cervical spinal cord 
of these animals.  Transduced spinal cord cells were rare in the animals treated by 
lumbar administration (Table 2-2).  The macaque treated with a high dose of intravenous 
AAV9 exhibited no GFP expression in the cerebrum or cerebellum, although several 
transduced neurons were observed in the thoracic and lumbar spinal cord (Figure 2-5, 
Table 2-2). 
Intrathecal AAV9 does not induce an inflammatory response in the nonhuman primate 
brain 
 As one previous study reported evidence of inflammation in the cerebrum of 
nonhuman  primates following intrathecal delivery of an AAV9 vector expressing GFP, 
we analyzed the brains of all treated animals for signs of inflammation (Samaranch et al. 
2014).  No untreated animal tissues were available for histology controls, so we 
analyzed brains from two cynomolgus macaques that were treated with an intravenous 
injection of an AAV serotype 2 vector expressing erythropoietin from a liver specific 
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promoter; these animals were previously found to have virtually no vector deposition in 
the brain (Gao et al. 2006).  Histopathology showed no evidence of cellular infiltrates in 
the brain parenchyma or in the meninges or perivascular spaces in any of the treated 
animals (Figure 2-9).  We quantified cells expressing GFAP, an intermediate filament 
protein that is upregulated in astrocytes in the setting of inflammation.  There were no 
differences in the frequency of GFAP positive cells in the brains of treated animals and 
controls (Figure 2-9, Table 2-3). We also quantified microglia by Iba1 staining.  The 
frequency of microglia was normal in all animals, and microglia exhibited morphology 
characteristic of a resting rather than an activated state (Figure 2-9, Table 2-3).  
Although there was no evidence of inflammation in brain tissue, we did observe a 
moderate lymphocytic pleocytosis in the CSF of two of the animals that were treated with 
intracisternal injection, which correlates with the higher CNS transduction in these 
animals (Table 2-4). 
Discussion 
As the first gene transfer strategy capable of achieving high levels of transduction 
throughout the CNS in large animals, intrathecal AAV delivery could greatly expand the 
applications of gene therapy in neurological disease.  Intrathecal AAV injection is a 
particularly attractive strategy because of the relative ease of accessing the intrathecal 
space compared to the invasive neurosurgical procedure required for intraparenchymal 
injection.  We found that vector delivery into the CSF at the level of the cisterna magna 
is far more efficient than lumbar intrathecal injection for gene transfer to the brain and 
spinal cord.  It is interesting that the level of CSF access had such a profound effect on 
vector distribution, as previous work has shown that a protein infused into the lumbar 
CSF is distributed throughout the CNS (Calias et al. 2012).  This may therefore 
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represent a property of the viral particle, and not reflect the behavior of other substances 
delivered into the intrathecal space.  One potential explanation is that the vector quickly 
binds to cell surfaces, which would allow for wide distribution from the rapidly dispersing 
cisternal CSF, but not from the slower moving CSF lying inferior to the spinal cord in the 
lumbar cistern.  Vector distribution in the CSF could be influenced by additional factors—
such as the volume and formulation of the injection—which should be evaluated in future 
studies.  Translation of this approach to humans may also benefit from further 
investigation of the impact of total CSF volume and cisternal volume on vector 
distribution, as these factors vary between species and among humans (Whitney et al. 
2013). 
Given the superior transduction efficiency achieved by vector delivery into the 
cisterna magna, it will be critical to develop a safe means of performing this procedure in 
patients.  Though cisternal injection is commonly performed in nonhuman primates and 
other animals, it is infrequently utilized in clinical practice.  Suboccipital puncture of the 
cisterna magna was first described in humans in 1920 as a technique for introduction of 
air or contrast material for diagnostic studies (Ayer 1920).  Traditional indications for 
cisternal puncture have also included CSF sampling.  The suboccipital puncture has 
largely been supplanted by noninvasive diagnostic studies including CT and MRI and by 
CSF sampling from lower levels of the spinal canal, such as between the first and 
second cervical vertebrae or between lumbar vertebrae below the level of the spinal 
cord, techniques which are associated with lower rates of complications.  The most 
serious complications associated with cisternal puncture include inadvertent injury to 
vascular structures with resultant hemorrhage as well as brainstem injury.  A 1929 
review of the literature identified 6 reported deaths in 2019 reported procedures in 535 
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patients (Ayer 1920).  These authors also identified 9 additional cases of medullary 
injury, noting however that in skilled hands the procedure should not be considered 
dangerous (Saunders and Riordan 1929).  In 1973, Keane again reviewed the literature 
finding that subarachnoid hemorrhage was the most common major complication of 
cisternal puncture, with at least 30 reported fatalities (Keane 1973).  He noted that other 
serious complications resulted from direct puncture of brain substance.  In 1989, Ward et 
al. evaluated cisternal puncture in cadavers, finding that “tenting” of the dura at the site 
of needle penetration could result in deeper than expected penetration prior to entry into 
the subarachnoid space (Ward, Orrison, and Watridge 1989). 
The few more recent publications available on suboccipital puncture suggest that 
modern day imaging equipment may improve safety by enhancing visualization of critical 
structures during the procedure. A recent report described better visualization of critical 
structures during a cisternal puncture by performing a contrast enhanced CT 
immediately prior to needle insertion (Pomerantz 2005). Axial and sagittal contrast 
enhanced CT images (Figure 2-6) would allow for visualization of the entire needle path, 
which courses in the midline between the base of the occiput and the first vertebra to the 
cisterna magna.  Contrast enhanced CT allows for visualization of the local vascular 
structures, particularly the posterior inferior cerebellar artery (PICA), which has 
historically been the source of bleeding in reported cases of subarachnoid hemorrhage 
following suboccipital puncture.  Employing imaging with suboccipital puncture could 
also be useful for preventing damage to the medulla, a previously reported complication 
resulting from advancing the needle beyond the cisterna magna.  The use of more 
sophisticated integrated navigation systems, like the Philips PercuNav system, may also 
provide an additional layer of safety by allowing real time needle visualization during the 
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procedure.  We therefore believe that suboccipital puncture, though uncommonly 
utilized, could represent a safe and feasible vector delivery approach for clinical use. 
Consistent with previous studies, we observed efficient transduction of motor 
neurons in the thoracic and lumbar spinal cord following intrathecal AAV9 delivery.  We 
found that transduction in the cerebrum, however, was much more diffuse, consisting of 
patches of GFP expressing cells.  The transduction efficiency we observed in the brain 
was much lower than that reported by others, particularly following lumbar intrathecal 
delivery (Gray et al. 2013).  Given the potential for immunohistochemistry to produce 
GFP false positive cells in the CNS, it is likely that this artifact may have contributed to 
exaggerated transduction efficiencies in some reports.  This possibility is supported by 
quantitive PCR data, which in one previous study show approximately one vector 
genome present per 100 cells in the brain—similar to our results for lumbar delivery—
which would preclude transduction of the nearly 50 percent of cells identified as GFP 
positive by immunohistochemistry in that study (Gray et al. 2013).  Other studies of 
intrathecal AAV9 injection have demonstrated a pattern of brain transduction more 
similar to that described here (Samaranch et al. 2012, Samaranch, Salegio, et al. 2013). 
Clinical trials of intraparenchymal injection of AAV serotypes 2 and rh.10 have 
demonstrated excellent tolerability despite the inherent invasiveness of this delivery 
method(Kaplitt et al. 2007, McPhee et al. 2006, Tardieu et al. 2013).  Several studies of 
intrathecal AAV9 administration in nonhuman primates have indicated that it is similarly 
well tolerated.  However, one study reported that macaques treated with intrathecal 
AAV9 expressing GFP developed neurologic deficits 2-3 weeks following vector 
administration (Samaranch et al. 2014).  These animals also exhibited histological signs 
of inflammation in the brain, including MHC class II upregulation and microglial 
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activation.  This was presumed to be due to an immune response against the foreign 
GFP transgene.  We did not identify similar clinical or histological findings in any treated 
animals.  It is possible that we did not observe the same phenomenon due to our shorter 
follow up period (two vs three weeks).  However, the same group previously reported 
treating four macaques with intrathecal AAV9, as well as two with AAV7, both 
expressing GFP, without any complications during the same three week follow up period 
(Samaranch et al. 2012, Samaranch, Salegio, et al. 2013).  Likewise, another group 
reported no adverse events or histological abnormalities after four weeks of follow up in 
10 macaques treated with intrathecal AAV9 expressing GFP (Gray et al. 2013).  It 
therefore appears that this isolated observation of an inflammatory response following 
intrathecal AAV9 delivery was unlikely due to the vector itself, though future studies 
should continue to monitor subjects for such a response.  Although we did not observe 
any clinical or histological abnormalities, we did observe elevated CSF lymphocytes in 
two of the treated animals. This suggests that there may be some degree of immune 
activation by the vector or GFP transgene, although we have not observed any clinical or 
histological consequences of this response. 
Our results demonstrate that delivery of an AAV9 vector into the cisterna magna 
is an effective approach to achieve transduction of cells throughout the nonhuman 
primate CNS.  The excellent safety and feasibility of this route of administration should 
enable rapid deployment into the clinic for a wide range of diseases affecting the CNS. 
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Figure 2-1. AAV9 biodistribution following intrathecal delivery in nonhuman primates 
AAV9 was administered to six cynomolgus macaques at doses of 2.5 – 5 x 10
12
 GC/kg 
by injection into the cisterna magna (n = 4) or the lumbar subarachnoid space (n = 2).  
An additional animal was treated intravenously with a high dose (2 x 10
13
 GC/kg) of 
AAV9.  All animals were sacrificed two weeks after injection and vector genomes were 
quantified in tissue samples by Taqman PCR. 
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Figure 2-2. Transduction throughout the brain following intracisternal AAV9 delivery 
AAV9 was administered to six cynomolgus macaques at doses of 2.5 – 5 x 10
12
 GC/kg 
by injection into the cisterna magna (n = 4) or the lumbar subarachnoid space (n = 2). 
Brain sections from animals treated by intracisternal injection (a-i) and those treated by 
lumbar puncture (j-l) were imaged for native GFP fluorescence.  Counterstain is DAPI (a, 
e, i-l). All images shown were negative for fluorescence in the red channel. (a) Meninges 
(b-d) Cerebral cortex (e) Dentate gyrus (f) Thalamus (g, h) Cerebellum with large 
Purkinje cells. (i) Cerebellum with transduced neurons in granular layer. (j-l). Direct GFP 
fluorescence in meninges (j), cerebral cortex (k), and cerebellum (l) after treatment by 
lumbar puncture. Scale bar: 100 µm (f, i, j), 200 µm (a, d, e, g, h, k, l), 500 µm (b, c). 
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Figure 2-3. Predominantly neuronal transduction of intrathecal AAV9 
Cortical brain sections from animals treated by intracisternal injection were imaged for 
native GFP fluorescence (a, e, i, m).  Images are overlaid with a fluorescent Nissl stain 
(NeuroTrace) for detection of neurons (b, c, d), GFAP immunostaining for astrocytes (f, 
g, h, j, k, l), or Iba1 staining for microglia (n, o, p). Counterstain is DAPI (d, h, l, p).  Scale 
bar =  50 µm. 
32 
 
 
 
Figure 2-4. Spinal cord transduction following intrathecal AAV9 administration by 
intracisternal or lumbar injection 
Direct fluorescence images were captured for three spinal cord segments from all 
treated animals.  Low magnification images show transduction primarily in the ventral 
gray matter (a). High magnification images of the ventral horn demonstrate transduction 
primarily of large neurons in the thoracic and lumbar segments, with occasional 
transduced cells in the cervical segment (white arrow). Scale bar: 1 mm. (b). As 
autofluorescence was observed in some spinal cord sections, an overlay of the red and 
green channels is shown to identify false positive GFP signal (yellow). Scale bar: 200 
µm. 
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Figure 2-5. Limited CNS transduction following intravascular AAV9 delivery 
A rhesus macaque was treated intravenously with an AAV9 vector (2 x 10
13
 GC/kg) 
expressing GFP.  Sections were imaged for native GFP fluorescence from cerebral 
meninges (a), cortex (b) and cerebellum (c). Some GFP expressing cells (arrows) were 
noted in the thoracic spinal cord (d). GFP expression was confirmed by absence of 
fluorescence in the red channel (e). In contrast to the CNS, peripheral organs including 
liver were heavily transduced (f). Counterstain is DAPI (a-c). Scale bar: 200 µm. 
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Figure 2-6. Evaluation of anatomic landmarks for suboccipital puncture 
Axial (a) and sagittal (b) contrast enhanced CT images illustrating key structures to 
identify when performing a suboccipital puncture. 
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Figure 2-7. Detection of false positive GFP expressing cells by immunohistochemistry  
Sections from cerebrum and cerebellum from the AAV9 treated animals (a and c) and an 
untreated control (b and d) were stained with a chicken anti-GFP antibody followed by a 
horseradish peroxidase labeled anti-chicken secondary. In order to identify the cause of 
nonspecific staining, sequential brain sections from an untreated animal were stained 
with H&E (e), primary and secondary antibodies for GFP detection as well as 
hematoxylin counterstain (f), IHC antibodies without counterstain (g), or hematoxylin and 
peroxidase substrate only (h). Scale bar: 100 μm. 
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Figure 2-8. Differentiating GFP fluorescence from autofluorescence in spinal cord  
Fixed frozen sections of a spinal cord expressing GFP (A-C) or not expressing GFP (D-
F) were imaged by fluorescence microscopy in both red and green channels. The 
overlaid images (C and F) distinguish autofluorescent material by its broader emission 
spectrum, which results in equal red and green channel signal. Scale bar: 200 μm. 
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Figure 2-9. Absence of an inflammatory response following intrathecal delivery of AAV9 
expressing GFP  
Brain sections from intrathecal AAV9 treated animals and control animals were stained 
with H&E, and immunostained for the astrocyte marker GFAP and the microglial marker 
IbaI. Scale bar: 100 μm. 
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Table 2-1. Summary of study subjects 
Animal # ROAA Vector Dose 
Weight 
(kg)  
Sex Age 
17 CM AAV9.CMV.eGFP 5 x 1012 GC/kg 3.60 F 8 years 
18 CM AAV9.CB7.eGFP 5 x 1012 GC/kg 3.85 F 8 years 
20 CM AAV9.CB7.eGFP 2.5 x 1012 GC/kg 5.40 F 8 years 
21 CM AAV9.CB7.eGFP 2.5 x 1012 GC/kg 8.75 F 8 years 
04 L AAV9.CB7.eGFP 2.5 x 1012 GC/kg 4.25 F 8 years 
05 L AAV9.CB7.eGFP 2.5 x 1012 GC/kg 4.85 F 8 years 
49 IV AAV9.CMV.eGFP 2.0 x 1013 GC/kg 3.30 F 8 years 
A. L = lumbar injection, CM = cisterna magna, IV = intravenous 
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Table 2-2. Quantification of transduced motor neurons throughout the spinal cord 
Animal # ROAA Promoter Percent GFP+ motor neuronsB 
Cervical Thoracic Lumbar 
17 CM CMV ND 10.7 ± 11.4 14.5 ± 17.6 
18 CM CB 0 ± 0 8.4 ± 2.3 20.3 ± 4.9 
20 CM CB 0.3 ± 0.6 25.1 ± 17.0 19.3 ± 11.0 
21 CM CB 1.5 ± 2.1 48.0 ± 15.6 38.2 ± 23.4 
04 L CB 0.3 ± 0.6 0 ± 0 0.6 ± 1.3 
05 L CB 0 ± 0 1.7 ± 2.9 2.6 ± 5.2 
49 IV CMV 0 ± 0 7.7 ± 10.5 0.2 ± 0.5 
A. L = lumbar injection, CM = cisterna magna, IV = intravenous 
B. Mean ± standard deviation in four fields 
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Table 2-3. Quantification of GFAP and IbaI positive cells in brain sections 
Animal # ROAA Vector GFAPB IbaI 
17 CM AAV9.CMV.eGFP 15.1 +/- 12 4.6 +/- 1.6 
18 CM AAV9.CB7.eGFP 14.1 +/- 8.4 4 +/- 1.6 
20 CM AAV9.CB7.eGFP 11.8 +/- 9.2 4.7 +/- 1.7 
21 CM AAV9.CB7.eGFP 19.6 +/- 16 4.8 +/- 0.3 
04 L AAV9.CB7.eGFP 9.6 +/- 11.2 4.7 +/- 1.4 
05 L AAV9.CB7.eGFP 16.5 +/- 19 4.2 +/- 1.8 
80 IV AAV2.TBG.EPO 14.6 +/- 7.5 9.2 +/- 2.9 
86 IV AAV2.TBG.EPO 12.7 +/- 3.8 8.4 +/- 1.9 
A. L = lumbar injection, CM = cisterna magna, IV = intravenous 
B. Mean number of positive cells ± standard deviation in 15 fields 
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Table 2-4. CSF analysis 
   Nucleated Cells/µl Total Protein (mg/dL) 
Animal # Treatment ROAA Day 0 Day 14 Day 0 Day 14 
04 AAV9.CB7.eGFP L 1 ND 12 ND 
05 AAV9.CB7.eGFP L 0 2B 15 25B 
20 AAV9.CB7.eGFP CM 2 41C 11 25 
21 AAV9.CB7.eGFP CM 4 13C 20 14 
A. L = lumbar injection, CM = cisterna magna 
B. traumatic tap; RBC count = 2090/µL  
C.  >70% lymphocytes 
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CHAPTER 3: Intrathecal gene therapy corrects CNS pathology in 
a feline model of mucopolysaccharidosis I 
 
 
 
 
 
 
 
 
Chapter 3 is adapted from: C. Hinderer, P. Bell, B. L. Gurda, Q. Wang, J.-P. Louboutin, 
Y. Zhu, J. Bagel, P. O'Donnell, T. Sikora, T. Ruane, P. Wang, M. E. Haskins, J. M. 
Wilson, Molecular therapy (2014). 
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Abstract 
 
Enzyme replacement therapy has revolutionized the treatment of the somatic 
manifestations of lysosomal storage diseases (LSD), although it has been ineffective in 
treating central nervous system (CNS) manifestations of these disorders. The 
development of neurotrophic vectors based on novel serotypes of adeno-associated 
viruses (AAV) such as AAV9 provides a potential platform for stable and efficient 
delivery of enzymes to the CNS. We evaluated the safety and efficacy of intrathecal 
delivery of AAV9 expressing α-l-iduronidase (IDUA) in a previously described feline 
model of mucopolysaccharidosis I (MPS I).  A neurological phenotype has not been 
defined in these animals, so our analysis focused on the biochemical and histological 
CNS abnormalities characteristic of MPS I.  Five MPS I cats were dosed with AAV9 
vector at 4-7 months of age and followed for 6 months. Treated animals demonstrated 
virtually complete correction of biochemical and histological manifestations of the 
disease throughout the CNS. There was a range of antibody responses against IDUA in 
this cohort which reduced detectable enzyme without substantially reducing efficacy; 
there was no evidence of toxicity. This first demonstration of the efficacy of intrathecal 
gene therapy in a large animal model of a LSD should pave the way for translation into 
the clinic. 
Introduction 
Mucopolysaccharidosis type I (MPS I, Hurler, Scheie, Hurler-Scheie syndromes) 
is a recessively inherited disease caused by deficiency of a ubiquitous lysosomal 
enzyme, α-l-iduronidase (IDUA), which is required for the degradation of the 
glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate.  Accumulation of 
these undegraded lysosomal substrates results in widespread tissue pathology, often 
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characterized by skeletal deformities, cardiac and pulmonary disease, upper airway 
obstruction, and in some cases, progressive neurological disease (Xing et al. 2014).  
The central nervous system manifestations of MPS I vary, with profound developmental 
decline occurring in early childhood in severely affected patients, while those with a 
more mild phenotype often maintain normal intelligence(Kachur and Del Maestro 2000, 
Taccone et al. 1993, Vijay and Wraith 2005, Zafeiriou and Batzios 2013, Furukawa et al. 
2011, Ahmed et al. 2014).  However, even the patients with attenuated disease 
sometimes face serious neurological complications such as communicating 
hydrocephalus, as well as spinal cord compression secondary to GAG storage in the 
meninges.   
The currently available treatments for MPS I include bone marrow transplantation 
(BMT) and intravenous enzyme replacement therapy (ERT).  Both modalities exploit the 
observation that the mannose-6-phosphate receptor, which is responsible for sorting 
lysosomal proteins from the trans-Golgi, is also expressed at the cell surface, allowing 
for receptor-mediated uptake and lysosomal trafficking of IDUA infused intravenously or 
secreted from donor-derived leukocytes following BMT (Dahms, Lobel, and Kornfeld 
1989),(Kakkis et al. 1994).   While both ERT and BMT  have demonstrated efficacy 
against many of the somatic features of MPS I, only BMT is believed to alter the course 
of CNS disease, presumably through IDUA secretion by donor derived cells that migrate 
into the CNS(Aldenboven, Boelens, and de Koning 2008).  Despite the promise of this 
approach, BMT has been associated with engraftment rates as low as 50% and mortality 
rates in excess of 10% in MPS I patients(Aldenboven, Boelens, and de Koning 2008).  
Studies in the canine model of MPS I and small clinical trials have indicated that it may 
be possible to instead achieve IDUA delivery throughout the CNS using intrathecal 
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injection of the enzyme, which would allow for distribution via the cerebrospinal 
fluid(Chen et al. 2011, Dickson, Ellinwood, et al. 2010, Dickson, Naylor, Mlikotic, 
Victoroff, Chen, Passage, and Le 2008, Dickson et al. 2009, Dickson, Hanson, et al. 
2010, Dickson, Naylor, Mlikotic, Victoroff, Chen, Passage, Le, et al. 2008, Kakkis, 
McEntee, et al. 2004, Munoz-Rojas et al. 2008).  While intrathecal ERT provides 
important proof of principle for achieving enzyme distribution in CNS via the CSF, it does 
not represent a practical treatment approach due to the need to repeatedly access the 
CSF for enzyme delivery for the lifetime of the patient.  This leaves a significant unmet 
need for a safe and effective long-term treatment for the CNS manifestations of MPS I. 
 Gene therapy offers an attractive alternative to BMT and intrathecal ERT for 
targeting the CNS in MPS I.  Gene transfer to the brain using adeno-associated viral 
(AAV) vectors has been found safe in multiple human trials, and delivery of the 
therapeutic transgene to quiescent cells within the CNS could provide a permanent 
source of secreted enzyme, obviating the need to repeatedly access the CSF (Mandel 
and Burger 2004, McPhee et al. 2006, Mittermeyer et al. 2012, Kaplitt et al. 2007).  In 
murine MPS models, CNS-directed AAV gene transfer has demonstrated complete 
correction of tissue lesions and improvements in disease-specific behavioral phenotypes 
(Wolf et al. 2011, Haurigot et al. 2013).  The primary obstacle to this approach has been 
translation to large animal models.  Direct intra-parenchymal brain injection of AAV 
vectors results in transgene expression constrained to the area surrounding the injection 
site, with histological correction limited to the adjacent tissue (Vite et al. 2005).  Although 
studies in both canine and feline models of lysosomal enzyme deficiencies have shown 
that this limitation can be overcome using multiple vector injections, this strategy is not 
readily scalable to the human brain (Vite et al. 2005, Ciron et al. 2006). Further, intra-
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parenchymal injections have been shown to induce a local inflammatory response that 
can be accompanied by elimination of transduced cells (Ciron et al. 2006).   A potential 
alternative delivery approach has been highlighted by recent studies of intrathecal AAV 
delivery, which show that in dogs, cats and nonhuman primates, an AAV9 vector 
delivered into the CSF transduces glial and neuronal cells throughout the brain and 
spinal cord (Gray et al. 2013, Haurigot et al. 2013, Bucher et al. 2014a).  This potential 
to transduce cells across the neuraxis in a large animal via a single minimally invasive 
injection could radically transform the therapeutic potential of AAV-mediated gene 
therapy for CNS disease.  We hypothesized that this capacity of intrathecal AAV9 to 
effect such widespread CNS transduction, coupled with the ability of genetically 
corrected cells to secrete enzyme to cross-correct untransduced cells, would make this a 
highly effective approach for the long-term treatment of CNS manifestations of MPS I. 
 In the present study, we tested the capacity of intrathecal delivery of an AAV9 
vector to correct storage lesions throughout the CNS in a large animal model of MPS I.  
We selected the feline MPS I model for these experiments because the CNS lesions in 
these animals closely resemble those of MPS I patients, with accumulation of 
gangliosides in neurons and GAGs in the meninges and around cerebral blood 
vessels(Vite et al. 2011).  We found that intrathecal delivery of a vector bearing the 
normal feline IDUA sequence resulted in global CNS correction of the histological and 
biochemical features of MPS I.  IDUA-specific antibody responses were elicited in the 
CNS of most treated animals, but were not associated with adverse clinical sequelae or 
loss of efficacy.  Together these results strongly support the development of intrathecal 
AAV9-mediated gene delivery as a therapeutic approach for MPS I. 
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Materials and Methods 
Vector production: The feline IDUA sequence was isolated as described (Wang et al., 
manuscript in preparation).  A codon-optimized version of the cDNA was cloned into 
expression constructs flanked by AAV2 terminal repeats that contained the CMV or CB 
promoter, a chimeric intron, and an SV40 or rabbit globin polyadenylation sequence.  
The constructs were packaged in an AAV9 capsid by triple transfection of 293 cells and 
purified as previously described (Wang et al. 2011).  
Animal procedures:  The MPS I cat colony was maintained at the University of 
Pennsylvania School of Veterinary Medicine under NIH and USDA guidelines for the 
care and use of animals in research.  All protocols were approved by the Institutional 
Animal Care and Use Committee of the University of Pennsylvania.  Approximately 3 mL 
of blood was collected from the jugular vein for serum analysis. For intrathecal injections, 
propofol-anesthetized animals were intubated, and the suboccipital region was clipped of 
hair and scrubbed. Using sterile technique, a suboccipital puncture was performed with a 
22 gauge spinal needle.  Placement was confirmed by CSF return.  After collecting 1 -2 
mL of CSF, vector diluted in sterile PBS (1-2 mL) was slowly injected by hand.  The 
animals were monitored to confirm complete recovery after the procedure. Euthanasia 
was by an intravenous overdose of sodium barbiturate, 80 mg/kg. 
Enzyme assays: Tissue, serum, and CSF samples were immediately frozen on dry ice 
and stored at -80 degrees until analysis.  Serum and CSF were used directly in IDUA 
and Hexosaminidase (Hex) assays. Tissue samples were homogenized in lysis buffer 
(0.2 % Triton-X100, 0.9% NaCl, pH 4.0), and briefly sonicated. Samples were then 
freeze-thawed and clarified by centrifugation.  Protein concentrations were determined 
by Bradford assay.  IDUA activity was measured by incubating sample diluted in 0.1 mL 
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water with 0.1 mL of 100 mM 4MU-iduronide (Toronto Research Chemicals; Glycosynth) 
in IDUA buffer (0.15 M NaCl, 0.05% Triton-X100, 0.1 M sodium acetate, pH 3.58) at 37 
degrees for 1-3 hours.  The reaction was stopped by addition of 2 mL 290 mM glycine, 
180 mM sodium citrate, pH 10.9.  The liberated 4MU was quantified by comparing 
fluorescence to standard dilutions of 4MU.  Units are given as nmol 4MU liberated per 
hour per mg of protein (tissues) or per mL of serum or CSF.  Hex assays were 
performed as described(Wendeler and Sandhoff 2009). 
HCII-thrombin western blot: 0.5 µL of serum in 1x LDS buffer was separated on a 4-12% 
Bis-Tris polyacrylamide gel (Novex) in MOPS buffer at 120 V for 2 hours.  Protein was 
transferred to a PVDF membrane at 30 V for 1.5 hours.  The membrane was blocked for 
1 hour in 5% NFDM, and then incubated overnight at 4 degrees in 5% NFDM containing 
a 1:25,000 dilution of HRP-conjugated goat anti-HCII antibody (Enzyme Research). The 
blot was washed and developed with a chemiluminescent substrate (Thermo Scientific).  
GAG assay:  Tissue samples were processed as for enzyme assays.  Tissue GAGs 
were quantified using the Blyscan assay (Biocolor, Carrickfergus, UK) according to the 
manufacturer’s instructions.  
ELISA for detection of antibodies to feline IDUA: A C-terminal his-tag was added to the 
feline IDUA cDNA by PCR. The tagged cDNA was cloned into an expression cassette 
driven by a CB promoter. This plasmid was transfected into six 90% confluent 10 cm 
plates of HEK 293 cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA).  
Supernatant was collected twice at 24-hour intervals; each time the supernatant pH was 
immediately titrated to pH 5.8, which vastly increased enzyme stability, and stored at 4 
degrees. The enzyme was purified on a 1 mL HisTrap FF column (GE).  The eluted 
fractions were immediately adjusted to pH 5.8.  The fractions containing purified feline 
IDUA were identified by enzyme assay and SDS-PAGE.  The purified protein was 
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incubated at 3 µg/mL in PBS, pH 5.8 on polystyrene ELISA plates overnight at 4 
degrees.  The plates were washed twice in PBS, pH 5.8, blocked in 3% BSA, pH 5.8, 
and then incubated with diluted samples for one hour at room temperature. The plates 
were washed 5 times, incubated 1 hour with a 1:10,000 dilution of HRP-conjugated goat 
anti-feline IgG (Peirce, Rockford, IL) in blocking solution, washed 5 times, and 
developed using TMB substrate.  
Quantitative PCR: Quantification of vector genomes in tissue was performed as 
previously described (Wang et al. 2011).  
Histology: Brains were divided into left and right hemisphere. The right half was sliced 
and, except for the distal occipital part, fixed in paraformaldehyde to be further 
processed for GM3 and cholesterol detection. Slices from the left half were used for all 
other stains as well as for PCR analysis and enzyme assays.  For PCR and enzyme 
analysis samples were collected from the frontal, temporal and occipital cortices as well 
as medulla, hippocampus and cerebellum.  Hippocampus samples included the entire 
dissected hippocampus, spanning from CA1 to the DG. 
Hematoxylin and eosin staining (H&E): H&E staining was performed on 6 µm sections 
from formalin-fixed paraffin-embedded tissues according to standard protocols. 
GM3 immunohistochemistry: Brain slices were fixed overnight in 4% 
paraformaldehyde/PBS, equilibrated sequentially in 15% and 30% sucrose, and frozen 
in OCT embedding medium.  
Immunostaining was performed on 30 µm thick floating cryosections as described 
(McGlynn, Dobrenis, and Walkley 2004) using monoclonal antibody DH2 (Glycotech, 
Gaithersburg, MD) as primary antibody followed by a biotinylated secondary anti-mouse 
antibody (Jackson Immunoresearch, West Grove, PA) and detection with a Vectastain 
Elite ABC kit (Vector Labs, Burlingame, CA). Stained sections were transferred onto 
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glass slides and mounted with Fluoromount G (Electron Microscopy Sciences, Hatfield, 
PA). 
GAG histochemistry: Brain samples were fixed overnight in methacarn (60% methanol, 
30% chloroform, 10% glacial acetic acid) at 4ºC, dehydrated through an ethanol series 
and xylene, and paraffin embedded. Deparaffinized 6 µm sections were stained in 1% 
Alcian Blue (Sigma)/0.1 N HCl (pH1.0) for 15 min, rinsed in water for 2-3 min, and 
counterstained with Nuclear Fast Red (Vector Labs). 
Filipin stain: Cholesterol was detected on 30 µm thick cryosections prepared as 
described for GM3 immunohistochemistry. Floating sections were stained with filipin 
(Sigma, St Louis, MO, 10 µg/ml prepared from 3 mg/ml stock solution) for 1.5 h. After 
washing in PBS (2 x 5 min), sections were mounted with Fluoromount G. 
Immunofluorescence: Immunostaining was performed on 6 µm sections from formalin-
fixed paraffin-embedded tissue samples. Sections were deparaffinized through an 
ethanol and xylene series, boiled in a microwave for 6 min in 10mM citrate buffer (pH 
6.0) for antigen retrieval, and blocked with 1% donkey serum in PBS + 0.2% Triton for 15 
min followed by sequential incubation with primary (1 h) and labeled secondary (45 min) 
antibodies diluted in blocking buffer. Primary antibodies used were rabbit antibodies 
against GFAP (Abcam, Cambridge, UK, 1:1000) and LIMP2 (Novus Biologicals, Littleton, 
CO, 1:200), and FITC- or TRITC-labeled donkey anti-rabbit (Jackson Immunoresearch) 
served as secondary antibody.  
Morphometric analyses: Images taken for quantification purposes were acquired using 
either a 4x (GM3), 10x (filipin), or 20x objective (GFAP,LIMP2, H&E) depending on the 
lowest magnification that still allowed accurate visualization of neurons or astrocytes. 
Images for GFAP and LIMP2 were taken from the area directly below the cerebral cortex 
surface and include the cerebral molecular layer; all other images were centered on the 
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middle to upper neuron layers of the cortex. The images shown for LIMP2, filipin and 
H&E stained sections correspond to the region depicted in the second column of Figure 
4.  Five images from each brain were taken for analyzing storage in H&E sections as 
well as GM3 and filipin staining which showed low variation between different brain 
parts, while a total of 20 images (10 each from two different sections) were acquired for 
GFAP and LIMP2 analyses. For quantification of GM3 and filipin positive neurons, 
ImageJ software (Rasband W. S., National Institutes of Health, USA; 
http://rsb.info.nih.gov/ij/) was used to first threshold images, i.e. to mark positively 
stained cells, and then to count the number of these cells with the “Analyze Particles” 
tool of ImageJ.  GFAP and LIMP2 positive cells as well as storage-positive H&E-stained 
neurons were counted manually. 
Results 
Intrathecal AAV9 delivery induced robust IDUA expression in CSF and serum 
 Eight MPS I cats between four and seven months of age were included in this 
study (Table 3-1).  These animals carried a three base pair deletion in the IDUA gene, 
resulting in omission of a single aspartate residue (He et al. 1999).  Three cats 
heterozygous for the IDUA mutation and two wild type animals from the same colony 
served as unaffected controls.  Five of the affected animals at ages 4 to 7 months were 
treated with a single intrathecal injection via the cisterna magna of 1012 GC/kg of an 
AAV9 vector bearing a codon-optimized normal feline IDUA sequence.  The vector 
administered to two of the cats carried a chicken beta actin (CB) promoter; the other 
three treated animals received a vector carrying a cytomegalovirus (CMV) promoter.  
One additional animal assigned to receive the CB vector died under anesthesia during 
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the pre-treatment CSF collection.  There were no other adverse events throughout the 
study period. 
 Serum and CSF were serially collected from the treated and naïve animals and 
assayed for IDUA enzyme activity (Fig. 3-1).  IDUA activity was not detected in samples 
from untreated MPS I cats. Treated animals exhibited a rapid elevation in both CSF and 
serum IDUA activity following vector injection, with peak activity exceeding that 
measured in normal cats. The CB promoter appeared to be more active, inducing higher 
enzyme levels in both CSF and serum.  Following a peak at 21 days post injection, CSF 
enzyme levels rapidly declined to near baseline in two animals, although activity 
remained detectable at most time points.  CSF IDUA activity stabilized at approximately 
normal levels in the other three cats.  Serum activity varied between the normal range 
and baseline values, although high background in the serum assay precluded accurate 
assessment of low levels of circulating enzyme. 
Heterogeneous antibody responses were elicited against the therapeutic enzyme 
 The sharp decline in IDUA activity in some of the treated animals did not appear 
to be consistent with a cellular immune response against the transduced cells, as 
residual expression was detectable and there were no clinical signs of meningitis or 
encephalitis.  CSF analysis revealed normal nucleated cell counts and only mildly 
elevated protein, which was also observed in untreated MPS I cats (Table 3-2).  We 
suspected that this decline in CSF enzyme could be due to the induction of antibodies 
against IDUA.  Indirect ELISA using purified feline IDUA as a target for capture of 
antibodies showed clear antibody responses in the CSF of some of the treated animals 
(Fig. 3-2a).  Within the CMV vector treated group, CSF IDUA activity decreased in 
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proportion to antibody titer, with animal 8982 having the highest titer corresponding to 
nearly undetectable CSF enzyme levels.  The same was true for the animals treated with 
the CB vector; animal 9050 exhibited elevated antibody titers and very low CSF IDUA 
activity whereas 9058 maintained normal CSF IDUA and did not have a detectable 
antibody response.  The correlation was not as clear between the groups treated with 
the different vectors, as the CB vector-treated animals appeared to have lower steady 
state CSF antibody titers overall.  Considering that these animals also had higher initial 
enzyme expression, it is likely that the additional antigen either sequestered antibody or 
interfered with ELISA-based detection, resulting in lower overall titer measurements in 
this group. In summary there was a correlation between CSF IDUA antibody and steady 
state level of CSF IDUA for all animals except 8911, which developed moderate levels of 
CSF antibodies but retained high levels of steady state CSF enzyme.  
Normalization of CSF hexosaminidase (Hex) activity despite antibody induction to the 
therapeutic enzyme 
 IDUA deficiency has been shown to induce secondary elevation of activity of 
other lysosomal glycohydrolases.  We found that elevated activity of one such enzyme, 
beta hexosamindase, was detectable in the CSF of MPS I cats (Fig. 3-2b).  This 
elevated Hex activity in CSF provided a potential non-invasive biomarker to detect 
aberrant cellular regulation in the CNS of MPS I cats.  Following vector delivery, we 
observed an approximately 2-fold decrease in CSF Hex activity in all treated animals.  
Animals receiving the CB vector, which induced higher initial expression, exhibited the 
most rapid normalization of CSF Hex.  Only one animal (8982), which had high anti-
IDUA titers and very low CSF IDUA activity, exhibited incomplete normalization of CSF 
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Hex.  This demonstrated that all treated animals, even those that lost nearly all CSF 
enzyme activity, exhibited a persistent biochemical response to gene transfer. 
Intrathecal AAV9 delivery resulted in global CNS transduction and normalization of 
tissue Hex activity 
 All treated animals were euthanized between 160 and 170 days following vector 
delivery.  We performed quantitative PCR analysis on DNA from tissue samples, which 
revealed substantial vector deposition throughout the brain and spinal cord (Fig. 3-3a).  
There were no differences in copy number in samples from animals with very low CSF 
IDUA levels, further confirming that elimination of transduced cells played no role in the 
decrease in circulating activity.  Vector bio-distribution to peripheral organs was limited, 
except to the liver, which contained very high vector copy numbers.  All subsequent 
analyses of transduction activity and biochemical and pathological correction are 
presented in subgroups of cats with high (8911, 8932 and 9058) or low (8982 and 9050) 
CSF IDUA.  
IDUA activity was measured in tissue samples collected from various regions of 
the brain and spinal cord (Fig. 3-3b).  Activity was undetectable in untreated MPS I cats.  
All treated animals exhibited elevated tissue IDUA activity, exceeding that of 
heterozygous control animals in several brain regions.  Tissue IDUA was lower in many 
regions of the CNS in the animals with the lowest CSF enzyme activity, although in all 
cases it was greater than that found in untreated MPS I cats. To evaluate tissue 
correction of the MPS I phenotype in the CNS, Hex activity was measured in CNS tissue 
lysates (Fig. 3-3c).  Similar to observations in the CSF, untreated animals had 
significantly elevated tissue Hex activity, which was normalized in all brain regions of 
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treated animals, including sites with very low IDUA activity.  This indicates an extremely 
low threshold for the expressed enzyme to effect changes in the abnormal cellular 
processes associated with MPS I in the CNS.  We also attempted to quantify total GAG 
concentrations in the brain, but we found that the dimethylmethylene blue assay used for 
these measurements exhibited high background in brain tissue and thus could not 
reliably distinguish between normal and MPS I cats. 
IDUA reconstitution reverses lysosomal storage lesions throughout the CNS 
 The CNS manifestations of MPS I are characterized histologically by intracellular 
accumulation of cholesterol and the gangliosides GM2 and GM3 in the brain 
parenchyma, with storage of GAGs prominent in the meninges and surrounding the 
cerebral vasculature (Vite et al. 2011, McGlynn, Dobrenis, and Walkley 2004).  
Untreated MPS I cats exhibited marked GM3 staining throughout multiple brain sections, 
which was absent in normal controls (Fig. 3-4, Table 3-3).  In treated animals, GM3 
storage was cleared throughout all brain regions analyzed, although scattered cells 
showing residual GM3 staining were visible in the animals with the lowest CSF enzyme 
activity.  The reduction in GM3 staining correlated with a reduced frequency of abnormal 
neurons exhibiting distended cytoplasm visible on histopathology; while these were 
frequently observed in the cortex of untreated cats, they were absent in treated animals 
with high CSF IDUA activity, and rare in treated animals with lower CSF enzyme (Fig. 3-
5, Table 3-3).  Filipin staining for cholesterol revealed a similar pattern of correction, with 
an average of 239 +/- 60 positive cells per field in untreated animals, which was reduced 
to an average of 2 positive cells per field in animals with high CSF IDUA activity and 38 
and 52 cells per field in treated animals with low CSF IDUA activity (Fig. 3-5, Table 3-3).  
We also stained for LIMP2, a lysosomal integral membrane protein, which has been 
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shown to accumulate in neurons in murine models of MPS (Haurigot et al. 2013).  This 
marker also showed considerable lysosomal storage in the brains of MPS I cats that was 
almost completely normalized following intrathecal vector administration in all treated 
animals (Fig. 3-5, Table 3-3).  
 To evaluate correction of storage pathology in the meninges and perivascular 
spaces, Alcian blue staining for GAGs was performed on cortical tissue sections (Fig. 3-
6). The untreated animals exhibited significant GAG accumulation in the thickened 
meninges, as well as in perivascular cells.  This GAG storage was almost completely 
reversed in all treated animals. 
Intrathecal AAV9 delivery corrects somatic lesions 
 It has previously been reported that AAV9 delivery into the CSF in a murine MPS 
model results in both CNS and peripheral organ transduction, with corresponding 
correction of peripheral pathology (Haurigot et al. 2013, Gray et al. 2013).  It has also 
been demonstrated that this distribution of vector to the periphery occurred after 
intrathecal administration in primates and dogs, an observation confirmed by our PCR 
analysis in the present study 29,(Gray et al. 2013).  Given the distribution of vector to the 
periphery and significant serum IDUA activity, we evaluated somatic tissues for evidence 
of disease correction.  Quantitative analysis of GAGs in liver and spleen showed 
normalization in the liver of all treated animals, whereas splenic GAG storage was 
corrected in animals which exhibited the lowest antibody titers in their treatment groups 
(8911, 8932, 9058) but not in those that had the highest antibody titers within their 
treatment group and had reduced CSF enzyme activity (Fig. 3-8).  This is consistent with 
IDUA being expressed primarily from the heavily transduced liver, with cross correction 
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of distant organs such as the spleen occurring only in the absence of an interfering 
antibody response.  Histological evaluation of GAG storage by Alcian blue stain 
confirmed correction in the liver and spleen, as well as improvement in the heart and 
lungs, which was more pronounced in the animals with lower antibody titers (Fig. 3-7).  
The kidney appeared to have significant GAG storage that did not respond as readily to 
treatment. 
Serum levels of the covalent complex formed by thrombin and the protease 
inhibitor heparin cofactor II (HCII) have been proposed as a biomarker in MPS I, as 
formation of this complex is catalyzed by GAGs such as dermatan sulfate (Langford-
Smith et al. 2011, Randall et al. 2008). We saw reductions in serum HCII-thrombin in all 
treated animals, consistent with reduction in peripheral GAGs (Fig. 3-9). The response 
appeared less robust in the two animals with high residual spleen GAGs.  
Intrathecal AAV9 does not induce an inflammatory response in the CNS 
 One report has suggested that intrathecal AAV9 delivery can result in a robust 
inflammatory response and cellular infiltration (Samaranch, San Sebastian, et al. 2013).  
We evaluated hematoxylin and eosin stained tissue sections from cerebrum and 
cerebellum for evidence of cellular infiltrates (Fig. 3-10). We also immunostained tissue 
sections for GFAP, an astrocyte intermediate filament protein that is highly upregulated 
in the context of inflammation (Fig. 3-11, Table 3-3).  We observed no evidence of 
cellular infiltration or astrocyte activation in any of the treated animals based on standard 
histopathology or GFAP staining. 
58 
 
Discussion 
The goal of this study was to evaluate the feasibility of intrathecal gene therapy 
for treating CNS manifestations of MPS I in an authentic large animal model as a 
necessary step toward human trials.  A previously described feline model of MPS I was 
further characterized for biochemical and histological abnormalities as a prelude to an 
evaluation of gene transfer.  Our study demonstrated diffuse CNS pathology in this 
model, including neuronal storage lesions staining strongly for gangliosides and 
cholesterol as well as pronounced meningeal and perivascular GAG storage, consistent 
with previous reports (Vite et al. 2011).  We also found accumulation of the lysomomal 
membrane protein LIMP2 and elevation of hexosaminidase activity in the brains of MPS 
I cats, as has been observed in other species (Haurigot et al. 2013).  We found that a 
single intrathecal administration of AAV9 expressing normal feline IDUA resulted in 
virtually complete correction of the histological and biochemical features of MPS I in the 
CNS.  We could not directly assess the clinical consequences of treatment because 
MPS I cats do not have a well-defined neurological phenotype, although mouse studies 
suggest that correction of CNS storage pathology correlates with normalization of 
cognitive deficits(Wolf et al. 2011). 
Intrathecal AAV9 delivery could potentially be applied to many lysosomal storage 
diseases affecting the CNS. However, MPS I may represent a particularly tractable 
target due to the extremely low levels of enzyme required to correct lysosomal storage.  
In vitro studies have shown that IDUA concentrations below 1 pM can reduce GAG 
accumulation in MPS I patient fibroblasts, which would predict extremely efficient cross 
correction of untransduced cells by enzyme secreted from even a small number of 
genetically modified cells (Kakkis et al. 1994).  MPS I is also an important target due to 
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the substantial CNS morbidity in this disease and the limited efficacy and availability of 
treatment options.  BMT is currently the only therapeutic option with the potential to 
modify the course of cognitive decline in patients with a severe phenotype, but this 
comes with high morbidity and mortality.  Other CNS manifestations such as 
communicating hydrocephalus and spinal cord compression also cause debilitating 
symptoms and necessitate surgical interventions such as ventriculoperitoneal shunting 
or spinal laminectomy (Kachur and Del Maestro 2000, Vijay and Wraith 2005, Taccone 
et al. 1993, Ahmed et al. 2014, Furukawa et al. 2011, Zafeiriou and Batzios 2013). Our 
results demonstrate that intrathecal AAV9 administration can reverse storage lesions in 
both the brain parenchyma and the surrounding meninges, indicating the potential to 
benefit patients with a variety of CNS sequelae of MPS I.  In addition to the unmet 
clinical need in MPS I and strong preclinical data, this disease presents some practical 
benefits as a target for human trials.  The ability to measure enzyme activity in the CSF 
would allow for direct confirmation of transgene expression, and a variety of potential 
biomarkers could be useful for assessing biological activity.   In this study we found that 
CSF hexosaminidase activity was elevated in MPS I animals and was normalized in 
proportion to histological CNS correction, making this a strong candidate for a biomarker 
in human trials.  Longitudinal evaluation of the MRI findings typical of MPS I— enhanced 
white matter signal intensity, enlarged perivascular spaces and meningeal thickening—
could also provide useful correlates of therapeutic activity (Zafeiriou and Batzios 2013).  
We found that a variable antibody response against normal feline IDUA was 
elicited by intrathecal AAV9-mediated expression. This might be expected, given that 
nearly all MPS I patients develop antibodies against the enzyme during the course of 
ERT.  The heterogeneity of clinical responses and high prevalence of antibodies make it 
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difficult to discern a clear effect of antibodies on therapeutic outcomes in humans, but 
studies in MPS I dogs indicate that tissue correction from systemic ERT is significantly 
reduced by high antibody titers (Dickson, Peinovich, et al. 2008).  A study examining the 
effect of antibody titer on the efficacy of intrathecal ERT in canine MPS I likewise 
showed that antibodies reduce treatment efficacy in the CNS (Dickson et al. 2012). Our 
results suggest that while anti-IDUA antibodies impact the efficiency of tissue correction, 
cross correction of untransduced cells remains reasonably effective in the setting of an 
antibody response. Some degree of residual efficacy after antibody induction against 
IDUA could also be explained by intracellular enzyme production alone; however, a 
previous study demonstrated that intracisternal AAV9 delivery at the dose tested 
transduces only a small fraction of cells in the feline brain, suggesting that widespread 
reversal of storage lesions is due to cross-correction.  Most critically, development of an 
antibody response against IDUA in the CSF was not associated with adverse clinical 
events or histological evidence of inflammation.  Together these data strongly support 
the safety and efficacy of this approach, even with the risk of developing antibodies 
against the therapeutic enzyme.  Given the correlation we observed between antibody 
titer and histological evidence of efficacy, measuring CSF antibody titers may be 
informative for predicting clinical outcomes in human trials.  Long-term follow up of 
patients treated with systemic ERT has shown that antibody titers fall to baseline levels 
in most patients within two years of treatment initiation, suggesting that a similar decline 
in titer may be seen in the context of gene therapy, which would further support the 
potential for robust long-term clinical benefit(Kakavanos et al. 2003).  Long-term 
evaluation of AAV9 intrathecal gene therapy in feline MPS I is currently underway. 
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Here, we have demonstrated proof-of-principle that intrathecal AAV9 delivery can 
globally correct CNS manifestations of MPS I in a high-fidelity large animal model, even 
when antibodies are elicited against the therapeutic enzyme.  The excellent tolerability 
and efficacy of this approach support progression into human trials for MPS I.  These 
promising results also suggest that this approach may serve as a broad platform for the 
treatment of other lysosomal storage diseases affecting the CNS. 
 
Figure 3-1. IDUA expression in CSF and serum following IT AAV9 delivery 
Five MPS I cats were treated with an intracisternal injection of an AAV9 vector (10
12
 
GC/kg) expressing feline IDUA  from a CB (gray symbols) or CMV (black symbols) 
promoter.  CSF and serum were serially collected from the treated animals as well as 
three untreated MPS I cats.  IDUA activity was measured using the fluorogenic substrate 
4MU-iduronide in CSF (a) and serum (b).  All values are the mean of duplicate assays. 
Normal serum and CSF activity (dashed line) are the mean values from two wild type 
animals. 
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Figure 3-2. Normalization of CSF hexosaminidase activity despite a transgene-specific 
antibody response 
CSF samples collected before vector administration and at the end of the study were 
tested for the presence of antibodies against IDUA by indirect ELISA (a). Titers are 
based on a standard curve of a serially diluted positive sample, which was arbitrarily 
assigned a titer of 1:1000.  (b) Total Hex activity was measured in CSF using the 
fluorogenic substrate MUG. Normal activity (dashed line) is the mean of two 
heterozygous control samples. The untreated MPS I level (dotted line) is the mean of 
untreated controls. 
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Figure 3-3. Global CNS transduction and biochemical correction following IT gene 
transfer 
Vector genomes were quantified in DNA extracted from CNS and peripheral tissues of 
treated cats by TaqMan PCR (a). Tissue samples from MPS I cats and heterozygous 
controls were collected from sites throughout the CNS for measurement of IDUA activity 
(b) and Hex activity (c). Treated animals are stratified into those with normal CSF IDUA 
activity (8911, 8932, 9058) and those with low CSF activity (8982, 9050).  All enzyme 
activities are normalized to protein concentration. 
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Figure 3-4.  Reversal of brain ganglioside storage 
Immunostaining for the ganglioside GM3 was performed on tissue sections from four 
brain regions in untreated MPS I cats (a-d), treated cats with high CSF IDUA activity (E-
H) and low CSF activity (i-l), as well as normal controls (m-p). Scale bar = 500 µM. 
66 
 
 
Figure 3-5. Correction of neuronal storage lesions 
Sections from the cerebral cortex were stained with H&E (a, f, k, p). Arrows indicate the 
distended neuron cell bodies typical of MPS I. The treated cats were stratified into those 
with low CSF IDUA activity and those with high activity. Cholesterol accumulation was 
evaluated in matched brain sections by filipin staining in untreated (b,c), treated (g, h, l, 
m) and normal control (q, r) cats. Immunostaining for the lysosomal integral membrane 
protein LIMP2 was performed on corresponding sections from each animal (d, e, i, j, n, 
o, s, t). Scale bar = 500 µM (4x),  200 µM (10x) or 100 µM (H&E).  
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Figure 3-6. Reduced GAG storage in the cerebral vasculature and meninges 
Cortical brain sections were stained for GAGs using alcian blue.  Low magnification 
images (a,d, g, j) show the cerebral cortex with the associated meninges. High 
magnification images show representative cortical blood vessels (b, e, h, k) and 
segments of meninges (c, f, i, l). Scale bars = 500 µM (left column) and 100 µM (middle 
and right columns). 
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Figure 3-7. Correction of somatic lesions 
Sections from heart, lung, liver, spleen and kidney were stained with Alcian blue. 
Animals are stratified according to antibody response and circulating enzyme activity as 
in Figure 6. Scale bar = 100 µM. 
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Figure 3-8. Peripheral GAG clearance following intrathecal AAV9 delivery  
GAG content of liver and spleen lysates was measured by dimethylmethylene blue 
binding assay. Animals are stratified into those that had the highest antibody titers and 
the lowest circulating CSF enzyme in their treatment group (9050, 8982) and those that 
exhibited more stable expression (8911, 8932, 9058). Values are normalized to sample 
protein concentration. 
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Figure 3-9. Reduced serum heparin cofactor II-thrombin complex concentration 
following intrathecal gene therapy  
Serum concentrations of the heparin cofactor II-thrombin complex were assessed by 
western blot, using a polyclonal anti-human HCII antibody for detection. Lane 1-3: 
heterozygous controls, lane 4-6: untreated controls, lane 7: 8911, lane 8: 8932, lane 9: 
8982, lane 10: 9050, lane 11: 9058. 
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Figure 3-10. Absence of inflammation or cellular infiltration in treated animals 
Tissue sections from cerebrum (A-H) and cerebellum (I-P) were stained with H&E.  
Images depict representative segments of meninges and blood vessels. Scale bar = 50 
µM. 
 
72 
 
 
Figure 3-11. Absence of astrocyte activation in treated animals 
Tissue sections from cerebral cortex were stained with an anti-GFAP antibody. Scale 
bars = 500 µM (low magnification) and 100 µM (high magnification). 
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Table 3-1. Summary of study subjects 
Animal 
# 
Genotype Treatment Dose 
Weight at 
injection 
Sex 
Age at study 
end 
9110 
WT Untreated 
- - M 7 months 
9115 
WT Untreated 
- - F 7 months 
7704 
MPS I Het Untreated 
- - F 58 months 
8991 
MPS I Het Untreated 
- - F 6 months 
8992 
MPS I Het Untreated 
- - F 6 months 
8922 
MPS I Untreated 
- - F 13 months 
9052 
MPS I Untreated 
- - F 10 months 
9055 
MPS I Untreated 
- - M 10 months 
8911 
MPS I 
AAV9-CMV-
fIDUA 
10
12
 
GC/kg 
2.43 kg F 13 months 
8932 
MPS I 
AAV9-CMV-
fIDUA 
10
12
 
GC/kg 
2.89 kg M 12 months 
8982 
MPS I 
AAV9-CMV-
fIDUA 
10
12
 
GC/kg 
1.83 kg F 10 months 
9050 
MPS I 
AAV9-CB-fIDUA 
10
12
 
GC/kg 
1.14 kg F 10 months 
9058 
MPS I 
AAV9-CB-fIDUA 10
12
 
GC/kg 
1.35 kg F 10 months 
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Table 3-2. CSF analysis in treated and control MPS I cats 
  Nucleated Cells/µlA Total Protein (mg/dL)B 
Animal 
ID 
Treatment Day 21 51 77 101-7 21 51 77 101-7 
8911 AAV9.CMV.fIDUA 0 1 ND 2 <25 <25 ND <25 
8932 AAV9.CMV.fIDUA 1 0 ND 1 <25 26 ND 29 
8982 AAV9.CMV.fIDUA 1 1 ND 1 <25 <25 ND 33 
9050 AAV9.CB7.fIDUA ND 1 1 1 ND 29 <25 26 
9058 AAV9.CB7.fIDUA ND 0 1 3 ND 30 29 25 
8922 Untreated 0 1 ND 1 <25 <25 ND 27 
9052 Untreated ND 0 0 1 ND <25 <25 <25 
9055 Untreated ND 0 1 1 ND 26 28 41 
A. Normal range ≤ 2 cells / µl 
B. Normal range ≤ 25 mg/dL 
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Table 3-3. Quantification of histopathology and GM3, LIMP2, filipin and GFAP 
positive cells per field in matched brain sectionsA 
Animal ID Treatment Genotype GM3 H&EB LIMP2 Filipin GFAP 
9110 Untreated WT 2.6 ± 1.9 
0.4 ± 0.5 
0.2 ± 0.4 3.5 ± 2 17.7 ± 8.1 
9115 Untreated WT 8.4 ± 7.3 
0.8 ± 0.8 
0.2 ± 0.4 3.8 ± 2.4 11.1 ± 8.2 
7704 Untreated MPS I Het 0.2 ± 0.45 
0.2 ± 0.4 
13.4 ± 3.2 0 ± 0 19.3 ± 7.4 
8992 Untreated MPS I Het 0.8 ± 0.84 
0.2 ± 0.4 
6.1 ± 3.8 0 ± 0 20.7 ± 6.6 
8991 Untreated MPS I Het 7.2 ± 6.0 
0.6 ± 0.9 
14.1 ± 4.5 0 ± 0 11.9 ± 2.9 
8922 Untreated MPS I 
380.4 ± 
88.8 
9.4 ± 3.6 
85.2 ± 6.2 
274.6 ± 
54.7 
29.4 ±5.7 
9052 Untreated MPS I 
239 ± 
89.13 
8.2 ± 2.4 
75.8 ± 7.9 
271.8 ± 
82.9 
28.8 ± 
12.6 
9055 Untreated MPS I 
272.2 ± 
66.2 
5.4 ± 4.7 
80 ± 7.6 
169.2 ± 
23.4 
25 ± 7.1 
8911 
AAV9.CM
V.fIDUA 
MPS I 7.2 ± 3.83 
0.6 ± 0.9 
16.3 ± 5.5 5.2 ± 4.3 18.6 ± 6.8 
8932 
AAV9.CM
V.fIDUA 
MPS I 8 ± 6.48 
0.6 ± 0.5 
11.4 ± 6.7 0.6 ± 1.3 23.3 ± 6.9 
8982 
AAV9.CM
V.fIDUA 
MPS I 
46.8 ± 
10.75 
1 ± 1 34.7 ± 
21.7 
52 ± 12.4 25.1 ± 5.8 
9050 
AAV9.CB.f
IDUA 
MPS I 
24 ± 
15.95 
1.8 ±  0.8 
9.2 ± 6.7 38 ± 26.5 16.4 ± 5.9 
9058 
AAV9.CB.f
IDUA 
MPS I 14 ± 5.43 
0.4 ± 0.5 
2.6 ± 1.2 0 ± 0 17.1 ± 7.1 
 
A. Cells staining positive for the indicated marker were quantified in 5 fields (GM3, Filipin, H&E) 
or 20 fields (LIMP2 and GFAP) from matched brain regions. Quantification is per 20x field for 
GFAP, LIMP2, and H&E, 10x field for filipin, and 4x field for GM3. 
B. Indicates number of cells exhibiting distended, asymmetric pale cytoplasm characteristic of 
neuronal storage  
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CHAPTER 4: Neonatal systemic AAV induces tolerance to CNS 
gene therapy in MPS I dogs and nonhuman primates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 is adapted from: C. Hinderer, P. Bell, J. P. Louboutin, Y. Zhu, H. Yu, G. Lin, R. 
Choa, B. L. Gurda, J. Bagel, P. O'Donnell, T. Sikora, T. Ruane, P. Wang, A. F. Tarantal, 
M. L. Casal, M. E. Haskins, J. M. Wilson. Molecular therapy (2015). 
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Abstract 
The potential host immune response to a non-self protein poses a fundamental 
challenge for gene therapies targeting recessive diseases. We demonstrate in both dogs 
and nonhuman primates that liver directed gene transfer using an adeno-associated 
virus (AAV) vector in neonates induces a persistent state of immunological tolerance to 
the transgene, substantially improving the efficacy of subsequent vector administration 
targeting the central nervous system (CNS). We applied this approach to a canine model 
of mucopolysaccharidosis type I (MPS I), a progressive neuropathic lysosomal storage 
disease caused by deficient activity of the enzyme α-l-iduronidase (IDUA). MPS I dogs 
treated systemically in the first week of life with a vector expressing canine IDUA did not 
develop antibodies against the enzyme and exhibited robust expression in the CNS 
upon intrathecal AAV delivery at one month of age, resulting in complete correction of 
brain storage lesions. Newborn rhesus monkeys treated systemically with AAV vector 
expressing human IDUA developed tolerance to the transgene, resulting in high CSF 
IDUA expression and no antibody induction after subsequent CNS gene therapy. These 
findings suggest that inducing tolerance to the transgene during a critical period in 
immunological development will improve the efficacy and safety of gene therapy. 
Introduction 
The lysosomal storage diseases (LSDs) are a broad class of inherited disorders 
caused by deficient activity of enzymes involved in the lysosomal catabolism of 
ubiquitous polysaccharides, glycoproteins, and lipids, leading to intracellular 
accumulation of these undegraded enzyme substrates and multi-organ pathology. LSDs 
are excellent targets for gene therapy because many of the associated lysosomal 
enzymes can be secreted by genetically corrected cells and endocytosed by neighboring 
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cells, allowing for widespread cross-correction even with modest gene transfer efficiency 
(Dahms, Lobel, and Kornfeld 1989, Sando and Neufeld 1977). Gene therapy may play a 
particularly important role in treating the central nervous system (CNS) manifestations 
associated with LSDs, because the CNS cannot be effectively targeted by intravenous 
(IV) delivery of the deficient enzymes, and chronic direct CNS administration is 
impractical as a long-term therapy. One LSD in which gene therapy has shown particular 
promise for treating CNS disease is mucopolysaccharidosis type I (MPS I), which is 
caused by deficient activity of the lysosomal enzyme α-l-iduronidase (IDUA). Currently, 
the only treatment capable of curbing the severe cognitive decline experienced by many 
MPS I patients is hematopoietic stem cell transplantation, which is associated with 
substantial morbidity and mortality (Aldenboven, Boelens, and de Koning 2008, Boelens 
et al. 2007, Clarke et al. 2009, Langford-Smith et al. 2011, Sifuentes et al. 2007, Souillet 
et al. 2003, Whitley et al. 1993). Using a naturally occurring cat model of MPS I, we 
found that a minimally invasive intrathecal injection of an AAV serotype 9 vector into the 
cerebrospinal fluid (CSF) achieved widespread gene transfer in the brain and sufficient 
secretion of the therapeutic enzyme into the CSF to correct storage pathology 
throughout the CNS (Hinderer, Bell, et al. 2014a). Intrathecal AAV delivery could, 
therefore, represent a vast improvement over the current standard of care for CNS 
disease in MPS I patients. 
Despite the promise of intrathecal AAV delivery for MPS I, we found that the 
efficacy of gene transfer was diminished in some MPS I cats due to development of 
antibodies to IDUA, resulting in reduced circulating enzyme in the CSF and less efficient 
correction of storage lesions.  Here we report that MPS I dogs, another naturally 
occurring disease model, also develop antibodies to the normal canine enzyme following 
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intrathecal gene therapy leading to less efficient correction of brain lesions. These 
findings reflect the clinical experience with enzyme replacement therapy in MPS I, as 
patients treated with recombinant IDUA almost universally develop antibodies to the 
enzyme, which correlate with a poor response to therapy (Wraith et al. 2007, Langereis 
et al. 2014).  
With the goal of developing a safe and effective method for the prevention of 
anti-transgene immune responses, we explored the possibility of exploiting the normal 
processes by which the immune system learns to distinguish self from non-self. Decades 
of evidence from transplantation studies suggest that neonatal rodents and humans, 
unlike adults, are prone to develop tolerance rather than immunity to alloantigens (Fan et 
al. 2004, McCarthy and Bach 1983, Billingham, Brent, and Medawar 1953). While this 
phenomenon has often been ascribed to an immature and poorly functional immune 
system, it has since become clear that neonates are indeed capable of eliciting 
functional immune responses, albeit with higher activation thresholds (Adkins 1999). The 
development of tolerance to neoantigens in newborns is instead an active process 
involving peripheral anergy and deletion of reactive T and B cells, as well as induction of 
regulatory T cells (Fan et al. 2004, McCarthy and Bach 1983, Wang et al. 2010). One 
recent report demonstrated that this phenomenon could be exploited to induce durable 
tolerance to factor VIII in hemophilic mice by performing gene transfer in neonates (Hu 
et al. 2011). While this effect in mice could be attributed to the relative immaturity of the 
murine immune system at birth, evidence for neonatal tolerance to a foreign transgene 
has also emerged in studies using retroviral vectors in newborn dogs (Traas et al. 2007, 
Xu et al. 2007). These experiments demonstrated sustained expression of relatively 
immunogenic transgenes after neonatal retroviral vector administration, although the 
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ineffectiveness of these vectors in adults precluded direct comparison of immune 
responses to the transgene in animals of different ages.   
In this study, we evaluated the potential for neonatal AAV-mediated systemic 
expression of a therapeutic protein to induce immunological tolerance that could 
subsequently allow for safe and effective CNS directed gene therapy. We found that 
MPS I dogs treated intravenously in the first week of life with an AAV vector expressing 
canine IDUA from a liver specific promoter did not develop antibodies to the transgene, 
and following subsequent intrathecal gene transfer at one month of age exhibited 3- to 
100-fold higher IDUA levels in CSF than naïve dogs, with complete resolution of brain 
storage lesions. Likewise, rhesus monkeys administered liver-directed human IDUA 
gene transfer at birth exhibited tolerance to the protein, allowing for robust CSF IDUA 
expression without antibody induction after intrathecal AAV injection one month later.  
These findings suggest a potential approach to prevent immune responses to a non-self 
transgene through neonatal gene transfer, which could significantly improve the efficacy 
of gene therapy for many recessive diseases. 
Materials and Methods 
Vector production 
The AAV8 vectors contained codon optimized canine or human IDUA cDNA downstream 
of the thyroid hormone binding globulin promoter. The AAV9 vector contained the 
chicken beta actin promoter with a cytomegalovirus immediate early enhancer. Both 
vectors included the rabbit beta-globin polyadenylation sequence. Vectors were 
produced by triple transfection of 293 cells and purified on iodixanol gradients as 
previously described (Wang et al. 2011). 
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MPS I dogs 
The MPS I dog colony was maintained at the University Of Pennsylvania School Of 
Veterinary Medicine under NIH and USDA guidelines for the care and use of animals in 
research. All MPS I dog study protocols were approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee. For vector injections in 
neonatal MPS I dogs, the AAV8 vector was diluted in 0.5-1 mL of sterile saline, and 
injected via the jugular vein. Intrathecal injections of AAV9 vectors and CSF collection 
were performed via the suboccipital approach as previously described (Hinderer, Bell, et 
al. 2014a). A total of 9 MPS I dogs were included in this study. Genotype was confirmed 
at birth by PCR and serum enzyme assay. Six dogs were administered an IV injection of 
the AAV serotype 8 vector (5 x 1012 genome copies per kilogram [GC/kg] body weight) 
on either the first (N=3) or seventh (N=3) day of life. One animal died on postnatal day 3. 
The remaining 5 treated animals as well as 3 naïve MPS I dogs were treated with 
intrathecal AAV9 (1012 GC/kg) at one month of age. Blood was collected from a 
peripheral vessel weekly for the first seven weeks of life then monthly thereafter. CSF (1 
mL) was collected at the time of intrathecal vector injection (one month of age), on days 
7 and 21 after injection, and monthly thereafter. Euthanasia was performed by 
administration of sodium pentobarbital (80 mg/kg IV). Five animals (I-549, I-550, I-552, I-
553, I-554) were euthanized at 9 months of age; 3 (I-562, I-563, I-564) were euthanized 
at 11 months of age. Untreated MPS I and controls were euthanized between 6 and 26 
months of age (Table 1). Tissues were collected and processed as previously described 
(Hinderer, Bell, et al. 2014a). 
Rhesus Monkeys 
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All animal procedures conformed to the requirements of the Animal Welfare Act and 
protocols were approved prior to implementation by the Institutional Animal Care and 
Use Committee at the University of California, Davis. Activities related to animal care 
were performed as per California National Primate Research Center standard operating 
procedures. Normally cycling, adult female rhesus monkeys (Macaca mulatta; N=4) with 
a history of prior pregnancy were bred and identified as pregnant, using established 
methods  (Tarantal 2005). All dams selected for the study were pre-screened to ensure 
they were seronegative for AAV antibodies. Fetuses were monitored sonographically 
during gestation to confirm normal growth and development (Tarantal 2005) and 
newborns were delivered by cesarean section at term (160±2 days gestation) according 
to established protocols (Tarantal et al. 2005). Newborns were placed in incubators post-
delivery and nursery-reared for the study. Infant health, food intake, and body weights 
were recorded daily or weekly (dependent on age) in the nursery according to 
established protocols. At birth all animals were administered the selected AAV vector IV. 
At one month postnatal age and at subsequent monthly time points (up to 2 months 
post-transfer, to date) infants were sedated with ketamine (10 mg/kg intramuscularly, IM) 
and dexmedetomidine (0.015-0.075 mg/kg IM) in preparation for collection of CSF (~0.5 
ml; pre-injection then weekly or monthly) and for intrathecal injection via the suboccipital 
approach (~ 0.5 ml volume; 1 month and immediately after collection of CSF), all under 
aseptic conditions. Blood samples were collected at birth then monthly from a peripheral 
vessel (~ 3-6 ml) to monitor CBCs and clinical chemistry panels, and for collection of 
serum and plasma. The reversal atipamezole was given IM at a comparable dose to 
dexmedetomidine when sample collection was completed.  
Vector Biodistribution  
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DNA was isolated from tissues and vector genomes quantified by TaqMan PCR as 
described (Wang et al. 2011). 
Enzyme activity assays 
Assays for IDUA and Hex activity were performed as described (Hinderer, Bell, et al. 
2014a). 
CSF pGAG measurement 
CSF pGAG measurement was performed by the Glycotechnology Core at the University 
of California, San Diego using previously described methods (Lawrence et al. 2012). 
Briefly, GAG was extracted from CSF samples and digested to disaccharides with 
heparinase I, II, and III. Disaccharides were tagged with aniline 12C by reductive coupling 
and dried by speed vac. Dried samples were reconstituted in LC-MS grade water and 
spiked with a known concentration of 12C-aniline tagged standard. Samples were 
analyzed on a LTQ Orbitrap Discovery electrospray ionization mass spectrometer 
(Thermo Scientific) equipped with Thermo Scientific Ultimate 3000 HPLC system. 
ELISA 
The ELISA for antibodies to canine IDUA was performed as described (Hinderer, Bell, et 
al. 2014a), except that the expression construct contained the canine cDNA under the 
control of the thyroid hormone binding globulin promoter, and the cIDUA protein was 
produced in Huh7 cells. The detection antibody used was HRP-conjugated sheep anti-
canine (Pierce, Rockford, IL). The assay for antibodies to human IDUA in rhesus 
monkeys was identical, except that Aldurazyme (Genzyme, Cambridge, MA) 10 µg/mL, 
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was used for coating antigen and the detection antibody was polyclonal goat anti-human 
(Jackson ImmunoResearch Laboratories, West Grove, PA). 
Histology 
Histological analysis of MPS I dog brains was performed as previously described 
(Hinderer, Bell, et al. 2014a) with the following modifications for quantifying neurons 
positive for GM3, cholesterol, and LIMP2 storage: Images of LIMP2- and filipin-stained 
sections of cerebral cortex were taken with a 10x objective such that the border between 
layer I (molecular layer) and layer II formed the upper border of the image. A total of 10 
images were acquired from each animal. Images of GM3-stained brain sections were 
taken with a 4x objective from the area directly below the cerebral cortex surface 
including the cerebral molecular layer. Seven images from each animal were analyzed. 
All images were processed with ImageJ software (Rasband W. S., National Institutes of 
Health, USA; http://rsb.info.nih.gov/ij/) using the “Threshold” and “Analyze particles” 
modules as described previously (3). 
Results 
Antibody Induction to Canine IDUA after Intrathecal AAV9-mediated Gene Transfer in 
MPS I Dogs  
The canine model of MPS I faithfully recapitulates many of the manifestations of 
the human disease (Kakkis, McEntee, et al. 2004, Shull et al. 1984). These animals 
have no detectable IDUA activity due to a splice site mutation that results in retention of 
the first intron of IDUA (Menon, Tieu, and Neufeld 1992). Given the absence of 
detectable IDUA expression in these animals, we anticipate that they will model the 
immune response to intrathecal gene therapy that would occur in patients with the 
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severe form of MPS I, as these individuals generally carry alleles that produce no full 
length IDUA, leaving them immunologically naïve to the protein (Terlato and Cox 2003). 
The brains of MPS I dogs show the characteristic pathology associated with MPS I, 
including widespread storage of gangliosides such as GM3 in neurons, as well as 
abnormal accumulation of cholesterol and lysosomal membrane proteins including 
LIMP2 (Shull et al. 1984). MPS I dogs also exhibit prominent storage of 
glycosaminoglycans (GAGs) in the meninges, resulting in significant meningeal 
thickening, a process which contributes to spinal cord compression in some MPS I 
patients (Kachur and Del Maestro 2000, Taccone et al. 1993, Vijay and Wraith 2005).  
We initially treated 3 dogs at one month of age with an intrathecal injection of an 
AAV9 vector carrying the canine IDUA sequence under the control of a ubiquitous 
promoter (Table 4-1). The injection was well tolerated in all animals; no clinical signs 
were observed throughout the study.  CSF analyses were generally unremarkable, with 
only a mild transient elevation of CSF lymphocytes occurring in 2 animals (Table 4-2). A 
single CSF sample in one animal showed a marked pleocytosis consisting primarily of 
monocytoid cells. A subsequent tap showed no evidence of pleocytosis, and at the time 
of euthanasia, there was no histological evidence of inflammation in the brain or spinal 
cord of any treated animal.   
The vector was distributed throughout the CNS, transducing cells in all analyzed 
regions of the brain and spinal cord (Table 4-3). All animals exhibited supraphysiologic 
expression of IDUA in CSF, which declined to the normal range in one animal (I-550) 
and to below normal levels in two animals (I-553 and I-554), after which CSF enzyme 
levels were essentially stable for 5 months until the animals were euthanized (Fig. 4-1a). 
The absence of clinical signs, vector genome loss, or histological evidence of 
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encephalitis indicated that the decline in CSF IDUA activity was not due to killing of 
transduced cells by cytotoxic T lymphocytes, which was also supported by persistent 
residual CSF IDUA activity. Instead, the decline in CSF IDUA activity was associated 
with the induction of high titer antibodies against canine IDUA in CSF (Fig. 4-1b). 
Induction of Tolerance to IDUA by Neonatal Gene Transfer  
To determine whether neonatal expression of canine IDUA could induce immune 
tolerance to the enzyme in MPS I dogs, we treated 6 animals with an IV injection of an 
AAV serotype 8 vector expressing canine IDUA from a liver selective promoter on either 
the first (N=3) or the seventh (N=3) day after birth (Table 4-1). One of the dogs treated 
on postnatal day one died two days after treatment. Overall survival of neonates was 
similar to historical data for untreated MPS I dogs, which have approximately 20% 
mortality in the first two weeks of life (Traas et al. 2007). The cause of this early mortality 
in MPS I dogs has not been determined; in this treated animal postmortem examination 
showed systemic lesions typical of MPS I as well as possible evidence of a systemic 
bacterial infection. Treated animals demonstrated an elevation in serum IDUA followed 
by a rapid decline (Fig. 4-5). This is consistent with observations of transient expression 
due to vector genome loss during hepatocyte division in previous studies utilizing non-
integrating vectors for hepatic gene transfer in newborns (Wang et al. 2012).  
At one month of age, the five surviving dogs that received IV AAV8 in the first 
week of life were given an injection of an AAV9 vector using an intrathecal approach. All 
5 animals exhibited greater than 30-fold normal peak levels of IDUA in CSF following 
intrathecal vector injection, with long term CSF enzyme levels 3- to 100-fold higher than 
those achieved in naïve animals (Fig. 4-1a). Antibodies to canine IDUA in the CSF were 
reduced nearly 100-fold compared to the animals treated with IT AAV9 alone, with 
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undetectable CSF antibodies in the dogs treated on postnatal day 1, and low but 
detectable responses in the animals treated on postnatal day 7 (Fig. 4-1b).  All animals 
treated as neonates exhibited no detectable serum antibodies against canine IDUA, 
whereas the animals treated with IT AAV9 alone at one month of age had elevated 
serum anti-cIDUA titers (Fig. 4-1c). 
Induction of tolerance to canine IDUA in neonates is not due to hepatic expression 
Previous studies in both mice and dogs have demonstrated tolerance induction 
to foreign proteins through AAV-mediated hepatic expression(LoDuca, Hoffman, and 
Herzog 2009, Crudele et al. 2015, Finn et al. 2010, Sun et al. 2010).  To determine 
whether immune tolerance in the animals treated with intravenous AAV8 as neonates 
was due to liver targeted expression rather than the age of the animal at the time of 
treatment, we treated 4 MPS I dogs at 3 months of age with an intravenous injection of 
the AAV8 vector expressing canine IDUA from a liver specific promoter.  All 4 animals 
developed serum antibodies against the transgene product (Fig. 4-1c).  This indicates 
that the lack of antibody response to IDUA in the neonatal gene transfer cohort is related 
to the age of the animal at the time of exposure to the transgene product, rather than the 
presence of hepatic expression. 
Correction of Biochemical and Histological Abnormalities in the CNS of MPS I Dogs  
The lysosomal enzyme hexosaminidase (Hex) is upregulated in tissues of MPS I 
animals, and the elevated Hex activity in both brain tissue and CSF serves as a useful 
marker for the aberrant cellular processes occurring downstream of IDUA deficiency 
(Hinderer, Bell, et al. 2014c). Measurement of CSF Hex activity at the time of intrathecal 
vector delivery (~1 month postnatal) revealed abnormally elevated Hex activity in all 
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MPS I dogs (Fig. 4-2a). The animals treated with intrathecal AAV9 alone exhibited 
modest reductions in CSF Hex activity, with only the animal with the highest residual 
IDUA expression (I-550) reaching the normal range. All 5 animals treated with neonatal 
systemic gene transfer followed by intrathecal vector administration demonstrated 
complete normalization of CSF Hex. Hex activity in brain tissue samples showed a 
greater response to therapy than CSF Hex, with substantial reductions in brain Hex 
activity in all treated animals, although the effect was slightly diminished in the two 
intrathecal-only treated animals with the lowest CSF IDUA levels (Fig. 4-2b). 
GAG concentrations in CSF were measured using an assay specific for the non-
reducing end of the pathologic GAGs (pGAG) that accumulate due to IDUA deficiency 
(Fig. 4-2c) (Lawrence et al. 2012). All animals exhibited a marked reduction in CSF 
pGAG concentration 3 weeks after intrathecal AAV injection. This reduction was 
sustained at day 112, although the dogs that were not immune tolerant to IDUA 
maintained higher residual CSF pGAG than immune tolerant dogs. 
Histological analysis revealed severe storage lesions throughout the brains of 
untreated MPS I dogs, with widespread neuronal accumulation of GM3, cholesterol, and 
LIMP2 (Fig. 4-3). The animals treated with intrathecal AAV9 alone demonstrated 
substantial improvements in storage lesions, although only the animal with the highest 
CSF IDUA (I-550) experienced complete resolution of neuronal storage. The other two 
intrathecal-treated dogs had residual storage lesions. CNS storage lesions were 
completely reversed in all 5 dogs treated with neonatal AAV8 systemic gene transfer 
followed by intrathecal AAV9 administration. 
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In addition to the storage lesions in the brain parenchyma, untreated MPS I dogs 
showed accumulation of GAGs in meninges visible by Alcian blue stain (Fig. 4-3). This 
meningeal GAG accumulation and the resulting thickening of the meninges is implicated 
in many cases of spinal cord compression requiring surgical intervention, and also likely 
contributes to the development of communicating hydrocephalus in some MPS I patients 
by interfering with normal routes of CSF resorption. All treated animals showed evidence 
of improvement in meningeal GAG storage. While the meninges appeared almost 
completely normal in all tolerant dogs and one nontolerant dog, the two nontolerant 
animals with the lowest CSF IDUA activity retained some meningeal GAG storage. 
Induction of Tolerance to Human IDUA in Newborn Rhesus Macaques 
To assess whether the neonatal window for immune tolerance induction that was 
observed in MPS I dogs could also be found in primates, a similar study was performed 
in newborn rhesus monkeys (N=4). Because these animals are not IDUA deficient, the 
human IDUA transgene was used to model the immune response that might be 
expected against a species-specific transgene in a patient lacking the endogenous 
protein. Two newborn rhesus monkeys were administered AAV8 vector expressing 
human IDUA from a liver specific promoter IV at birth. Both demonstrated a brief 
increase in serum IDUA activity (Fig. 4-6). Two additional newborns were administered 
an AAV8 vector expressing an irrelevant transgene (human factor IX) IV at birth. All four 
animals were administered AAV9 vector expressing human IDUA at one-month 
postnatal age by intrathecal injection. Similar to the MPS I dogs, the IDUA naïve animals 
exhibited declining CSF IDUA activity 3 weeks after injection, with a return to near 
baseline levels by 2 months post-administration (Fig. 4-4a). These animals also 
developed transgene specific antibodies in the CSF (Fig. 4-4b). The two animals 
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administered IDUA gene transfer IV at birth did not develop antibodies to human IDUA in 
CSF (Fig. 4-4b), and maintained CSF enzyme activity greater than 10-fold normal (Fig. 
4-4a) two months after intrathecal AAV9 administration. Unlike the kinetics of CSF IDUA 
expression observed in dogs, CSF IDUA activity continued to increase 60 days after IT 
vector administration, although overall expression was lower in NHP as previously 
described(Nietupski et al. 2011).  The animals developed neutralizing antibodies to the 
vector capsids following both the IV administration at birth and the subsequent IT 
injection (Table 4-2).  All animals remained robust and healthy during the study period 
with no evidence of adverse effects, normal growth trajectories, and complete blood 
counts (CBCs) and chemistry panels within normal limits based on age and when 
compared to historical controls. 
Discussion  
 
Immune activation to a wild type therapeutic protein is a potential obstacle to the 
successful treatment of any recessive disease. Antibody responses to protein 
replacement therapy have been particularly challenging for some LSDs, as antibodies 
can interfere with the distribution and uptake of the intravenously delivered enzyme 
(Langereis et al. 2014). Antibodies may be equally problematic for gene therapies 
targeting these disorders, as they can interfere with cross-correction mediated by 
enzyme secreted from transduced cells. 
In this study we demonstrated that intrathecal AAV9 delivery can effectively 
target cells throughout the CNS in dogs and achieve sufficient expression to correct the 
biochemical and histological abnormalities associated with MPS I in the brain of a large 
animal. Previous work has demonstrated that even doses of intrathecal AAV9 much 
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greater than those employed in this study result in transduction of a small fraction of 
cells in the canine brain, suggesting that the widespread reduction in storage pathology 
observed was due to cross-correction by secreted enzyme (Haurigot et al. 2013). 
However, of the three animals treated with intrathecal vector alone, two developed 
sufficiently robust anti-transgene antibody responses to prevent complete resolution of 
CNS storage lesions. Only the animal that maintained near-normal CSF IDUA activity 
after antibody induction to the transgene demonstrated a complete response to CNS 
gene therapy. From this outcome, we conclude that IDUA activity in CSF is a reasonable 
predictor of efficacy following intrathecal gene transfer, with approximately normal levels 
required for full therapeutic benefit. This is consistent with our findings with intrathecal 
gene therapy in MPS I cats(Hinderer, Bell, et al. 2014c). MPS I cats generally exhibited 
weaker antibody responses to intrathecal gene transfer and more stable CSF IDUA 
activity than MPS I dogs. This may relate to the underlying mutation in the two models, 
as MPS I cats express an inactive mutant IDUA, potentially rendering them partially 
immunologically tolerant to the enzyme. Importantly, the present data in MPS I dogs 
indicate that even for MPS I patients with severe disease who, like the dogs, have no 
residual IDUA expression, the anti-transgene antibody response that may occur after 
intrathecal gene transfer does not result in adverse clinical events, and substantial 
efficacy is retained despite the antibody response. However, these data also suggest 
that preventing antibody responses against IDUA in the CNS could improve the efficacy 
of intrathecal gene therapy for MPS I. 
Using liver-directed gene transfer, we tested the effect of early exposure to IDUA 
on subsequent immune responses following intrathecal gene therapy. Neonatal IDUA 
expression induced tolerance to the enzyme in MPS I dogs, which markedly increased 
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CSF enzyme levels achieved with intrathecal gene therapy at one month of age. The 
high CSF IDUA levels in the immune tolerant group consistently resulted in complete 
reversal of neuropathology, providing a strong example of the efficacy that is possible 
with intrathecal gene therapy for LSDs when interfering antibody responses are 
overcome. The finding that this neonatal window for induction of immune tolerance to a 
transgene also exists in nonhuman primates appears promising for translation to the 
clinic.  Interestingly, neutralizing antibodies were elicited against the vector capsid in 
newborn NHPs, demonstrating that while neonates may be relatively tolerant to foreign 
proteins, they are fully capable of eliciting functional immune responses to pathogens.  
This finding has important clinical implications; while neonatal gene transfer may provide 
a method to circumvent immunity to the transgene, it does not provide a means of 
avoiding the antibody response to the AAV capsid.  Thus vector readministration—a 
likely necessity in the setting of a life-saving gene therapy administered to a newborn—
will depend on the development of alternative serotypes or other methods to evade 
capsid antibodies.  In the case of intrathecal AAV delivery, readministration may be 
possible due to the remarkable insensitivity of this approach to pre-existing capsid 
antibodies (Haurigot et al. 2013). 
Previous studies in mice, cats, and nonhuman primates have demonstrated 
vector escape to the peripheral circulation following intrathecal AAV delivery, often 
resulting in significant hepatic gene transfer and therapeutic levels of systemic transgene 
expression (Hinderer, Bell, et al. 2014c, Hinderer, Bell, Vite, et al. 2014, Haurigot et al. 
2013).  We did not directly evaluate somatic disease correction in treated MPS I dogs 
due to the confounding effects of anti-IDUA antibodies in the naïve cohort or previous 
systemic gene transfer in the immune-tolerant cohort. Notably we observed minimal 
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hepatic gene transfer following intrathecal AAV9 injection, consistent with the relatively 
low permissivity of canine liver to AAV-mediated transduction(Bell et al. 2011).   Given 
the low level of hepatic gene transfer and serum IDUA activity in treated dogs, 
improvement in somatic disease is unlikely. However it should be emphasized that this 
inefficient peripheral transduction is inconsistent with that observed following intrathecal 
AAV delivery in other species, and may be specific to the canine model. 
There are several limitations of the present study. Due to the increased risks 
associated with performing intrathecal vector injections in newborn MPS I pups, we 
chose to use systemic gene transfer as a means of inducing tolerance rather than 
performing CNS directed gene therapy in neonates. We therefore cannot conclude 
whether route of administration plays a role in the induction of tolerance. Hepatic gene 
transfer has often been associated with transgene specific tolerance, although we 
observed antibody responses against IDUA in 3-month-old MPS I dogs treated with 
AAV8-mediated hepatic gene therapy, indicating that liver directed gene transfer alone is 
insufficient to induce tolerance in this model (Crudele et al. 2015, Finn et al. 2010, 
LoDuca, Hoffman, and Herzog 2009, Sun et al. 2010).  In this study we also did not rule 
out the possibility that prior liver directed gene therapy contributed to the improved 
correction of brain pathology in immune tolerant animals, although this appears unlikely 
given that IDUA was undetectable in CSF in these animals at the time of intrathecal 
vector injection, and CSF Hex activity and pGAG concentration showed no evidence of 
correction before intrathecal gene transfer. This is consistent with our studies in MPS I 
cats, in which even extremely high serum IDUA activity had no impact on brain lesions 
(Hinderer, Bell, et al. 2014b).  Additionally, while we focused this study entirely on the 
observation of neonatal tolerance and its potential utility for therapeutic applications, we 
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did not evaluate the mechanisms responsible for this phenomenon. This model could 
serve as a powerful tool for better understanding the development of immunological 
recognition of self and non-self, and future studies should explore possible mechanisms. 
Finally, the present study did not define the temporal window in which tolerance 
induction is possible. Based on the observation that detectable antibody responses 
began to appear in the MPS I dogs treated on postnatal day 7, we estimate that this 
period lasts no more than one to two weeks, which could serve as a useful starting point 
for human studies. 
If human neonates are found to exhibit the same potential for transgene-specific 
immunological tolerance that we have demonstrated in dogs and nonhuman primates, 
neonatal gene transfer could have enormous potential to treat many genetic disorders 
for which immune responses limit the safety or efficacy of therapy. In order for clinical 
trials to be feasible, newborn screening will be essential for identifying patients 
sufficiently early for this approach to be effective. For MPS I, newborn screening is now 
being implemented in several states, providing a potential opportunity to conduct first-in-
human trials (Hopkins et al. 2014). 
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Figure 4-1. Neonatal systemic IDUA gene transfer induces tolerance to subsequent 
CNS gene therapy in MPS I dogs. MPS I dogs were treated with an intrathecal injection 
of an AAV9 vector encoding canine IDUA at one month of age (I-550, I-553, I-554) or 
were first treated with an intravenous injection of an AAV8 vector encoding IDUA under 
control of a liver specific promoter on postnatal day 1 (I-549, I-552) or postnatal day 7 (I-
562, I-563, I-564) followed by intrathecal vector injection at one month of age. (a) CSF 
was serially collected from treated animals and assayed for IDUA enzyme activity. The 
dotted line represents the mean CSF IDUA activity in normal control animals. (b) 
Antibodies against canine IDUA were detected in CSF samples at baseline and on day 
80 after intrathecal vector injection by indirect ELISA. Error bars represent standard error 
of replicate wells. The dashed line is the upper limit of pretreatment samples.  
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Figure 4-2. Biochemical markers are normalized following intrathecal gene therapy in 
MPS I dogs. (a) CSF samples from treated dogs and untreated controls were analyzed 
for Hexosaminidase (Hex) activity at the time of intrathecal vector injection (pre) and at 
the time of tissue harvest (post). The dotted line indicates the upper limit of CSF Hex 
activity in normal control samples. (b) Hex activity was also measured in brain lysates. 
Values are the mean +/- SEM of samples collected from six brain regions (frontal cortex, 
temporal cortex, occipital cortex, hippocampus, medulla, cerebellum).  (c) Pathogenic 
GAGs were measured in CSF at the time of intrathecal vector injection and on day 21 
and 112 post injection. 
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Figure 4-3. CNS storage lesions are more effectively cleared by intrathecal gene 
therapy in MPS I dogs tolerized to IDUA as neonates. (a) Representative brain sections 
are shown for normal, untreated MPS I, and tolerized intrathecal treated MPS I dogs. For 
the three animals treated with AAV9 alone, images are shown for each animal. 
Immunostaining was performed on cortical brain sections for the ganglioside GM3 and 
the lysosomal membrane protein LIMP2. Unesterified cholesterol was detected by filipin 
stain. GAG storage in meninges is stained with Alcian blue. Scale bar = 200 µM. (b) 
Automated quantification was performed on GM3, and (c) LIMP2, and filipin stained 
sections. Values are the mean +/- SEM of 10 sections. 
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Figure 4-4. Neonatal gene transfer induces tolerance in nonhuman primates. Four 
newborn rhesus monkeys were administered an AAV8 vector expressing either human 
IDUA (Animal #s 1 and 2) or human factor IX (3 and 4) intravenously. All animals were 
administered AAV9 expressing human IDUA using the intrathecal approach at 1 month 
postnatal age.  (a) IDUA activity was measured in CSF after intrathecal vector injection 
weekly then monthly. The dotted line represents the mean IDUA activity in pretreatment 
CSF samples. (b) Antibodies were detected in CSF by indirect ELISA 2 months after 
intrathecal vector administration. The dashed line indicates the upper limit of baseline 
samples.  Error bars represent SEM. 
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Fig 4-5: Serum IDUA activity in MPS I dogs. MPS I dogs were treated with an 
intravenous injection of an AAV8 vector encoding canine IDUA under control of a liver 
specific promoter on postnatal day 1 (I-549, I-552) or postnatal day 7 (I-562, I-563, I-564) 
followed by intrathecal injection of an AAV9 vector at one month of age. Serum was 
serially collected from treated animals and assayed for IDUA enzyme activity. 
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Fig 4-6. Serum IDUA activity in rhesus monkeys.  
Newborn rhesus macaques were administered an AAV8 vector intravenously expressing 
human IDUA (animal 1 and 2) or human factor IX (3 and 4). All four were administered 
an intrathecal injection of an AAV9 vector expressing human IDUA at one month of age. 
Serum was serially collected from treated animals and assayed for IDUA enzyme 
activity. 
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Table 4-1. Summary of Study Subjects 
A. 5 x 1012 genome copies per kilogram (GC/kg); IV=intravenous; IT=intrathecal 
B. 1012 GC/kg 
C. 1012 GC/kg  D. 3 x 1012 GC/kg 
 
 
Animal 
ID 
Genotype IV vector 
Age at IV 
treatment 
(days) 
IT vector 
Age at IT 
treatment 
(days) 
Age at 
necropsy 
(months) 
MPS I 
dogs 
 
I-550 MPS I - - AAV9.CB.cIDUAC 28 9 
 
I-553 MPS I - - AAV9.CB.cIDUA 28 9 
 
I-554 MPS I - - AAV9.CB.cIDUA 28 9 
 
I-549 MPS I AAV8.TBG.cIDUAA 1 AAV9.CB.cIDUA 28 9 
 
I-552 MPS I AAV8.TBG.cIDUA 1 AAV9.CB.cIDUA 28 9 
 
I-562 MPS I AAV8.TBG.cIDUA 7 AAV9.CB.cIDUA 28 11 
 
I-563 MPS I AAV8.TBG.cIDUA 7 AAV9.CB.cIDUA 28 11 
 
I-564 MPS I AAV8.TBG.cIDUA 7 AAV9.CB.cIDUA 28 11 
 
I-497 MPS I - - - - 12 
 
I-498 MPS I - - - - 12 
 
I-500 MPS I - - - - 12 
 
I-503 MPS I - - - - 12 
 
I-504 MPS I - - - - 12 
 
I-343 MPS I - - - - 18 
 
I-416 MPS I - - - - 6 
 
I-472 MPS I - - - - 18 
 
I-421 Normal - - - - 26 
 
DM-
154 Normal - - - - 12 
Rhesus 
macaques 
 
1 Normal AAV8.TBG.hIDUAB 1 AAV9.CB.hIDUAD 30 ongoing 
2 Normal AAV8.TBG.hIDUA 1 AAV9.CB.hIDUA 30 ongoing 
3 Normal AAV8.TBG.hFIX 1 AAV9.CB.hIDUA 30 ongoing 
4 Normal AAV8.TBG.hFIX 1 AAV9.CB.hIDUA 30 ongoing 
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Table 4-2: CSF nucleated cell counts in MPS I dogs following vector injection 
(Cells/µL) 
 
Day 
post IT 
vector 
Animal No. 0 7 21 51 81 
549 1 ND 2 0 0 
550 2 ND 11A BC 2 
552 0 ND ND 2 2 
553 2 ND 1485C 2 2 
554 0 ND 14B 1 2 
 562 2 BC 1 0 0 
563 BC 1 29B 1 0 
564 1 1 4 0 0 
      
ND = not done, BC = Blood contamination of CSF 
sample (>500 erythrocytes/µL), IT=intrathecal.  
Normative range ≤ 5 cells/µL. 
A. 317 erythrocytes/µL 
B. >70% lymphocytes 
C. >70% monocytes 
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Table 4-3: Vector biodistributionA  
 
   
I-550 I-553 I-554 I-549 I-552 I-562 I-563 I-564 
Frontal cortex 0.207224 0.032837 0.037931 0.195879 0.311028 0.053383 0.014606 0.41984 
Temporal cortex 0.324461 0.015715 0.042556 0.682856 0.024615 0.075457 0.539041 0.541367 
Occipital cortex 0.240198 0.03092 0.068607 0.585868 0.158689 0.006249 0.021576 0.724321 
Hippocampus 0.007486 0.032587 0.058214 0.008692 0.336849 0.01288 0.056152 0.065506 
Medulla 0.156078 0.012703 0.004936 0.063498 0.194763 0.294345 0.032355 0.020695 
Cerebellum 0.022631 0.014178 0.010712 0.061944 0.046369 0.025023 0.026128 0.02586 
Spinal cord 
cervical 0.257116 0.034117 0.014234 0.165666 0.509951 0.510722 0.046194 0.093024 
Spinal cord 
thoracic 0.43775 0.063695 0.02829 0.359055 0.140467 0.120746 0.079992 0.100718 
Spinal cord 
lumbar 0.190243 0.03037 0.116436 0.460682 0.313737 0.225627 0.241252 0.263238 
Heart 0.001076 <0.0005B 0.001983 0.00145 0.001454 0.02967 0.005545 0.005753 
Lung 0.000879 0.002424 0.001887 0.000491 0.000538 0.000667 0.001105 0.001883 
Liver 0.001304 0.004242 0.001918 0.010545 0.206071 0.030681 0.006334 0.028654 
Spleen 0.002579 0.001543 0.001228 0.002596 0.002229 0.044439 0.003144 0.008972 
 
A. Values are genome copies (GC) per diploid genome.  The assay does not distinguish between the AAV8 and AAV9 
vectors. 
B. Limit of detection 
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CHAPTER 5: Induction of transgene-specific immune tolerance 
enables evaluation of a human gene therapy for 
mucopolysaccharidosis type I in an authentic dog model 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 is adapted from the manuscript: C. Hinderer, P. Bell, J. P. Louboutin, Y. Zhu, 
H. Yu, G. Lin, R. Choa, B. L. Gurda, J. Bagel, P. O'Donnell, T. Sikora, T. Ruane, P. 
Wang, M. L. Casal, M. E. Haskins, J. M. Wilson. In preparation. 
106 
 
Abstract: 
 
High fidelity animal models of human disease are essential for preclinical 
evaluation of novel gene and protein therapeutics.  However, these studies can be 
complicated by exaggerated immune responses against the human protein that preclude 
meaningful assessment of safety and efficacy.  Here we demonstrate that dogs with a 
genetic deficiency of the enzyme α-l-iduronidase (IDUA), a model of the neuropathic 
lysosomal storage disease mucopolysaccharidosis type I (MPS I), can be rendered 
immunologically tolerant to human IDUA through neonatal exposure to the enzyme.  
Using MPS I dogs tolerized to human IDUA as neonates, we evaluated intrathecal 
delivery of an adeno-associated virus serotype 9 vector expressing human IDUA as a 
therapy for the central nervous system manifestations of MPS I.  These studies 
established the efficacy of the human clinical candidate vector in the canine model, and 
allowed for estimation of the minimum effective dose, providing key information for the 
design of first in human trials.  This approach has considerable potential to facilitate 
evaluation of human therapeutics in relevant animal models.  If the neonatal tolerance 
induction strategy employed can be translated to humans, it may also have clinical 
applications for the prevention of immune responses to gene and protein replacement 
therapies.  
Introduction 
Mucopolysaccharidosis type I (MPS I) is a rare inherited lysosomal storage 
disease caused by deficiency of IDUA, an enzyme required for the catabolism of 
ubiquitous glycosaminoglycans (GAGs).  GAG accumulation leads to a variety of clinical 
manifestations including bone and joint deformities, corneal clouding, and cardiac valve 
insufficiency.  MPS I patients frequently experience neurological complications including 
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communicating hydrocephalus and spinal cord compression.  The impact of the disease 
on cognitive function varies; in the attenuated form of MPS I (Scheie syndrome or 
Hurler-Scheie syndrome) in which there is residual IDUA activity, cognition is affected in 
only about one third of patients.  In the more common severe form of MPS I (Hurler 
syndrome), patients universally exhibit rapid cognitive decline in early childhood(Wraith 
et al. 2007).  MPS I is currently treated with intravenous infusion of the recombinant 
enzyme, which can be internalized by cells from the circulation via mannose 6-
phosphate receptor binding (Sando and Neufeld 1977, Dahms, Lobel, and Kornfeld 
1989).  Enzyme replacement improves many disease symptoms, but does not reach the 
CNS, and therefore has no impact on cognitive function (Wraith et al. 2007).  MPS I can 
also be treated with hematopoietic stem cell transplantation (HSCT) which provides a 
constant source of circulating IDUA through enzyme secretion by engrafted donor cells.  
Unlike enzyme replacement, HSCT can improve cognitive outcomes, apparently due to 
migration of donor derived cells across the blood-brain barrier, where they serve as a 
source of secreted enzyme within the CNS.  However, HSCT suffers from numerous 
complications including graft failure, infection, graft versus host disease, and transplant-
associated mortality as high as 20%(Aldenboven, Boelens, and de Koning 2008, 
Boelens et al. 2007, Braunlin et al. 2003, de Ru et al. 2011, Souillet et al. 2003, Staba et 
al. 2004, Whitley et al. 1993).  After transplant many patients also exhibit residual 
cognitive deficits, which may be a consequence of disease progression during the slow 
engraftment of donor cells in the CNS (Kennedy and Abkowitz 1997).  These 
shortcomings leave a significant unmet need for a safe and effective therapy for the CNS 
manifestations of MPS I. 
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Gene therapy is a promising alternative to HSCT for the treatment of cognitive 
decline in MPS I patients.  Gene transfer has the potential to induce rapid reconstitution 
of IDUA in the CNS without the adverse effects of HSCT, and targeting even a small 
number of cells in the CNS could provide a depot of secreted IDUA in the brain, leading 
to widespread improvement of storage pathology.  We previously demonstrated that 
injection of an adeno-associated virus serotype 9 vector into the cerebrospinal fluid 
(CSF) can efficiently deliver the IDUA gene to cells throughout the CNS, and that the 
enzyme secreted by transduced cells mediates global resolution of brain storage lesions.  
These proof-of concept studies for intrathecal AAV9 gene therapy relied on two naturally 
occurring large animal disease models, the MPS I dog and MPS I cat.  The use of these 
models was critical for evaluating the efficacy of the approach, not only because they 
accurately reproduce the CNS pathology of MPS I, but also because these large animals 
better reflect the human CNS anatomy and CSF circulation than rodent models, allowing 
for realistic representation of the clinical route of administration and the resulting vector 
distribution.  While these initial experiments in the MPS I dog and cat were carried out 
using vectors expressing species-specific transgenes, advancing this approach toward 
human trials necessitated the evaluation of a clinical candidate vector bearing the 
human IDUA transgene.  However, studies of the clinical candidate vector in the MPS I 
dog model were complicated by an exaggerated immune response to the human 
enzyme.  Building on our previous finding that neonatal gene transfer could induce 
persistent tolerance to the transgene product, we applied this approach to induce 
tolerance to human IDUA in MPS I dogs, which subsequently allowed for the evaluation 
of the efficacy of the human vector in this model. 
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Materials and Methods 
Vector production:  A codon optimized human IDUA cDNA was cloned into an 
expression construct bearing the cytomegalovirus immediate early enhancer, chicken 
beta-actin promoter and rabbit globin polyadenylation sequence flanked by AAV2 
inverted terminal repeats.  The construct was packaged in an AAV9 capsid, purified and 
titered as previously described.  
Animal procedures: 
The MPS I dog colony was maintained at the University Of Pennsylvania School Of 
Veterinary Medicine under NIH and USDA guidelines for the care and use of animals in 
research. All study protocols were approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee.  For infusions of recombinant human 
IDUA, laronidase (Genzyme) was diluted 5 –fold in saline immediately before use.  
Infusions were performed through a peripheral venous catheter over two hours.  Vector 
injections, serum and CSF collection, and euthanasia were performed as previously 
described(Hinderer et al. 2015). 
Enzyme assays: 
IDUA and Hex activity were measured in tissue lysates and CSF as previously 
described(Hinderer, Bell, et al. 2014c). 
Anti-hIDUA ELISA: 
Polystyrene ELISA plates were coated overnight at 4 degrees with recombinant human 
IDUA (Genzyme) diluted to 5micrograms/mL in phosphate buffer pH 5.8. The plate was 
washed and blocked in 2% BSA in phosphate buffer.  The plate was incubated 1 hour at 
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room temperature with CSF samples diluted 1:50 in PBS. The plate was washed and 
bound antibody detected with HRP conjugated anti-canine IgG (Pierce, Rockford, IL) 
diluted 1:10,000 in 2% BSA.  The ELISA was developed with tetramethylbenzidine 
substrate for 15 minutes, then stopped with 2 N sulfuric acid and absorbance was 
measured at 450 nm.  Titers were calculated from a standard curve of a serially diluted 
positive sample. 
Histology: 
Tissue processing, immunostaining and quantification were performed as previously 
described (Hinderer et al. 2015). 
Biodistribution: 
Vector biodistribution was evaluated as described (Hinderer et al. 2015). 
Results 
Intrathecal AAV9 expressing human IDUA elicits robust transgene-specific immunity in 
MPS I dogs 
Five MPS I dogs were treated at one month of age with a single intrathecal 
injection into the cisterna magna of an AAV9 vector expressing human IDUA.  Vector 
doses ranged from 1011 genome copies per kg (GC/kg) to 1012 GC/kg.  The procedure 
was well tolerated in all subjects.  IDUA activity in CSF rapidly increased following vector 
administration, exceeding that of normal controls by day 7 (Figure  5-1). However, by 
day 21 post vector administration CSF IDUA levels fell to baseline, accompanied by an 
elevation in CSF anti-hIDUA titers (Figure 5-2).  Day 21 CSF samples also revealed a 
lymphocytic pleocytosis in all animals (Figure 5-3A). In these cohorts the elevated CSF 
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antibodies and cell counts were not associated with clinical signs or other laboratory 
abnormalities, and the pleocytosis spontaneously resolved.  At the time of necropsy six 
months after injection, histological evaluation revealed no evidence of pathology in the 
brain or spinal cord.  Vector biodistribution demonstrated widespread CNS transduction 
and persistence of the vector genome (Table 5-1).  Histology also showed some 
improvement in brain storage lesions (Figure 5-7). 
Based on the favorable safety profile observed in these dogs we dosed an 
additional two MPS I dogs with a 10-fold higher dose of vector (i.e., 1013 GC/kg).  These  
dogs developed CSF pleocytosis with similar kinetics to the animals treated at the lower 
two doses; however in these two subjects the response was more pronounced, and the 
pleocytosis was temporally associated with the onset of neurological signs.  Beginning 
21 days after vector administration, the animals exhibited hyporeflexia and weakness of 
the hind limbs, and pain upon flexion of the neck.  The animals were treated with 
corticosteroids and analgesics, after which the pain and CSF pleocytosis began to 
resolve.  However, the hind limb weakness persisted, and the animals were euthanized 
two weeks after symptom onset.  Histopathology demonstrated robust transduction of 
spinal motor neurons, particularly in the lumbar spinal cord, and lymphocytic infiltrates 
surrounding transduced neurons (Figure 5-4).  Immunostaining revealed that the 
infiltrating mononuclear cells consisted primarily of B cells, with occasional CD4 and 
CD8 T cells infiltrating the associated spinal nerves.  The correlation between the clinical 
signs of hind limb weakness and the histological evidence for high levels of transgene 
expression in the lumbar spinal motor neurons and selective lymphocytic infiltration at 
this level suggests that neurological toxicity was driven by a transgene specific immune 
response targeting heavily transduced motor neurons.  An interferon gamma ELISPOT 
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assay performed on PBMCs collected at necropsy was negative for T cell responses to 
the transgene or the vector capsid (data not shown) although these results may be 
confounded by the preceding course of corticosteroids.   
Neonatal exposure to human IDUA through hepatic gene transfer induces tolerance to 
subsequent intrathecal gene transfer 
In order to evaluate the AAV9 vector expressing human IDUA in the absence of 
an exaggerated immune response to the human protein, 6 MPS I dogs were tolerized to 
human IDUA with a single intravenous injection of an AAV serotype 8 vector expressing 
human IDUA from a liver specific promoter on postnatal day 5. At one month of age the 
animals were treated with different doses of an intrathecal injection of the AAV9 vector 
expressing human IDUA in three cohorts (N=2 animals per cohort) as follows: 1010, 1011 
and 1012 GC/kg.  All animals exhibited dose-dependent elevation in CSF IDUA activity 
similar to the non-tolerized dogs; however, in this cohort CSF enzyme expression 
persisted beyond day 21 and remained relatively stable for the duration of the 
experiment (Figure 5-1).  CSF antibody responses were blunted compared to what was 
observed when  naïve (i.e., non-tolerized animals) were dosed with intrathecal vector, 
with only two animals of the tolerized cohorts (I-602 and I-606) exhibiting detectable 
titers, which were approximately 20 fold lower than naïve animals treated with an 
equivalent vector dose (Figure 5-2).  Only the dog with the highest antibody titer in this 
cohort exhibited elevated CSF lymphocytes at day 21, albeit at lower levels than in the 
naïve animals (Figure 5-3).  There were no clinical adverse events in these cohorts.  
Intrathecal AAV9-mediated hIDUA expression effects dose-dependent correction of 
brain biochemical abnormalities and storage lesions 
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The MPS I dog carries an IDUA mutation resulting in inclusion of the first intron in 
the mature mRNA, creating an immediate stop codon. The mutation in MPS I dogs 
yields no detectable IDUA activity (Menon, Tieu, and Neufeld 1992, Terlato and Cox 
2003, He et al. 1999).  In the absence of lysosomal IDUA activity, undegraded GAGs 
accumulate in the cell (Sando and Neufeld 1977).  This primary GAG storage material in 
affected tissues can be directly detected histologically by Alcian blue staining (Shull et al. 
1984, Shull et al. 1994, Clarke et al. 2009, Ellinwood et al. 2007, Haskins et al. 1983, 
Terlato and Cox 2003, Chen et al. 2011, Hinderer, Bell, et al. 2014c). In addition to the 
primary GAG storage pathology, lysosomal GAG accumulation leads to a characteristic 
cascade of cellular abnormalities.  The un-degraded GAGs cause lysosomal distention, 
visible on histology by increased staining for lysosomal membrane proteins such as 
LIMP2.  Neurons also exhibit secondary accumulation of substances such as 
gangliosides (e.g. GM3) and un-esterified cholesterol. These secondary storage 
materials can be detected by microscopy using immunostaining (GM3) or filipin staining 
(cholesterol).  Lysosomal storage also induces aberrant overexpression of lysosomal 
enzymes such as hexosaminidase.  
The six MPS I dogs tolerized to human IDUA through neonatal gene transfer 
were sacrificed 6 months post intrathecal AAV9 injection.  Brain lysates demonstrated 
normalization of hexosaminidase activity, which correlated with vector dose (Figure 5-5). 
Hexosaminidase activity was normalized in CSF at all vector doses (Figure 5-8). There 
were also dose-dependent decreases in LIMP2 and ganglioside storage (Figure 5-6).  
CNS pathology was almost completely reversed at the highest vector dose.  At the 
lowest dose, there were measurable improvements in some markers (LIMP2 and Hex) 
whereas ganglioside accumulation was not clearly reduced.  The low dose of 1010 GC/kg 
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therefore appeared to be the minimum effective dose.  Scaled to the 45g brain mass of a 
one-month old dog, and with an average body weight of 2 kg, this dose would 
correspond to an MED of 4.4 x 108 GC/g brain mass, or approximately 6.2 x 1011 GC in 
an adult human. 
Infusion of recombinant hIDUA in newborn MPS I dogs is sufficient to induce tolerance 
to intrathecal AAV9-mediated hIDUA expression 
In order to determine whether hepatic expression of human IDUA was necessary 
for tolerance induction, we treated two MPS I dogs (I-663 and I-664) with infusions of 
recombinant human IDUA (0.58 mg/kg) on postnatal day 7 and 14 before intrathecal 
AAV9 injection at one month of age.  Similar to dogs treated as newborns with a vector 
expressing human IDUA, the enzyme treated dogs exhibited persistently high levels of 
CSF IDUA activity (Figure 5-1) and no antibody response against human IDUA (Figure 
5-2) or CSF pleocytosis (Figure 5-3).  Brain storage lesions were effectively cleared in 
both animals (Figure 5-6). 
Discussion 
Evaluating the efficacy of intrathecal AAV9 delivery for the treatment of MPS I 
required assessment of both the vector distribution that could be achieved via injection 
into the CSF, and the impact of that degree of transduction on measures of disease 
activity.  These studies necessitated the use of an animal model that could accurately 
reflect the disease pathophysiology while also displaying sufficiently similar size and 
anatomy to allow for meaningful evaluation of the clinical delivery method and the 
resulting vector distribution.  The canine model of MPS I faithfully replicates the human 
phenotype, exhibiting not only the same biochemical and histological lesions, but also 
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many of the same clinical manifestations (Ciron et al. 2006, Dickson, Ellinwood, et al. 
2010, Dickson et al. 2009, Menon, Tieu, and Neufeld 1992, Shull et al. 1984, Shull et al. 
1994, Traas et al. 2007).  Due to the phenotypic similarity to MPS I in humans, MPS I 
dogs were used extensively in the development of enzyme replacement therapy for the 
treatment of systemic disease (Dickson, Peinovich, et al. 2008, Shull et al. 1994).  MPS I 
dogs also mimic CNS manifestations of the disease, sporadically developing spinal cord 
compression and hydrocephalus (Dickson, Ellinwood, et al. 2010, Dickson et al. 2009, 
Vite et al. 2013).  Though cognitive studies have not been reported for MPS I dogs, the 
histological and biochemical manifestations in the brain have been well characterized, 
and faithfully recapitulate the findings in humans with the severe from of the disease 
(Ciron et al. 2006, Shull et al. 1984, Walkley, Haskins, and Shull 1988).  MPS I dogs 
demonstrate accumulation in the brain of lysosomal membrane proteins (LIMP2) and 
gangliosides (GM3), and upregulation of lysosomal enzymes such as hexosaminidase 
(Hex).  Ganglioside accumulation correlates with cognitive function in MPS I and other 
lysosomal storage diseases, and thus is a critical marker for evaluating disease severity 
and therapeutic outcomes (Walkley and Vanier 2009, Constantopoulos, Iqbal, and 
Dekaban 1980).  MPS I dogs also exhibit changes in neuronal morphology like those 
identified in patients (Walkley, Haskins, and Shull 1988).  These striking similarities 
between this model and MPS I patients made this a compelling model for the evaluation 
of intrathecal AAV delivery as novel therapy for the CNS manifestations of the disease.  
The capacity of large animal models to replicate the route of administration that would be 
used clinically for IT AAV9 delivery, as well as the resulting vector distribution in the 
CNS, further supported the relevance of the MPS I dog for these studies. 
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Although the MPS I dog appeared to be an excellent model for evaluation of the 
clinical vector, the immune response to human IDUA presented a critical obstacle. From 
previous studies it is clear that the immune response to human IDUA in MPS I dogs is 
much more extreme than that observed in patients.  Intravenous delivery of the protein in 
both dogs and MPS I patients often results in the development of serum antibodies; 
however in dogs these responses are more robust, less likely to decline upon continued 
administration, and more often associated with anaphylactic responses to subsequent 
infusions (Kakkis, Lester, et al. 2004, Shull et al. 1994).  The difference in immune 
response to human IDUA in the CNS is even more striking; in MPS I dogs treated with 
intrathecal infusions of laronidase there was evidence of meningitis in addition to 
antibody responses detectable in CSF; in both pediatric and adult MPS I patients treated 
with repeated IT infusions of the protein there have been no similar adverse effects, and 
in the 5 patients that have been tested for CSF antibodies against IDUA only one has 
been positive(Chen et al. 2011, Dickson, Ellinwood, et al. 2010, Dickson et al. 2009, 
Dickson, Hanson, et al. 2010, Dickson, Naylor, Mlikotic, Victoroff, Chen, Passage, Le, et 
al. 2008, Kakkis, McEntee, et al. 2004, Lund et al. 2014, Vera et al. 2013).  Interestingly 
MPS I dogs also develop antibodies to canine IDUA, albeit at lower levels than to the 
human enzyme, suggesting that this model has a greater overall tendency toward 
immunity to IDUA which is exacerbated by the use of the non-species specific protein 
(Hinderer et al. 2015).  These marked differences in the outcome of both intravenous 
and intrathecal delivery of human IDUA in MPS I dogs and patients indicate a 
consistently exaggerated immune response to human IDUA in MPS I dogs, and suggest 
that preventing this response will be necessary to replicate the anticipated vector activity 
in humans.  Inducing tolerance to the protein through neonatal exposure allowed for the 
evaluation of the efficacy of the human vector in this model without the interference of 
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the exaggerated immune response. This provided critical information, allowing for the 
determination of the minimum effective dose—an essential factor in the design of first-in 
human gene therapy trials—in the most relevant animal model.  Without this approach, 
the only options would be to extrapolate efficacy data from vectors with species specific 
transgenes, which could have important differences in potency, or move studies to a less 
representative animal model that is more immune tolerant to the human protein.  
Pharmacologic immune suppression can also be employed in this setting, although the 
neonatal tolerance induction protocol has the clear advantage of avoiding secondary 
consequences of the immune suppressing drugs. 
Though efficacy assessment was confounded by the immune response and loss 
of circulating IDUA in the non-tolerized dogs treated with the human vector, some useful 
data can be derived from these animals. While the strong immune response is not likely 
to represent the immune response in humans, it could inform monitoring plans for first in 
human studies by demonstrating key characteristics of immune-mediated toxicity.  In this 
case we saw that immune-mediated toxicity was dose-dependent, the peak of the 
immune response occurred 3 weeks after vector administration, presented with focal 
motor symptoms likely due to high transduction of spinal motor neurons, and was 
accompanied by CSF pleocytosis.  These findings could be directly integrated into the 
phase 1 trial protocol, with intensive monitoring for immune-mediated toxicity and 
neurological symptoms extending for several weeks after vector administration, and CSF 
analysis for pleocytosis occurring 3-4 weeks after injection.  If neurological symptoms 
accompanied by pleocytosis appeared with similar kinetics in a human study subject, the 
findings in naïve dogs would suggest that the toxicity is due to an immune response (as 
opposed to overexpression toxicity, for example) and could guide therapeutic decisions. 
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The present findings indicate that neonatal exposure to human IDUA can induce 
tolerance regardless of the source of the enzyme.  While we had previously found that 
AAV-mediated expression could induce tolerance in neonates, here we found that 
infusion of the recombinant enzyme could also induce tolerance.  If this approach is 
generalizable to other proteins, it could be useful for preclinical evaluation of many 
human therapeutics in animal models.  Further, if a similar approach could induce 
tolerance to foreign proteins in human neonates, it could have enormous potential to 
improve the efficacy of protein replacement therapies for diseases in which antibody 
responses to the normal protein limit efficacy.  In the case of MPS I, while most patients 
appear to tolerate intrathecal IDUA infusions, the vast majority develop serum antibodies 
against intravenous enzyme replacement, and these antibodies can diminish the 
response to therapy.  Combining neonatal tolerance induction with a gene or protein 
replacement therapy may substantially improve patient outcomes.  The availability of an 
approved recombinant enzyme would make MPS I an excellent candidate for an initial 
human trial of this approach.   If human neonates exhibit the same window of 1-2 weeks 
for tolerance induction, newborn screening would be essential for identifying patients 
early enough for successful intervention.  The ongoing implementation of newborn 
screening for MPS I and other lysosomal storage diseases will therefore be critically 
important for clinical evaluation of a neonatal tolerance induction protocol. 
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Figure 5-1. CSF IDUA activity in MPS I dogs treated with intrathecal AAV9 expressing 
human IDUA.  Dogs were treated at one month of age with an intrathecal injection of the 
vector into the cisterna magna. IDUA activity was measured in subsequent CSF 
samples.  Vector doses (GC/kg) are indicated for each animal.  The dashed lines 
represent animals treated with intrathecal vector only.  The solid lines with filled symbols 
represent animals pretreated on postnatal day five with intravenous AAV8 expressing 
human IDUA from a liver-specific promoter.  Solid lines with open symbols represent 
animals pretreated on postnatal day 7 and 14 with intravenous infusion of recombinant 
human IDUA.  Animals I-665 and I-666 were euthanized on day 36 due to neurological 
signs.  The dotted line represents mean CSF IDUA activity in normal dogs. 
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Figure 5-2. CSF antibody titer against human IDUA.  Antibody titers against human 
IDUA were measured by ELISA in CSF samples collected 50 days post vector 
administration.  CSF samples tested from I-665 and I-666 were collected at the time of 
necropsy (day 36 post injection).  The dashed line represents the upper limit of CSF 
antibody titers measured in naïve control dogs.  Error bars = SEM. Antibody titers were 
significantly lower in the animals pre-treated as neonates with AAV8 vector or 
recombinant human IDUA compared to controls (Mann-Whitney test). 
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Figure 5-3. CSF nucleated cell counts following intrathecal AAV9 injection. Total 
nucleated cell counts were measured in CSF samples from naïve dogs treated with 
intrathecal AAV9 (left panel) as well as animals treated as neonates with systemic IDUA 
protein (I-663 and I-664) or IDUA expressing vector before receiving intrathecal AAV9 
(right panel). 
 
 
Figure 5-4. Lymphocyte infiltration of the lumbar spinal cord in MPS I dogs exhibiting 
hind limb weakness     following human IDUA gene transfer.  Representative sections of 
the lumbar spinal cord (A,B) and lumbar spinal nerve (C-E) are shown for the two naïve 
dogs (I-665 and I-666) treated with the highest dose of AAV9 expressing human IDUA.  
Sections were stained with H&E (A) or immunostained for human IDUA (red) and CD20 
(green) (B,C), CD4 (D), or CD8 (E). 
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Figure 5-5. Normalization of brain hexosaminidase activity in human IDUA tolerant MPS 
I dogs treated with intrathecal AAV9.  Hexosaminidase activity was measured in 
samples collected from six brain regions (frontal cortex, temporal cortex, occipital cortex, 
hippocampus, medulla and cerebellum). The mean activity is shown for a normal control 
dog, untreated MPS I dogs, and the six hIDUA tolerant dogs treated with intrathecal 
AAV9 expressing human IDUA.  Error bars = SEM. Hex activity was significantly 
reduced in the high dose cohort compared to untreated controls (Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test). 
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Figure 5-6. Dose-dependent correction of brain storage lesions in human IDUA tolerant 
dogs treated with intrathecal AAV9.  Brains were sectioned and stained for LIMP2 and 
GM3 (A).  Meningeal GAG accumulation was imaged using Alcian blue staining.  
Automated quantification of GM3 (B) and LIMP2 (C) positive cells was performed on 
cortical brain images (n = 10 per animal). Open symbols indicate animals tolerized with 
infusion of recombinant human IDUA.  GM3 and LIMP2 were significantly reduced in the 
high dose cohort compared to untreated controls (Kruskal-Wallis test followed by Dunn’s 
multiple comparisons test). 
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Figure 5-7. Partial correction of brain storage lesions in dogs treated with intrathecal 
AAV9 expressing human IDUA.  Brains were sectioned and stained for LIMP2 and GM3. 
 
 
Figure 5-8. Normalization of CSF hexosaminidase activity after IT AAV9 treatment. Hex 
activity was measured in CSF of MPS I dogs tolerized to human IDUA at the end of the 
study. The shaded region represents CSF hex acitivity in untreated MPS I dogs.  The 
dotted region indicates the normal range. 
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Table 5-1. Vector biodistribution 
Dose Animal 
Number 
  
Frontal 
Cortex 
Temporal 
Cortex 
Occipital 
Cortex 
Hippocampu
s 
Medulla Cerebellum Cervical 
Spinal 
Cord 
Thoracic 
Spinal 
Cord 
Lumbar 
Spinal 
Cord 
Heart Lung Liver Spleen 
  
  
  
1e10 
GC / 
kg 
  
  
652
†
 
  
  
0.0021 
  
  
0.0043 
  
  
0.0620 
  
  
0.0441 
  
  
0.0980 
  
  
0.0214 
  
  
0.0123 
  
  
0.0096 
  
  
0.0170 
  
  
0.0077 
  
  
0.0022 
  
  
0.0050 
  
  
0.0015 
  
  
653
†
 
  
  
0.0087 
  
  
0.0046 
  
  
0.0008 
  
  
0.0054 
  
  
0.0044 
  
  
0.0011 
  
  
0.0020 
  
  
0.0016 
  
  
NA 
  
  
‹0.0005 
  
  
0.0025 
  
  
0.0010 
  
  
0.0014 
  
  
  
  
  
1e11 
GC / 
kg 
  
  
  
  
  
  
604 
  
  
0.0078 
  
  
0.0122 
  
  
0.0033 
  
  
0.0112 
  
  
0.0071 
  
  
0.0008 
  
  
0.0150 
  
  
0.0129 
  
  
0.0063 
  
  
‹0.0005 
  
  
‹0.0005 
  
  
0.0016 
  
  
0.0031 
  
  
608 
  
  
0.0480 
  
  
0.0043 
  
  
0.0031 
  
  
0.0624 
  
  
0.0087 
  
  
0.0108 
  
  
0.0025 
  
  
0.0079 
  
  
0.0063 
  
  
‹0.0005 
  
  
0.0005 
  
  
0.0009 
  
  
0.0014 
  
  
602
†
 
  
  
0.0151 
  
  
   0.0033 
  
  
0.0029 
  
  
0.0178 
  
  
0.0144 
  
  
0.0011 
  
  
0.1120 
  
  
0.0006 
  
  
0.0077 
  
  
0.0012 
  
  
‹0.0005 
  
  
0.0054 
  
  
0.0008 
  
  
607
†
 
  
  
0.0069 
  
  
0.0079 
  
  
0.0025 
  
  
0.0041 
  
  
0.0030 
  
  
0.0012 
  
  
0.0028 
  
  
0.0039 
  
  
‹0.0005 
  
  
0.0008 
  
  
‹0.0005 
  
  
0.0013 
  
  
0.0025 
  
  
  
  
1e12 
GC / 
kg 
  
  
  
  
  
605
†
 
  
  
0.0153 
  
  
0.0040 
  
  
0.0166 
  
  
0.0078 
  
  
0.0325 
  
  
0.0033 
  
  
0.0447 
  
  
0.2899 
  
  
0.0592 
  
  
0.0226 
  
  
‹0.0005 
  
  
0.0011 
  
  
‹0.0005 
  
  
601
†
 
  
  
0.1587 
  
  
0.4328 
  
  
0.1720 
  
  
NA 
  
  
0.1339 
  
  
0.0113 
  
  
0.1128 
  
  
0.0701 
  
  
0.0466 
  
  
0.0013 
  
  
‹0.0005 
  
  
0.0010 
  
  
0.0005 
  
  
606 
  
  
0.0831 
  
  
0.1264 
  
  
0.0725 
  
  
0.0209 
  
  
0.0682 
  
  
0.0188 
  
  
0.0531 
  
  
0.0242 
  
  
0.0663 
  
  
0.0008 
  
  
‹0.0005 
  
  
0.0025 
  
  
0.0027 
  
  
  
1e13 
GC / 
kg 
  
  
  
  
665 
  
  
0.3790 
  
  
0.7676 
  
  
0.2262 
  
  
0.0324 
  
  
0.0484 
  
  
0.0518 
  
  
0.7661 
  
  
0.5163 
  
  
0.6688 
  
  
0.0110 
  
  
0.0055 
  
  
0.3554 
  
  
0.1286 
  
  
666 
  
  
2.3428 
  
  
0.4896 
  
  
0.4006 
  
  
NA 
  
  
0.1169 
  
  
0.0938 
  
  
0.3797 
  
  
1.5287 
  
  
0.8769 
  
  
0.0056 
  
  
0.0008 
  
  
0.2507 
  
  
0.1418 
 
† = Tolerized with 5e12 GC / kg hIDUA on postnatal day 5 
NA = (sample) not analyzed 
Limit of detection = 0.0005 GC/dg 
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CHAPTER 6: General discussion 
Three decades ago it was demonstrated that the coding sequences of the adeno-
associated virus genome could be provided in trans, allowing for the generation of 
infectious particles in which the endogenous genome was replaced with a transgene 
(Samulski, Chang, and Shenk 1989, 1987).  This discovery would revolutionize gene 
therapy—for the first time it became possible to achieve in vivo gene transfer with a 
vector that did not cause insertional mutagenesis, nor elicit destructive immune 
responses against the transgene product.  The emergence of AAV for in vivo gene 
therapy left only two major challenges: a relatively limited packaging capacity of around 
5 kb, and because of the non-integrating nature of the vector, only quiescent tissues 
such as heart, skeletal muscle, liver, retina and brain could be stably transduced.  The 
past two decades have seen rapid development of AAV based therapies targeting these 
tissues, with repeated demonstrations of efficacy in animal models. Targeting the retina 
yielded one of the first clinical successes; subretinal delivery of an AAV vector 
expressing RPE65 rescued vision loss in a canine model of Leber's congenital 
amaurosis, and soon after demonstrated efficacy in children with the disease (Acland et 
al. 2001, Bainbridge et al. 2008, Maguire et al. 2009).  Though many other early 
successes in animal models of liver and muscle directed gene therapy couldn’t be 
replicated in the clinic, the development of a second generation of more efficient vectors 
made targeting these tissues a reality, leading to successful trials for hemophilia B and 
lipoprotein lipase deficiency (Nathwani et al. 2011, Bryant et al. 2013, Gao et al. 2002, 
Gao et al. 2004, Xiao et al. 1999). 
Among the tissues initially targeted with AAV gene therapy, the brain has lagged 
behind in terms of clinical success.  Trials of AAV mediated gene transfer to the brain 
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have demonstrated possible small benefits in Canavan disease and aromatic amino acid 
decarboxylase (AADC) deficiency, and expression of AADC in the brain has been 
demonstrated for several years after gene transfer by PET imaging (Mittermeyer et al. 
2012, Janson et al. 2002, Leone et al. 2012, Hwu et al. 2012).  While these studies and 
others have established a strong safety profile for AAV in the brain, there has yet to be a 
major clinical success for CNS-directed gene transfer.  The primary obstacle to the field 
has been delivery—injection into the brain requires an invasive neurosurgical procedure, 
and can only transduce a small region surrounding the injection site (Vite et al. 2005).  
Some diseases affecting a single brain nucleus may be responsive to localized injection 
of the vector, but many genetic diseases affect cells throughout the CNS, making 
localized delivery ineffective.  Studies in dog and cat models of genetic diseases 
demonstrated that reasonably widespread correction could sometimes be achieved with 
as few as 4-6 injections, however  scaled from a 30-70 g cat or dog brain to a 1.4 kg 
human brain, more than 100 injections would be required for equivalent breadth of 
transduction (Vite et al. 2005, Ciron et al. 2006).  Vector injection into the brain 
parenchyma can also induce inflammation that may elicit adaptive immune response to 
the transgene product; in studies in both dogs and NHP, transduced cells surrounding 
the injection site have been the target of T cell mediated killing (Ciron et al. 2006, 
Samaranch, San Sebastian, et al. 2013).   
A critical advance for CNS gene therapy was the discovery that some novel AAV 
serotypes, particularly AAV9, could transduce neurons in the brain and spinal cord after 
intravascular delivery (Foust et al. 2009).  This made it possible for the first time to 
achieve transduction of a large number of cells throughout the CNS without an invasive 
procedure.  Intravenous AAV9 delivery demonstrated remarkable success in a mouse 
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model of spinal muscular atrophy (SMA), a disease affecting lower motor neurons 
throughout the spinal cord (Foust et al. 2010).  Treating newborn animals allowed for 
transduction of a large fraction of spinal cord motor neurons, leading to increased 
survival and improved motor function.  This approach is now progressing into clinical 
trials for SMA, as well as the lysosomal storage disease MPS IIIa. However, while 
intravenous AAV9 delivery has been an important step for the field, CNS transduction is 
much less efficient in large animals than in newborn mice, with very limited transduction 
in the brain even at extremely large vector doses (Hinderer, Bell, Vite, et al. 2014, Bevan 
et al. 2011, Gray et al. 2011).  The resulting high levels of peripheral transduction limit 
this approach to diseases in which the vector has no peripheral toxicity even at very high 
doses.  Intravenous AAV9 delivery is also very sensitive to the presence of pre-existing 
capsid antibodies, limiting the number of patients eligible for therapy.  This approach 
may be clinically useful for select applications, but will not be sufficient for many 
diseases affecting the CNS. 
The shortcomings of both intraparenchymal and systemic AAV delivery for CNS 
gene transfer have left a need for an efficient, non-invasive method to target a vector to 
large regions of the CNS.  Delivery into CSF seems a reasonable option, given that this 
approach can theoretically achieve high vector concentrations in the CNS, and allow for 
broad distribution throughout the brain and spinal cord. However, intrathecal delivery has 
not often been pursued as a method for delivery of biologics to the CNS.  This is rooted 
in a widely held perception that there is minimal interaction between CSF and the brain 
parenchyma, as the CSF is confined to the space between the arachnoid and the pia 
mater covering the brain (Papisov, Belov, and Gannon 2013).  However, many studies 
have now demonstrated the exchange of CSF with brain interstitial fluid and the ability of 
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macromolecules to distribute to the brain following intrathecal delivery (Iliff et al. 2013, 
Iliff et al. 2012, Calias et al. 2012).  This observation has extended to AAV vectors; there 
have been multiple demonstrations of transduction in the brain and spinal cord after 
intrathecal AAV delivery in mice, dogs, cats, and nonhuman primates (Haurigot et al. 
2013, Gray et al. 2013, Samaranch, Salegio, et al. 2013, Hinderer, Bell, Vite, et al. 2014, 
Bucher et al. 2014b).  These studies demonstrated widespread transduction of both 
neurons and glial cells throughout the brain following AAV9 delivery into the CSF.  
Transduction in the brain was not associated with inflammation or immune responses 
directed against transduced cells, as had been seen in some studies of 
intraparenchymal injection.  In addition to brain transduction, a very large proportion of 
spinal cord motor neurons can be transduced by a single intrathecal vector injection.  
This approach thus offers the potential for widespread CNS transduction with a 
minimally invasive injection.   An added advantage is that very little serum IgG crosses 
into the CSF, making intrathecal vector delivery insensitive to the presence of pre-
existing antibodies against the AAV capsid, potentially extending this approach to 
individuals who would not be candidates for systemic vector delivery (Haurigot et al. 
2013). 
The transduction pattern achieved with IT AAV suggests some clear clinical 
applications. The efficient transduction of spinal cord motor neurons shows strong 
potential for the treatment of lower motor neuron disease.  The transduction of a fraction 
of cells throughout the cerebrum may not be sufficient for many diseases in which a 
defective gene is essential for function of every cell. However, for many of the lysosomal 
storage diseases, in which some of the enzyme produced can be secreted and taken up 
by neighboring cells, even a relatively small number of cells spread throughout the brain 
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could lead to widespread correction (Sando and Neufeld 1977).  Efficacy has already 
been demonstrated in animal models of diseases such as MPS IIIa, and MPS I, and 
other diseases that exhibit cross correction may also be good targets for intrathecal AAV 
delivery (Haurigot et al. 2013, Hinderer, Bell, et al. 2014a).  For lower motor neurons, an 
extremely promising target is SMA.  Intrathecal AAV9 delivery has been shown to 
efficiently rescue the neuromuscular phenotype in mice, and parallel studies in 
nonhuman primates demonstrate that levels of transduction required for efficacy can 
readily be achieved in large animals at moderate vector doses (Meyer et al. 2014, 
Passini et al. 2014).  Intrathecal AAV9 expressing an shRNA against superoxide 
dismutase 1 (SOD1) has also shown promise in animal models of dominantly inherited 
amyotrophic lateral sclerosis, effectively reducing levels of the toxic protein in lower 
motor neurons (Foust et al. 2013).  However, ALS also affects upper motor neurons 
residing in the cerebral cortex, and the impact of the vector on SOD1 expression in 
these cells has not been demonstrated. 
Expanding on the success of intrathecal AAV delivery and bringing this approach 
to new disease targets will require that several issues are addressed. One is a problem 
of animal models.  Preclinical studies should ideally be carried out in a model that not 
only reflects that pathophysiology of the disease, but also is amenable to the clinical 
route of administration and consequently exhibits the vector biodistribution expected 
patients.  Knockout mouse models may be problematic for these studies, since some 
routes of intrathecal administration are technically challenging to replicate in these 
animals.  Intraventricular delivery is readily carried out in mice, although the vector 
distribution resulting from intraventricular delivery in the small mouse CNS clearly differs 
from that in larger animals (Haurigot et al. 2013).  For some diseases the availability of 
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large animal models will facilitate this process.  We used canine and feline models to 
develop IT gene therapy for MPS I.  Large animal models have been identified for many 
other lysososmal storage diseases, such as MPS VII, mannosidosis, GM1 and GM2 
gangliosidoses, and an induced model was developed in pigs to evaluate IT gene 
transfer for SMA (Duque et al. 2015, Haskins 2009). For many other diseases, however, 
no large animal model will be available.  Extrapolating biodistribution data from large 
animals may help to inform efficacy assessments in mouse models.  For example, 
studies using SMA mice evaluated the extent of motor neuron transduction necessary to 
rescue the disease phenotype, then used reporter gene studies in nonhuman primates 
to identify a dose capable of similar transduction levels (Meyer et al. 2014, Passini et al. 
2014).  More creative approaches like this may be essential to developing IT gene 
therapy for diseases for which only mouse models are available.   
A second important issue that will need to be considered is the potential for 
systemic distribution of a vector after IT delivery.  Studies in dogs, mice, nonhuman 
primates, and cats have shown peripheral transduction after IT delivery (Hinderer, Bell, 
et al. 2014a, Hinderer, Bell, Vite, et al. 2014, Haurigot et al. 2013).   This finding has 
revealed further limitations of the prevailing view of CSF circulation—in the past it was 
thought that CSF was resorbed entirely through arachnoid granulations of the meninges, 
which is inconsistent with the observation of efficient and rapid escape of viral particles 
from CSF to blood.  This finding is, however, consistent with the more recent 
identification of perivascular channels and CNS lymphatics that allow for drainage of 
particles from CSF to the periphery (Iliff et al. 2012, Iliff et al. 2013).   The implications of 
peripheral distribution will vary depending on disease—in the lysosomal storage 
diseases, systemic distribution and liver transduction may actually be beneficial, as 
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these enzymes are ubiquitously expressed and can treat somatic as well as CNS 
disease. However, for many other diseases hepatic targeting may be detrimental and 
additional measures such as tissue specific promoters may be needed to achieve 
adequate safety. 
 Another important issue for IT AAV delivery is that of dose scaling between 
animal models and patients.  For systemic applications dosing has typically been based 
on body weight.  For intrathecal delivery, the vector dose should presumably be based 
on the targeted compartment, since the primary activity and toxicity of the vector would 
be expected to be based on the concentration of vector in CSF.  CSF volume does not 
exhibit a static relationship with body weight across species or animals of different ages, 
so it will be important to scale doses according to the actual size of CNS.   Rather than 
basing doses on CSF volume, our approach has been to scale doses based on brain 
mass, since much more detailed data are available for humans and animals of different 
ages, and because brain size appears to have a linear relationship with CSF volume 
across species.  Since there is systemic distribution of vector after IT delivery, it will be 
important to also consider the dose relative to body weight when comparing doses found 
to be safe in preclinical studies with those used in first in human trials to avoid potential 
systemic toxicity.  This could be especially important in infants, whose brain to body 
mass ratio is greater than that of animal species commonly used for toxicology studies. 
To expand IT AAV delivery to new targets it will be important to better elucidate 
the transduction patterns in the CNS.  Motor neurons are clearly efficiently targeted in all 
species, but the other cell types transduced have varied between studies.  In nonhuman 
primates we have observed predominately neuron-restricted expression, particularly the 
pyramidal cortical neurons and purkinje cells in cerebellum (Hinderer, Bell, Vite, et al. 
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2014).  Others have reported more extensive glial transduction, including astrocytes and 
oligodendrocytes (Samaranch, Salegio, et al. 2013, Bucher et al. 2014b).  For some 
disorders in which the transgene product can be secreted, targeting any cells in the CNS 
could potentially be beneficial.  For other disorders, particular cell types and even very 
specific functional subsets of neurons may need to be transduced for efficacy, and 
transduction of other cell types may be toxic.  This may necessitate careful capsid and 
promoter selection to achieve the required degree of selectivity.   
Progressing IT gene transfer will also require a broader understanding of the 
factors leading to immune responses in CNS and the consequences of immunity.  IT 
delivery appears to circumvent the T cell-mediated immune response to transgene 
products that has been observed with intraparenchymal delivery; however there has 
been one report of potential immunological toxicity after intrathecal AAV9 delivery 
expressing GFP in a nonhuman primate, indicating the need for careful monitoring and 
more detailed studies (Samaranch, San Sebastian, et al. 2013).  The potential for 
antibody responses to secreted transgenes in the CNS will also be important.  In MPS I 
dogs there was a high rate of antibody induction to the transgene product, which while 
not associated with toxicity, did reduce the efficacy of cross-correction. The clinical 
experience with intrathecal delivery of the enzyme indicates that antibody induction 
against the protein in CSF is not likely to occur in humans, but this provides an important 
example of a potential challenge for IT gene therapy with secreted transgene products 
(Vera et al. 2013).  We have demonstrated that such responses can be prevented in 
MPS I dogs and nonhuman primates through exposure to the enzyme in the first week of 
life, which could be a viable approach for diseases in which newborn screening is 
commonly employed.  This method can also be useful for preclinical studies of vectors 
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expressing human proteins as a means of preventing antibody responses to the non-
species-specific transgene which would otherwise preclude evaluation of efficacy in 
animal models. 
Another critical issue for IT AAV delivery will be the route of administration.  
There are many potential routes for CSF access; lumbar puncture is the most common, 
but cannulation of the lateral ventricle is also possible, and CSF can be accessed at the 
cervical level by lateral C1-2 puncture or suboccipital puncture.  Our group and others 
have found that lumbar puncture results in very inefficient delivery of vector to the brain, 
whereas delivery into the cisterna magna by suboccipital puncture results in efficient 
transduction in both brain and spinal cord (Hinderer, Bell, Vite, et al. 2014).  Suboccipital 
puncture is not commonly used clinically due to the greater risks that were associated 
with targeting near the brainstem and surrounding vessels in the pre-imaging era, 
although today the procedure can be readily performed with image guidance (Saunders 
and Riordan 1929, Pomerantz, Buchbinder, and Hirsh 2005).  CSF access is also 
routinely achieved at approximately the same location by lateral puncture of the dorsal 
subarachnoid space between the first and second vertebrae.  We have found that this 
approach is not feasible in MPS I patients due to abnormal thickening of the cervical 
meninges, although C1-2 puncture may be a reasonable option for many other 
applications. Future preclinical studies would be needed to verify similar distribution after 
C1-2 puncture relative to suboccipital puncture.  Finally intraventricular delivery is a 
possibility, and has been shown to result in biodistribution similar to intracisternal 
delivery in dogs (Haurigot et al. 2013).  However, ventricular delivery has the 
disadvantage of the requirement for a neurosurgical procedure. Also, the penetration of 
the brain parenchyma raises the possibility for the same type of localized inflammatory 
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response and induction of immunity against the transgene product that has been 
observed following intraparenchymal vector delivery. 
IT AAV delivery represents a critical advance in our approach to the treatment of 
inherited neurologic disease.  Gene therapy targeting the brain has slowly become 
possible through the advent of AAV vectors, followed by the discovery of more efficient 
serotypes for CNS gene transfer. The development of IT delivery represents a critical 
next step in this process, providing for the first time a minimally invasive method to 
deliver the vector to large portions of the brain and spinal cord.  This will not be the final 
solution for CNS gene therapy—there are still many diseases for which more extensive 
transduction, precise regulation of transgene expression, or specific cell targeting will be 
necessary for successful treatment.  However, IT AAV delivery has unlocked the 
possibility of gene therapy for many previously elusive targets, and could pave way for 
the first clinical successes for neurological disorders. 
 
 
 
 
 
 
 
 
 
 
 
136 
 
BIBLIOGRAPHY 
 
Acland, G. M., G. D. Aguirre, J. Ray, Q. Zhang, T. S. Aleman, A. V. Cideciyan, S. E. 
Pearce-Kelling, V. Anand, Y. Zeng, A. M. Maguire, S. G. Jacobson, W. W. 
Hauswirth, and J. Bennett. 2001. "Gene therapy restores vision in a canine 
model of childhood blindness." Nat Genet 28 (1):92-5. doi: 10.1038/88327. 
Adkins, B. 1999. "T-cell function in newborn mice and humans." Immunol Today 20 
(7):330-5. 
Ahmed, Alia, Chester B. Whitley, Renee Cooksley, Kyle Rudser, Stephanie Cagle, Nadia 
Ali, Kathleen Delaney, Brianna Yund, and Elsa Shapiro. 2014. "Neurocognitive 
and neuropsychiatric phenotypes associated with the mutation L238Q of the 
alpha-L-iduronidase gene in Hurler-Scheie syndrome." Molecular Genetics and 
Metabolism 111 (2):123-127. doi: 10.1016/j.ymgme.2013.11.014. 
Aldenboven, M., F. Boelens, and T. F. de Koning. 2008. "The clinical outcome of Hurler 
syndrome after stem cell transplantation." Biology of Blood and Marrow 
Transplantation 14 (5):485-498. doi: 10.1016/j.bbmt.2008.01.009. 
Ayer, J. B. 1920. "Puncture of the cisterna magna." Archives of Neurology & Psychiatry 
4 (5):529-541. doi: 10.1001/archneurpsyc.1920.02180230052005. 
Bainbridge, James W.B., Alexander J. Smith, Susie S. Barker, Scott Robbie, Robert 
Henderson, Kamaljit Balaggan, Ananth Viswanathan, Graham E. Holder, Andrew 
Stockman, Nick Tyler, Simon Petersen-Jones, Shomi S. Bhattacharya, Adrian J. 
Thrasher, Fred W. Fitzke, Barrie J. Carter, Gary S. Rubin, Anthony T. Moore, and 
Robin R. Ali. 2008. "Effect of Gene Therapy on Visual Function in Leber's 
Congenital Amaurosis." New England Journal of Medicine 358 (21):2231-2239. 
doi: doi:10.1056/NEJMoa0802268. 
Bankiewicz, K. S., J. L. Eberling, M. Kohutnicka, W. Jagust, P. Pivirotto, J. Bringas, J. 
Cunningham, T. F. Budinger, and J. Harvey-White. 2000. "Convection-enhanced 
delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene 
expression and restoration of dopaminergic function using pro-drug approach." 
Exp Neurol 164 (1):2-14. doi: 10.1006/exnr.2000.7408. 
Bankiewicz, Krystof S., John Forsayeth, Jamie L. Eberling, Rosario Sanchez-Pernaute, 
Philip Pivirotto, John Bringas, Peter Herscovitch, Richard E. Carson, William 
Eckelman, Bryan Reutter, and Janet Cunningham. 2006. "Long-Term Clinical 
Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-
hAADC." Mol Ther 14 (4):564-570. 
Bartus, R. T., M. S. Weinberg, and R. J. Samulski. 2014. "Parkinson's disease gene 
therapy: success by design meets failure by efficacy." Mol Ther 22 (3):487-97. 
doi: 10.1038/mt.2013.281. 
Bartus, Raymond T., Christopher D. Herzog, Yaping Chu, Alistair Wilson, Lamar Brown, 
Joao Siffert, Eugene M. Johnson, C. Warren Olanow, Elliott J. Mufson, and 
Jeffrey H. Kordower. 2011. "Bioactivity of AAV2-neurturin gene therapy (CERE-
120): Differences between Parkinson's disease and nonhuman primate brains." 
Movement Disorders 26 (1):27-36. doi: 10.1002/mds.23442. 
Beck, M., P. Arn, R. Giugliani, J. Muenzer, T. Okuyama, J. Taylor, and S. Fallet. 2014. 
"The natural history of MPS I: global perspectives from the MPS I Registry." 
Genet Med 16 (10):759-65. doi: 10.1038/gim.2014.25. 
137 
 
Bell, Peter, Guangping Gao, Mark E Haskins, Lili Wang, Meg Sleeper, Huan Wang, 
Roberto Calcedo, Luk H Vandenberghe, Shu-Jen Chen, and Chick Weisse. 
2011. "Evaluation of adeno-associated viral vectors for liver-directed gene 
transfer in dogs." Human gene therapy 22 (8):985-997. 
Bevan, A. K., S. Duque, K. D. Foust, P. R. Morales, L. Braun, L. Schmelzer, C. M. Chan, 
M. McCrate, L. G. Chicoine, B. D. Coley, P. N. Porensky, S. J. Kolb, J. R. 
Mendell, A. H. M. Burghes, and B. K. Kaspar. 2011. "Systemic gene delivery in 
large species for targeting spinal cord, brain, and peripheral tissues for pediatric 
disorders." Molecular Therapy 19 (11):1971-1980. doi: 10.1038/mt.2011.157. 
Billingham, R. E., L. Brent, and P. B. Medawar. 1953. "Actively acquired tolerance of 
foreign cells." Nature 172 (4379):603-6. 
Björklund, A., D. Kirik, C. Rosenblad, B. Georgievska, C. Lundberg, and R. J. Mandel. 
2000. "Towards a neuroprotective gene therapy for Parkinson’s disease: use of 
adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the 
nigrostriatal system in the rat Parkinson model." Brain Research 886 (1–2):82-98. 
doi: http://dx.doi.org/10.1016/S0006-8993(00)02915-2. 
Boelens, J. J., R. F. Wynn, A. O'Meara, P. Veys, Y. Bertrand, G. Souillet, J. E. Wraith, A. 
Fischer, M. Cavazzana-Calvo, K. W. Sykora, P. Sedlacek, A. Rovelli, Cspm 
Uiterwaal, and N. Wulffraat. 2007. "Outcomes of hematopoietic stem cell 
transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft 
failure." Bone Marrow Transplantation 40 (3):225-233. doi: 
10.1038/sj.bmt.1705718. 
Bohn, M. C., D. L. Choi-Lundberg, B. L. Davidson, C. Leranth, D. A. Kozlowski, J. C. 
Smith, M. K. O'Banion, and D. E. Redmond, Jr. 1999. "Adenovirus-mediated 
transgene expression in nonhuman primate brain." Hum Gene Ther 10 (7):1175-
84. doi: 10.1089/10430349950018166. 
Braunlin, E. A., N. R. Stauffer, C. H. Peters, J. L. Bass, J. M. Berry, J. J. Hopwood, and 
W. Krivit. 2003. "Usefulness of bone marrow transplantation in the Hurler 
syndrome." American Journal of Cardiology 92 (7):882-886. doi: 10.1016/s0002-
9149(03)00909-3. 
Bryant, Laura M., Devin M. Christopher, April R. Giles, Christian Hinderer, Jesse L. 
Rodriguez, Jenessa B. Smith, Elizabeth A. Traxler, Josh Tycko, Adam P. Wojno, 
and James M. Wilson. 2013. "Lessons learned from the clinical development and 
market authorization of Glybera." Human gene therapy. Clinical development 24 
(2):55-64. doi: 10.1089/humc.2013.087. 
Bucher, T., L. Dubreil, M. A. Colle, M. Maquigneau, J. Deniaud, M. Ledevin, P. Moullier, 
and B. Joussemet. 2014a. "Intracisternal delivery of AAV9 results in 
oligodendrocyte and motor neuron transduction in the whole central nervous 
system of cats." Gene Ther. doi: 10.1038/gt.2014.16. 
Bucher, Thomas, Laurence Dubreil, Marie-Anne Colle, M Maquigneau, Johan Deniaud, 
Mireille Ledevin, Philippe Moullier, and Béatrice Joussemet. 2014b. 
"Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron 
transduction in the whole central nervous system of cats." Gene therapy 21 
(5):522-528. 
Buchlis, G., G. M. Podsakoff, A. Radu, S. M. Hawk, A. W. Flake, F. Mingozzi, and K. A. 
High. 2012. "Factor IX expression in skeletal muscle of a severe hemophilia B 
patient 10 years after AAV-mediated gene transfer." Blood 119 (13):3038-41. doi: 
10.1182/blood-2011-09-382317. 
138 
 
Burns, R S, C C Chiueh, S P Markey, M H Ebert, D M Jacobowitz, and I J Kopin. 1983. 
"A primate model of parkinsonism: selective destruction of dopaminergic neurons 
in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine." Proceedings of the National Academy of Sciences 80 
(14):4546-4550. 
Calias, P., M. Papisov, J. Pan, N. Savioli, V. Belov, Y. Huang, J. Lotterhand, M. 
Alessandrini, N. Liu, A. J. Fischman, J. L. Powell, and M. W. Heartlein. 2012. 
"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and 
mouse: implications for neurological outcomes of lysosomal storage disorder." 
Plos One 7 (1):13. doi: 10.1371/journal.pone.0030341. 
Castle, M. J., E. Perlson, E. L. Holzbaur, and J. H. Wolfe. 2014. "Long-distance axonal 
transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly 
motile Rab7-positive compartment." Mol Ther 22 (3):554-66. doi: 
10.1038/mt.2013.237. 
Chen, A., C. Vogler, M. McEntee, S. Hanson, N. M. Ellinwood, J. Jens, E. Snella, M. 
Passage, S. Le, C. Guerra, and P. Dickson. 2011. "Glycosaminoglycan storage 
in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal 
recombinant human iduronidase." Apmis 119 (8):513-521. doi: 10.1111/j.1600-
0463.2011.02760.x. 
Ciron, C., N. Desmaris, M. A. Colle, S. Raoul, B. Joussemet, L. Verot, J. Ausseil, R. 
Froissart, F. Roux, Y. Cherel, Y. Lajat, B. Schwartz, M. T. Vanier, I. Maire, M. 
Tardieu, P. Moullier, and J. M. Heard. 2006. "Gene therapy of the brain in the 
dog model of Hurler's syndrome." Annals of Neurology 60 (2):204-213. doi: 
10.1002/ana.20870. 
Clarke, L. A., J. E. Wraith, M. Beck, E. H. Kolodny, G. M. Pastores, J. Muenzer, D. M. 
Rapoport, K. I. Berger, M. Sidman, E. D. Kakkis, and G. F. Cox. 2009. "Long-
term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis 
I." Pediatrics 123 (1):229-40. doi: 10.1542/peds.2007-3847. 
Constantopoulos, George, Khalid Iqbal, and Anatole S. Dekaban. 1980. 
"Mucopolysaccharidosis Types IH, IS, II and IIIA: Glycosaminoglycans and Lipids 
of Isolated Brain Cells and Other Fractions from Autopsied Tissues." Journal of 
Neurochemistry 34 (6):1399-1411. doi: 10.1111/j.1471-4159.1980.tb11220.x. 
Crudele, J. M., J. D. Finn, J. I. Siner, N. B. Martin, G. P. Niemeyer, S. Zhou, F. Mingozzi, 
C. D. Lothrop, Jr., and V. R. Arruda. 2015. "AAV liver expression of FIX-Padua 
prevents and eradicates FIX inhibitor without increasing thrombogenicity in 
hemophilia B dogs and mice." Blood. doi: 10.1182/blood-2014-07-588194. 
Dahms, N. M., P. Lobel, and S. Kornfeld. 1989. "Mannose 6-phosphate receptors and 
lysosomal-enzyme targeting." Journal of Biological Chemistry 264 (21):12115-
12118. 
de Ru, M. H., J. J. Boelens, A. M. Das, S. A. Jones, J. H. van der Lee, N. Mahlaoui, E. 
Mengel, M. Offringa, A. O'Meara, R. Parini, A. Rovelli, K. W. Sykora, V. 
Valayannopoulos, A. Vellodi, R. F. Wynn, and F. A. Wijburg. 2011. "Enzyme 
replacement therapy and/or hematopoietic stem cell transplantation at diagnosis 
in patients with mucopolysaccharidosis type I: results of a European consensus 
procedure." Orphanet Journal of Rare Diseases 6:9. doi: 10.1186/1750-1172-6-
55. 
Dickson, P., N. M. Ellinwood, A. Dierenfeld, K. Kline, J. Parkes, S. Hanson, C. Vite, A. 
Mlikotic, A. Chen, W. Gross, M. Haskins, K. Ponder, and S. Le. 2010. "Intrathecal 
enzyme replacement therapy treats meningeal storage and spinal cord 
139 
 
compression in MPS I dogs." Molecular Genetics and Metabolism 99 (2):S15-
S15. doi: 10.1016/j.ymgme.2009.10.053. 
Dickson, P. I., N. M. Ellinwood, S. Hanson, C. Vite, M. Passage, S. Le, and C. Guerra. 
2009. "Intrathecal enzyme replacement therapy may stabilize or reverse signs of 
spinal cord compression in MPS I dogs." Molecular Genetics and Metabolism 98 
(1-2):70-70. 
Dickson, P. I., S. Hanson, M. F. McEntee, C. H. Vite, C. A. Vogler, A. Mlikotic, A. H. 
Chen, K. P. Ponder, M. E. Haskins, B. L. Tippin, S. Q. Le, M. B. Passage, C. 
Guerra, A. Dierenfeld, J. Jens, E. Snella, S. H. Kan, and N. M. Ellinwood. 2010. 
"Early versus late treatment of spinal cord compression with long-term intrathecal 
enzyme replacement therapy in canine mucopolysaccharidosis type I." Molecular 
Genetics and Metabolism 101 (2-3):115-122. doi: 10.1016/j.ymgme.2010.06.020. 
Dickson, P. I., D. Naylor, A. Mlikotic, A. Victoroff, A. Chen, M. Passage, S. Le, and M. P. 
S. Intrathecal Res Collaborat. 2008. "Intrathecal recombinant human a-L-
iduronidase alleviates spinal cord compression symptoms and is well-tolerated in 
attenuated MPS I patients." Molecular Genetics and Metabolism 93 (3):247-247. 
Dickson, P., D. Naylor, A. Mlikotic, A. Victoroff, A. Chen, M. Passage, and S. Le. 2008. 
"Initial experience with intrathecal recombinant human alpha-L-iduronidase for 
spinal cord compression in two mucopolysaccharidosis I patients." Molecular 
Genetics and Metabolism 93 (2):S19-S19. doi: 10.1016/j.ymgine.2007.10.034. 
Dickson, Patricia I., N. Matthew Ellinwood, Jillian R. Brown, Robert G. Witt, Steven Q. 
Le, Merry B. Passage, Moin U. Vera, and Brett E. Crawford. 2012. "Specific 
antibody titer alters the effectiveness of intrathecal enzyme replacement therapy 
in canine mucopolysaccharidosis I." Molecular Genetics and Metabolism 106 
(1):68-72. doi: 10.1016/j.ymgme.2012.02.003. 
Dickson, Patricia, Maryn Peinovich, Michael McEntee, Thomas Lester, Steven Le, 
Aimee Krieger, Hayden Manuel, Catherine Jabagat, Merry Passage, and Emil D. 
Kakkis. 2008. "Immune tolerance improves the efficacy of enzyme replacement 
therapy in canine mucopolysaccharidosis I." Journal of Clinical Investigation 118 
(8):2868-2876. doi: 10.1172/jci34676. 
Duque, Sandra I, W David Arnold, Philipp Odermatt, Xiaohui Li, Paul N Porensky, Leah 
Schmelzer, Kathrin Meyer, Stephen J Kolb, Daniel Schümperli, and Brian K 
Kaspar. 2015. "A large animal model of spinal muscular atrophy and correction of 
phenotype." Annals of neurology 77 (3):399-414. 
Ellinwood, N. M., M. A. Colle, M. A. Well, M. L. Casal, C. H. Vite, S. Wiemelt, C. W. 
Hasson, T. M. O'Malley, X. X. He, U. Prociuk, L. Verot, J. R. Melniczek, A. 
Lannon, G. D. Aguirre, V. W. Knox, S. M. Evans, M. T. Vanier, E. H. Schuchman, 
S. U. Walkley, and M. E. Haskins. 2007. "Bone marrow transplantation for feline 
mucopolysaccharidosis I." Molecular Genetics and Metabolism 91 (3):239-250. 
doi: 10.1016/j.ymgme.2007.03.001. 
Ellinwood, N. Matthew, Jerome Ausseil, Nathalie Desmaris, Stephanie Bigou, Song Liu, 
Jackie K. Jens, Elizabeth M. Snella, Eman E. A. Mohammed, Christopher B. 
Thomson, Sylvie Raoul, Beatrice Joussemet, Francoise Roux, Yan Cherel, 
Yaouen Lajat, Monique Piraud, Rachid Benchaouir, Stephan Hermening, Harald 
Petry, Roseline Froissart, Marc Tardieu, Carine Ciron, Philippe Moullier, Jennifer 
Parkes, Karen L. Kline, Irene Maire, Marie-Therese Vanier, Jean-Michel Heard, 
and Marie-Anne Colle. 2011. "Safe, Efficient, and Reproducible Gene Therapy of 
the Brain in the Dog Models of Sanfilippo and Hurler Syndromes." Mol Ther 19 
140 
 
(2):251-259. doi: 
http://www.nature.com/mt/journal/v19/n2/suppinfo/mt2010265s1.html. 
Emborg, M. E., M. Carbon, J. E. Holden, M. J. During, Y. Ma, C. Tang, J. Moirano, H. 
Fitzsimons, B. Z. Roitberg, E. Tuccar, A. Roberts, M. G. Kaplitt, and D. Eidelberg. 
2007. "Subthalamic glutamic acid decarboxylase gene therapy: changes in motor 
function and cortical metabolism." J Cereb Blood Flow Metab 27 (3):501-9. doi: 
10.1038/sj.jcbfm.9600364. 
Fan, X., A. Ang, S. M. Pollock-Barziv, A. I. Dipchand, P. Ruiz, G. Wilson, J. L. Platt, and 
L. J. West. 2004. "Donor-specific B-cell tolerance after ABO-incompatible infant 
heart transplantation." Nat Med 10 (11):1227-33. doi: 10.1038/nm1126. 
Finn, Jonathan D., Margareth C. Ozelo, Denise E. Sabatino, Helen W. G. Franck, 
Elizabeth P. Merricks, Julie M. Crudele, Shangzhen Zhou, Haig H. Kazazian, 
David Lillicrap, Timothy C. Nichols, and Valder R. Arruda. 2010. "Eradication of 
neutralizing antibodies to factor VIII in canine hemophilia A after liver gene 
therapy." Blood 116 (26):5842-5848. 
Fleming, D. R., P. J. Henslee-Downey, G. Ciocci, E. H. Romond, E. Marciniak, R. K. 
Munn, and J. S. Thompson. 1998. "The use of partially HLA-mismatched donors 
for allogeneic transplantation in patients with mucopolysaccharidosis-I." Pediatr 
Transplant 2 (4):299-304. 
Foust, K. D., E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan, and B. K. Kaspar. 
2009. "Intravascular AAV9 preferentially targets neonatal neurons and adult 
astrocytes." Nat Biotechnol 27 (1):59-65. doi: 10.1038/nbt.1515. 
Foust, Kevin D, Desirée L Salazar, Shibi Likhite, Laura Ferraiuolo, Dara Ditsworth, 
Hristelina Ilieva, Kathrin Meyer, Leah Schmelzer, Lyndsey Braun, and Don W 
Cleveland. 2013. "Therapeutic AAV9-mediated suppression of mutant SOD1 
slows disease progression and extends survival in models of inherited ALS." 
Molecular Therapy 21 (12):2148-2159. 
Foust, Kevin D, Xueyong Wang, Vicki L McGovern, Lyndsey Braun, Adam K Bevan, 
Amanda M Haidet, Thanh T Le, Pablo R Morales, Mark M Rich, and Arthur HM 
Burghes. 2010. "Rescue of the spinal muscular atrophy phenotype in a mouse 
model by early postnatal delivery of SMN." Nature biotechnology 28 (3):271-274. 
Furukawa, Yutaka, Ayumi Hamaguchi, Ichiro Nozaki, Takashi Iizuka, Takeshi 
Sasagawa, Yosuke Shima, Satoru Demura, Hideki Murakami, Norio Kawahara, 
Torayuki Okuyama, Kazuo Iwasa, and Masahito Yamada. 2011. "Cervical 
pachymeningeal hypertrophy as the initial and cardinal manifestation of 
mucopolysaccharidosis type I in monozygotic twins with a novel mutation in the 
alpha-l-iduronidase gene." Journal of the Neurological Sciences 302 (1-2):121-
125. doi: 10.1016/j.jns.2010.11.022. 
Gao, G. P., M. R. Alvira, L. L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson. 2002. 
"Novel adeno-associated viruses from rhesus monkeys as vectors for human 
gene therapy." Proceedings of the National Academy of Sciences of the United 
States of America 99 (18):11854-11859. doi: 10.1073/pnas.182412299. 
Gao, G. P., Y. Lu, R. Calcedo, R. L. Grant, P. Bell, L. L. Wang, J. Figueredo, M. Lock, 
and J. M. Wilson. 2006. "Biology of AAV serotype vectors in liver-directed gene 
transfer to nonhuman primates." Molecular Therapy 13 (1):77-87. doi: 
10.1016/j.ymthe.2005.08.017. 
Gao, G. P., L. H. Vandenberghe, M. R. Alvira, Y. Lu, R. Calcedo, X. Y. Zhou, and J. A. 
Wilson. 2004. "Clades of Adeno-associated viruses are widely disseminated in 
141 
 
human tissues." Journal of Virology 78 (12):6381-6388. doi: 
10.1128/jvi.78.12.6381-6388.2004. 
Gray, S. J., S. N. Kalburgi, T. J. McCown, and R. J. Samulski. 2013. "Global CNS gene 
delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV 
administration in non-human primates." Gene Therapy 20 (4):450-459. doi: 
10.1038/gt.2012.101. 
Gray, S. J., V. Matagne, L. Bachaboina, S. Yadav, S. R. Ojeda, and R. J. Samulski. 
2011. "Preclinical differences of intravascular AAV9 delivery to neurons and glia: 
A comparative study of adult mice and nonhuman primates." Molecular Therapy 
19 (6):1058-1069. doi: 10.1038/mt.2011.72. 
Hadaczek, Piotr, Jamie L. Eberling, Philip Pivirotto, John Bringas, John Forsayeth, and 
Krystof S. Bankiewicz. 2010. "Eight Years of Clinical Improvement in MPTP-
Lesioned Primates After Gene Therapy With AAV2-hAADC." Mol Ther 18 
(8):1458-1461. 
Haskins, Mark. 2009. "Gene therapy for lysosomal storage diseases (LSDs) in large 
animal models." ILAR journal 50 (2):112-121. 
Haskins, Mark E, Gustavo D Aguirre, Peter F Jezyk, Robert J Desnick, and Donald F 
Patterson. 1983. "The pathology of the feline model of mucopolysaccharidosis I." 
The American journal of pathology 112 (1):27. 
Haskins, Mark E, Peter F Jezyk, Robert J Desnick, Susan K Mcdonough, and Donald F 
Patterson. 1979. "Alpha-L-iduronidase deficiency in a cat: a model of 
mucopolysaccharidosis I." Pediatric research 13 (11):1294-1297. 
Haskins, ME, RJ Desnick, SK McDonough, and DF Patterson. 1979. 
"Mucopolysaccharidosis in a domestic short-haired cat--a disease distinct from 
that seen in the Siamese cat." Journal of the American Veterinary Medical 
Association 175 (4):384-387. 
Haurigot, V., S. Marco, A. Ribera, M. Garcia, A. Ruzo, P. Villacampa, E. Ayuso, S. Anor, 
A. Andaluz, M. Pineda, G. Garcia-Fructuoso, M. Molas, L. Maggioni, S. Munoz, 
S. Motas, J. Ruberte, F. Mingozzi, M. Pumarola, and F. Bosch. 2013. "Whole 
body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene 
therapy." Journal of Clinical Investigation 123 (8):3254-3271. doi: 
10.1172/jci66778. 
He, X. X., C. M. Li, C. M. Simonaro, Q. Wan, M. E. Haskins, R. J. Desnick, and E. H. 
Schuchman. 1999. "Identification and characterization of the molecular lesion 
causing mucopolysaccharidosis type I in cats." Molecular Genetics and 
Metabolism 67 (2):106-112. doi: 10.1006/mgme.1999.2860. 
Hinderer, C., P. Bell, B. L. Gurda, Q. Wang, J. P. Louboutin, Y. Zhu, J. Bagel, P. 
O'Donnell, T. Sikora, T. Ruane, P. Wang, M. E. Haskins, and J. M. Wilson. 
2014a. "Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of 
Mucopolysaccharidosis I." Mol Ther. doi: 10.1038/mt.2014.135. 
Hinderer, C., P. Bell, B. L. Gurda, Q. Wang, J. P. Louboutin, Y. Zhu, J. Bagel, P. 
O'Donnell, T. Sikora, T. Ruane, P. Wang, M. E. Haskins, and J. M. Wilson. 
2014b. "Liver-directed gene therapy corrects cardiovascular lesions in feline 
mucopolysaccharidosis type I." Proc Natl Acad Sci U S A 111 (41):14894-9. doi: 
10.1073/pnas.1413645111. 
Hinderer, C., P. Bell, J. P. Louboutin, Y. Zhu, H. Yu, G. Lin, R. Choa, B. L. Gurda, J. 
Bagel, P. O'Donnell, T. Sikora, T. Ruane, P. Wang, A. F. Tarantal, M. L. Casal, 
M. E. Haskins, and J. M. Wilson. 2015. "Neonatal Systemic AAV Induces 
142 
 
Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates." Mol 
Ther 23 (8):1298-307. doi: 10.1038/mt.2015.99. 
Hinderer, Christian, Peter Bell, Brittney L. Gurda, Qiang Wang, Jean-Pierre Louboutin, 
Yanqing Zhu, Jessica Bagel, Patricia O'Donnell, Tracey Sikora, Therese Ruane, 
Ping Wang, Mark E. Haskins, and James M. Wilson. 2014c. "Intrathecal Gene 
Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I." 
Mol Ther 22 (12):2018-2027. doi: 10.1038/mt.2014.135. 
Hinderer, Christian, Peter Bell, Charles H. Vite, Jean-Pierre Louboutin, Rebecca Grant, 
Erin Bote, Hongwei Yu, Bryan Pukenas, Robert Hurst, and James M. Wilson. 
2014. "Widespread gene transfer in the central nervous system of cynomolgus 
macaques following delivery of AAV9 into the cisterna magna." Molecular 
Therapy — Methods & Clinical Development 1. doi: 10.1038/mtm.2014.51 
http://www.nature.com/articles/mtm201451#supplementary-information. 
Hopkins, P. V., C. Campbell, T. Klug, S. Rogers, J. Raburn-Miller, and J. Kiesling. 2014. 
"Lysosomal Storage Disorder Screening Implementation: Findings from the First 
Six Months of Full Population Pilot Testing in Missouri." J Pediatr 166 (1):172-
177. doi: 10.1016/j.jpeds.2014.09.023. 
Hu, C., R. G. Cela, M. Suzuki, B. Lee, and G. S. Lipshutz. 2011. "Neonatal helper-
dependent adenoviral vector gene therapy mediates correction of hemophilia A 
and tolerance to human factor VIII." Proc Natl Acad Sci U S A 108 (5):2082-7. 
doi: 10.1073/pnas.1015571108. 
Hwu, Wuh-Liang, Shin-ichi Muramatsu, Sheng-Hong Tseng, Kai-Yuan Tzen, Ni-Chung 
Lee, Yin-Hsiu Chien, Richard O Snyder, Barry J Byrne, Chun-Hwei Tai, and 
Ruey-Meei Wu. 2012. "Gene therapy for aromatic L-amino acid decarboxylase 
deficiency." Science translational medicine 4 (134):134ra61-134ra61. 
Iliff, J. J., M. Wang, Y. Liao, B. A. Plogg, W. Peng, G. A. Gundersen, H. Benveniste, G. 
E. Vates, R. Deane, S. A. Goldman, E. A. Nagelhus, and M. Nedergaard. 2012. 
"A paravascular pathway facilitates CSF flow through the brain parenchyma and 
the clearance of interstitial solutes, including amyloid beta." Sci Transl Med 4 
(147):147ra111. doi: 10.1126/scitranslmed.3003748. 
Iliff, Jeffrey J., Hedok Lee, Mei Yu, Tian Feng, Jean Logan, Maiken Nedergaard, and 
Helene Benveniste. 2013. "Brain-wide pathway for waste clearance captured by 
contrast-enhanced MRI." The Journal of Clinical Investigation 123 (3):1299-1309. 
doi: 10.1172/JCI67677. 
Janson, C., S. McPhee, L. Bilaniuk, J. Haselgrove, M. Testaiuti, A. Freese, D. J. Wang, 
D. Shera, P. Hurh, J. Rupin, E. Saslow, O. Goldfarb, M. Goldberg, G. Larijani, W. 
Sharrar, L. Liouterman, A. Camp, E. Kolodny, J. Samulski, and P. Leone. 2002. 
"Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for 
neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain." Hum 
Gene Ther 13 (11):1391-412. doi: 10.1089/104303402760128612. 
Jarraya, B., S. Boulet, G. S. Ralph, C. Jan, G. Bonvento, M. Azzouz, J. E. Miskin, M. 
Shin, T. Delzescaux, X. Drouot, A. S. Herard, D. M. Day, E. Brouillet, S. M. 
Kingsman, P. Hantraye, K. A. Mitrophanous, N. D. Mazarakis, and S. Palfi. 2009. 
"Dopamine gene therapy for Parkinson's disease in a nonhuman primate without 
associated dyskinesia." Sci Transl Med 1 (2):2ra4. doi: 
10.1126/scitranslmed.3000130. 
143 
 
Jortner, B. S. 2006. "The return of the dark neuron. A histological artifact complicating 
contemporary neurotoxicologic evaluation." Neurotoxicology 27 (4):628-634. doi: 
10.1016/j.neuro.2006.03.002. 
Kachur, E., and R. Del Maestro. 2000. "Mucopolysaccharidoses and spinal cord 
compression: Case report and review of the literature with implications of bone 
marrow transplantation." Neurosurgery 47 (1):223-228. doi: 10.1097/00006123-
200007000-00046. 
Kakavanos, R., C. T. Turner, J. J. Hopwood, E. D. Kakkis, and D. A. Brooks. 2003. 
"Immune tolerance after long-term enzyme-replacement therapy among patients 
who have mucopolysaccharidosis I." Lancet 361 (9369):1608-1613. doi: 
10.1016/s0140-6736(03)13311-9. 
Kakkis, E. D., A. Matynia, A. J. Jonas, and E. F. Neufeld. 1994. "Overexpression of the 
human lysosomal-enzyme alpha-l-iduronidase in chinese-hamster ovary cells." 
Protein Expression and Purification 5 (3):225-232. doi: 10.1006/prep.1994.1035. 
Kakkis, E., T. Lester, R. Yang, C. Tanaka, V. Anand, J. Lemontt, M. Peinovich, and M. 
Passage. 2004. "Successful induction of immune tolerance to enzyme 
replacement therapy in canine mucopolysaccharidosis I." Proc Natl Acad Sci U S 
A 101 (3):829-34. doi: 10.1073/pnas.0305480101. 
Kakkis, E., M. McEntee, C. Vogler, S. Le, B. Levy, P. Belichenko, W. Mobley, P. 
Dickson, S. Hanson, and M. Passage. 2004. "Intrathecal enzyme replacement 
therapy reduces lysosomal storage in the brain and meninges of the canine 
model of MPS I." Molecular Genetics and Metabolism 83 (1-2):163-174. doi: 
10.1016/j.ymgme.2004.07.003. 
Kaplitt, M. G., A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor, R. J. Bland, 
D. Young, K. Strybing, D. Eidelberg, and M. J. During. 2007. "Safety and 
tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD 
gene for Parkinson's disease: an open label, phase I trial." Lancet 369 
(9579):2097-2105. doi: 10.1016/s0140-6736(07)60982-9. 
Keane, J. R. 1973. "Cisternal puncture complications. Treatment of coccidioidal 
meningitis with amphotericin B." CALIF.MED. 119 (3):10-15. 
Kennedy, D. W., and J. L. Abkowitz. 1997. "Kinetics of central nervous system microglial 
and macrophage engraftment: analysis using a transgenic bone marrow 
transplantation model." Blood 90 (3):986-93. 
Langereis, E. J., N. van Vlies, H. J. Church, R. B. Geskus, C. E. Hollak, S. A. Jones, W. 
Kulik, H. van Lenthe, J. Mercer, L. Schreider, K. L. Tylee, T. Wagemans, F. A. 
Wijburg, and B. W. Bigger. 2014. "Biomarker responses correlate with antibody 
status in mucopolysaccharidosis type I patients on long-term enzyme 
replacement therapy." Mol Genet Metab. doi: 10.1016/j.ymgme.2014.10.012. 
Langford-Smith, K. J., J. Mercer, J. Petty, K. Tylee, H. Church, J. Roberts, G. Moss, S. 
Jones, R. Wynn, J. E. Wraith, and B. W. Bigger. 2011. "Heparin cofactor II-
thrombin complex and dermatan sulphate:chondroitin sulphate ratio are 
biomarkers of short- and long-term treatment effects in mucopolysaccharide 
diseases." Journal of Inherited Metabolic Disease 34 (2):499-508. doi: 
10.1007/s10545-010-9254-8. 
Lawrence, R., J. R. Brown, K. Al-Mafraji, W. C. Lamanna, J. R. Beitel, G. J. Boons, J. D. 
Esko, and B. E. Crawford. 2012. "Disease-specific non-reducing end 
carbohydrate biomarkers for mucopolysaccharidoses." Nat Chem Biol 8 (2):197-
204. doi: 10.1038/nchembio.766. 
144 
 
Leone, Paola, David Shera, Scott W.J. McPhee, Jeremy S. Francis, Edwin H. Kolodny, 
Larissa T. Bilaniuk, Dah-Jyuu Wang, Mitra Assadi, Olga Goldfarb, H. Warren 
Goldman, Andrew Freese, Deborah Young, Matthew J. During, R. Jude 
Samulski, and Christopher G. Janson. 2012. "Long-Term Follow-Up After Gene 
Therapy for Canavan Disease." Science Translational Medicine 4 
(165):165ra163. doi: 10.1126/scitranslmed.3003454. 
Liu, Q., and D. A. Muruve. 2003. "Molecular basis of the inflammatory response to 
adenovirus vectors." Gene Ther 10 (11):935-940. 
LoDuca, P. A., B. E. Hoffman, and R. W. Herzog. 2009. "Hepatic Gene Transfer as a 
Means of Tolerance Induction to Transgene Products." Current Gene Therapy 9 
(2):104-114. 
Lund, Troy C., Weston Miller, Lynda Polgreen, Lisa Baso, Gerald Raymond, Jakub 
Tolar, and Paul Orchard. 2014. "Improvement in biomarkers after intrathecal 
iduronidase for children with MPS IH." Molecular Genetics and Metabolism 111 
(2):S74. doi: http://dx.doi.org/10.1016/j.ymgme.2013.12.168. 
Maguire, Albert M., Katherine A. High, Alberto Auricchio, J. Fraser Wright, Eric A. Pierce, 
Francesco Testa, Federico Mingozzi, Jeannette L. Bennicelli, Gui-shuang Ying, 
Settimio Rossi, Ann Fulton, Kathleen A. Marshall, Sandro Banfi, Daniel C. 
Chung, Jessica I. W. Morgan, Bernd Hauck, Olga Zelenaia, Xiaosong Zhu, Leslie 
Raffini, Frauke Coppieters, Elfride De Baere, Kenneth S. Shindler, Nicholas J. 
Volpe, Enrico M. Surace, Carmela Acerra, Arkady Lyubarsky, T. Michael 
Redmond, Edwin Stone, Junwei Sun, Jennifer Wellman McDonnell, Bart P. 
Leroy, Francesca Simonelli, and Jean Bennett. 2009. "Age-dependent effects of 
RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-
escalation trial." The Lancet 374 (9701):1597-1605. doi: 
http://dx.doi.org/10.1016/S0140-6736(09)61836-5. 
Maita, Nobuo, Takahiro Tsukimura, Takako Taniguchi, Seiji Saito, Kazuki Ohno, Hisaaki 
Taniguchi, and Hitoshi Sakuraba. 2013. "Human α-l-iduronidase uses its own N-
glycan as a substrate-binding and catalytic module." Proceedings of the National 
Academy of Sciences 110 (36):14628-14633. doi: 10.1073/pnas.1306939110. 
Mandel, R. J., and C. Burger. 2004. "Clinical trials in neurological disorders using AAV 
vectors: Promises and challenges." Current Opinion in Molecular Therapeutics 6 
(5):482-490. 
McCarthy, S. A., and F. H. Bach. 1983. "The cellular mechanism of maintenance of 
neonatally induced tolerance to H-2 class I antigens." J Immunol 131 (4):1676-
82. 
McCurdy, Victoria J., Aime K. Johnson, Heather L. Gray-Edwards, Ashley N. Randle, 
Brandon L. Brunson, Nancy E. Morrison, Nouha Salibi, Jacob A. Johnson, 
Misako Hwang, Ronald J. Beyers, Stanley G. Leroy, Stacy Maitland, Thomas S. 
Denney, Nancy R. Cox, Henry J. Baker, Miguel Sena-Esteves, and Douglas R. 
Martin. 2014. "Sustained normalization of neurological disease after intracranial 
gene therapy in a feline model." Science Translational Medicine 6 (231):231ra48. 
doi: 10.1126/scitranslmed.3007733. 
McGlynn, R., K. Dobrenis, and S. U. Walkley. 2004. "Differential subcellular localization 
of cholesterol, gangliosides, and glycosaminoglycans in murine models of 
mucopolysaccharide storage disorders." Journal of Comparative Neurology 480 
(4):415-426. doi: 10.1002/cne.20355. 
McPhee, S. W. J., C. G. Janson, C. Li, R. J. Samulski, A. S. Camp, J. Francis, D. Shera, 
L. Lioutermann, M. Feely, A. Freese, and P. Leone. 2006. "Immune responses to 
145 
 
AAV in a phase I study for Canavan disease." Journal of Gene Medicine 8 
(5):577-588. doi: 10.1002/jgm.885. 
Menon, K. P., P. T. Tieu, and E. F. Neufeld. 1992. "Architecture of the canine IDUA gene 
and mutation underlying canine mucopolysaccharidosis I." Genomics 14 (3):763-
8. 
Meyer, K., L. Ferraiuolo, L. Schmelzer, L. Braun, V. McGovern, S. Likhite, O. Michels, A. 
Govoni, J. Fitzgerald, P. Morales, K. D. Foust, J. R. Mendell, A. H. Burghes, and 
B. K. Kaspar. 2014. "Improving Single Injection CSF Delivery of AAV9-mediated 
Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman 
Primates." Mol Ther. doi: 10.1038/mt.2014.210. 
Mittermeyer, Gabriele, Chadwick W Christine, Kathryn H Rosenbluth, Suzanne L Baker, 
Philip Starr, Paul Larson, Paul L Kaplan, John Forsayeth, Michael J Aminoff, and 
Krystof S Bankiewicz. 2012. "Long-term evaluation of a phase 1 study of AADC 
gene therapy for Parkinson's disease." Human gene therapy 23 (4):377-381. 
Moore, D., M. J. Connock, E. Wraith, and C. Lavery. 2008. "The prevalence of and 
survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie 
syndromes in the UK." Orphanet Journal of Rare Diseases 3. doi: 10.1186/1750-
1172-3-24. 
Munoz-Rojas, M. V., T. Vieira, R. Costa, S. Fagondes, A. John, L. B. Jardim, L. M. 
Vedolin, M. Raymundo, P. I. Dickson, E. Kakkis, and R. Giugliani. 2008. 
"Intrathecal Enzyme Replacement Therapy in a Patient With 
Mucopolysaccharidosis Type I and Symptomatic Spinal Cord Compression." 
American Journal of Medical Genetics Part A 146A (19):2538-2544. doi: 
10.1002/ajmg.a.32294. 
Muramatsu, S., K. Fujimoto, K. Ikeguchi, N. Shizuma, K. Kawasaki, F. Ono, Y. Shen, L. 
Wang, H. Mizukami, A. Kume, M. Matsumura, I. Nagatsu, F. Urano, H. Ichinose, 
T. Nagatsu, K. Terao, I. Nakano, and K. Ozawa. 2002. "Behavioral recovery in a 
primate model of Parkinson's disease by triple transduction of striatal cells with 
adeno-associated viral vectors expressing dopamine-synthesizing enzymes." 
Hum Gene Ther 13 (3):345-54. doi: 10.1089/10430340252792486. 
Nagahara, Alan H., David A. Merrill, Giovanni Coppola, Shingo Tsukada, Brock E. 
Schroeder, Gideon M. Shaked, Ling Wang, Armin Blesch, Albert Kim, James M. 
Conner, Edward Rockenstein, Moses V. Chao, Edward H. Koo, Daniel 
Geschwind, Eliezer Masliah, Andrea A. Chiba, and Mark H. Tuszynski. 2009. 
"Neuroprotective effects of brain-derived neurotrophic factor in rodent and 
primate models of Alzheimer's disease." Nat Med 15 (3):331-337. doi: 
http://www.nature.com/nm/journal/v15/n3/suppinfo/nm.1912_S1.html. 
Nathwani, Amit C., Edward G. D. Tuddenham, Savita Rangarajan, Cecilia Rosales, 
Jenny McIntosh, David C. Linch, Pratima Chowdary, Anne Riddell, Arnulfo 
Jaquilmac Pie, Chris Harrington, James O'Beirne, Keith Smith, John Pasi, Bertil 
Glader, Pradip Rustagi, Catherine Y. C. Ng, Mark A. Kay, Junfang Zhou, Yunyu 
Spence, Christopher L. Morton, James Allay, John Coleman, Susan Sleep, John 
M. Cunningham, Deokumar Srivastava, Etiena Basner-Tschakarjan, Federico 
Mingozzi, Katherine A. High, John T. Gray, Ulrike M. Reiss, Arthur W. Nienhuis, 
and Andrew M. Davidoff. 2011. "Adenovirus-Associated Virus Vector-Mediated 
Gene Transfer in Hemophilia B." New England Journal of Medicine 365 
(25):2357-2365. doi: 10.1056/NEJMoa1108046. 
Nietupski, Jennifer B., Gregory D. Hurlbut, Robin J. Ziegler, Qiuming Chu, Bradley L. 
Hodges, Karen M. Ashe, Mark Bree, Seng H. Cheng, Richard J. Gregory, John 
146 
 
Marshall, and Ronald K. Scheule. 2011. "Systemic Administration of AAV8-
[alpha]-galactosidase A Induces Humoral Tolerance in Nonhuman Primates 
Despite Low Hepatic Expression." Mol Ther 19 (11):1999-2011. doi: 
http://www.nature.com/mt/journal/v19/n11/suppinfo/mt2011119s1.html. 
Papisov, Mikhail I., Vasily V. Belov, and Kimberley S. Gannon. 2013. "Physiology of the 
intrathecal bolus: the leptomeningeal route for macromolecule and particle 
delivery to CNS." Molecular pharmaceutics 10 (5):1522-1532. doi: 
10.1021/mp300474m. 
Passini, Marco A, Jie Bu, Amy M Richards, Christopher M Treleaven, Jennifer A 
Sullivan, Catherine R O'Riordan, Abraham Scaria, Adrian P Kells, Lluis 
Samaranch, and Waldy San Sebastian. 2014. "Translational Fidelity of 
Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for 
Spinal Muscular Atrophy." Human gene therapy 25 (7):619-630. 
Pomerantz, S., Buchbinder, B., Hirsch, J. 2005. "Suboccipital puncture of the cisterna 
magna under CT-guidance with intravenous enhancement in order to circumvent 
anomalous course of posterior inferior cerebellar artery." American Society of 
Spine Radiology meeting abstract. 
Pomerantz, Stuart, Bradley Buchbinder, and Joshua Hirsh. 2005. "Suboccipital Puncture 
of the Cisterna Magna under CT-Guidance with Intravenous Enhancement in 
order to Circumvent Anomalous Course of Posterior Inferior Cerebellar Artery." 
American Society of Spine Radiology. 
Randall, Derrick R., Karen E. Colobong, Harmony Hemmelgarn, Graham B. Sinclair, Elly 
Hetty, Anita Thomas, Olaf A. Bodamer, Barbara Volkmar, Paul M. Fernhoff, 
Robin Casey, Alicia K. Chan, Grant Mitchell, Silvia Stockler, Serge Melancon, 
Tony Rupar, and Lorne A. Clarke. 2008. "Heparin cofactor II-thrombin complex: A 
biomarker of MPS disease." Molecular Genetics and Metabolism 94 (4):456-461. 
doi: 10.1016/j.ymgme.2008.05.001. 
Samaranch, L., E. A. Salegio, W. San Sebastian, A. P. Kells, K. D. Foust, J. R. Bringas, 
C. Lamarre, J. Forsayeth, B. K. Kaspar, and K. S. Bankiewicz. 2012. "Adeno-
associated virus serotype 9 transduction in the central nervous system of 
nonhuman primates." Human Gene Therapy 23 (4):382-389. doi: 
10.1089/hum.2011.200. 
Samaranch, L., E. A. Salegio, W. S. Sebastian, A. P. Kells, J. R. Bringas, J. Forsayeth, 
and K. S. Bankiewicz. 2013. "Strong cortical and spinal cord transduction after 
AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates." 
Human Gene Therapy 24 (5):526-532. doi: 10.1089/hum.2013.005. 
Samaranch, L., W. S. Sebastian, A. P. Kells, E. A. Salegio, G. Heller, J. R. Bringas, P. 
Pivirotto, S. DeArmond, J. Forsayeth, and K. S. Bankiewicz. 2014. "AAV9-
mediated expression of a non-self protein in nonhuman primate central nervous 
system triggers widespread neuroinflammation driven by antigen-presenting cell 
transduction." Molecular Therapy 22 (2):329-337. doi: 10.1038/mt.2013.266. 
Samaranch, Lluis, Waldy San Sebastian, Adrian P. Kells, John Bringas, Phillip Pivirotto, 
John Forsayeth, and Krystof S. Bankiewicz. 2013. "Immune Response Activation 
and Neurotoxicity after Intrathecal Infusion of AAV9 Vector Encoding a Non-Self 
Reporter Protein in the Non-Human Primate." Molecular Therapy 21:S227-S227. 
Samulski, R J, L S Chang, and T Shenk. 1987. "A recombinant plasmid from which an 
infectious adeno-associated virus genome can be excised in vitro and its use to 
study viral replication." Journal of Virology 61 (10):3096-3101. 
147 
 
Samulski, R J, L S Chang, and T Shenk. 1989. "Helper-free stocks of recombinant 
adeno-associated viruses: normal integration does not require viral gene 
expression." Journal of Virology 63 (9):3822-3828. 
Samulski, R. Jude, and Nicholas Muzyczka. 2014. "AAV-Mediated Gene Therapy for 
Research and Therapeutic Purposes." Annual Review of Virology 1 (1):427-451. 
doi: doi:10.1146/annurev-virology-031413-085355. 
Sando, Gloria N., and Elizabeth F. Neufeld. 1977. "Recognition and receptor-mediated 
uptake of a lysosomal enzyme, α-l-iduronidase, by cultured human fibroblasts." 
Cell 12 (3):619-627. doi: http://dx.doi.org/10.1016/0092-8674(77)90262-8. 
Saunders, Harry C., and Timothy J. Riordan. 1929. "Cisternal or suboccipital puncture." 
New England Journal of Medicine 201 (4):166-168. doi: 
doi:10.1056/NEJM192907252010406. 
Shull, R. M., R. G. Helman, E. Spellacy, G. Constantopoulos, R. J. Munger, and E. F. 
Neufeld. 1984. "Morphologic and biochemical studies of canine 
mucopolysaccharidosis I." Am J Pathol 114 (3):487-95. 
Shull, R. M., E. D. Kakkis, M. F. McEntee, S. A. Kania, A. J. Jonas, and E. F. Neufeld. 
1994. "Enzyme replacement in a canine model of Hurler-syndrome." Proceedings 
of the National Academy of Sciences of the United States of America 91 
(26):12937-12941. doi: 10.1073/pnas.91.26.12937. 
Sifuentes, M., R. Doroshow, R. Hoft, G. Mason, I. Walot, M. Diament, S. Okazaki, K. 
Huff, G. F. Cox, S. J. Swiedler, and E. D. Kakkis. 2007. "A follow-up study of 
MPS I patients treated with laronidase enzyme replacement therapy for 6 years." 
Molecular Genetics and Metabolism 90 (2):171-180. doi: 
10.1016/j.ymgme.2006.08.007. 
Sonntag, Florian, Kristin Schmidt, and Jürgen A. Kleinschmidt. 2010. "A viral assembly 
factor promotes AAV2 capsid formation in the nucleolus." Proceedings of the 
National Academy of Sciences 107 (22):10220-10225. doi: 
10.1073/pnas.1001673107. 
Souillet, G., N. Guffon, I. Maire, M. Pujol, P. Taylor, F. Sevin, N. Bleyzac, C. Mulier, A. 
Durin, K. Kebaili, C. Galambrun, Y. Bertrand, R. Froissart, C. Dorche, L. 
Gebuhrer, C. Garin, J. Berard, and P. Guibaud. 2003. "Outcome of 27 patients 
with Hurler's syndrome transplanted from either related or unrelated 
haematopoietic stem cell sources." Bone Marrow Transplantation 31 (12):1105-
1117. doi: 10.1038/sj.bmt.1704105. 
Staba, Susan L., Maria L. Escolar, Michele Poe, Young Kim, Paul L. Martin, Paul 
Szabolcs, June Allison-Thacker, Susan Wood, David A. Wenger, Pablo 
Rubinstein, John J. Hopwood, William Krivit, and Joanne Kurtzberg. 2004. "Cord-
Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome." 
New England Journal of Medicine 350 (19):1960-1969. doi: 
10.1056/NEJMoa032613. 
Sun, B., M. D. Kulis, S. P. Young, A. C. Hobeika, S. Li, A. Bird, H. Zhang, Y. Li, T. M. 
Clay, W. Burks, P. S. Kishnani, and D. D. Koeberl. 2010. "Immunomodulatory 
gene therapy prevents antibody formation and lethal hypersensitivity reactions in 
murine pompe disease." Mol Ther 18 (2):353-60. doi: 10.1038/mt.2009.195. 
Taccone, A., P. T. Donati, A. Marzoli, A. Dellacqua, R. Gatti, and D. Leone. 1993. 
"Mucopolysaccharidosis - thickening of dura-mater at the craniocervical junction 
and other CT/MRI findings." Pediatric Radiology 23 (5):349-352. doi: 
10.1007/bf02011954. 
148 
 
Tarantal, A. F. 2005. "Ultrasound Imaging in Rhesus (Macaca Mulatta) and Long-Tailed 
(Macaca fascicularis) Macaques: Reproductive and Research Applications." In 
The Laboratory Primate, edited by Wolfe-Coote S, 317-352. London: Academic 
Press. 
Tarantal, A. F., R. J. McDonald, D. F. Jimenez, C. C. Lee, C. E. O'Shea, A. C. Leapley, 
R. H. Won, C. G. Plopper, C. Lutzko, and D. B. Kohn. 2005. "Intrapulmonary and 
intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and 
efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery." Mol Ther 12 
(1):87-98. doi: S1525-0016(05)00040-7 [pii] 
10.1016/j.ymthe.2005.01.019. 
Tardieu, M., M. Zerah, B. Husson, S. de Bournonville, K. Deiva, C. Adamsbaum, F. 
Vincent, M. Hocquemiller, C. Broissand, V. Furlan, R. G. Crystal, T. Baugnon, T. 
Roujeau, J. M. Heard, and O. Danos. 2013. "Intra cerebral administration of 
AAVrh.10 carrying human SGSH and SUMF1 cDNAs in children with MPSIIIA 
disease: result of a phase I/II trial." Human Gene Therapy 24 (12):A23-A24. 
Terlato, N. J., and G. F. Cox. 2003. "Can mucopolysaccharidosis type I disease severity 
be predicted based on a patient's genotype? A comprehensive review of the 
literature." Genet Med 5 (4):286-94. doi: 10.1097/01.gim.0000078027.83236.49. 
Traas, A. M., P. Wang, X. Ma, M. Tittiger, L. Schaller, P. O'Donnell, M. M. Sleeper, C. 
Vite, R. Herati, G. D. Aguirre, M. Haskins, and K. P. Ponder. 2007. "Correction of 
clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral 
vector gene therapy." Mol Ther 15 (8):1423-31. doi: 10.1038/sj.mt.6300201. 
Vera, M., S. Le, S. H. Kan, H. Garban, D. Naylor, A. Mlikotic, I. Kaitila, P. Harmatz, A. 
Chen, and P. Dickson. 2013. "Immune response to intrathecal enzyme 
replacement therapy in mucopolysaccharidosis I patients." Pediatric Research 74 
(6):712-720. doi: 10.1038/pr.2013.158. 
Vijay, S., and J. E. Wraith. 2005. "Clinical presentation and follow-up of patients with the 
attenuated phenotype of mucopolysaccharidosis type I." Acta Paediatrica 94 
(7):872-877. doi: 10.1080/08035250510031584. 
Vite, C. H., J. C. McGowan, S. N. Niogi, M. A. Passini, K. J. Drobatz, M. E. Haskins, and 
J. H. Wolfe. 2005. "Effective gene therapy for an inherited CNS disease in a large 
animal model." Annals of Neurology 57 (3):355-364. doi: 10.1002/ana.20392. 
Vite, Charles H., Igor Nestrasil, Anton Mlikotic, Jackie K. Jens, Elizabeth M. Snella, 
William Gross, Elsa G. Shapiro, Victor Kovac, James M. Provenzale, Steven 
Chen, Steven Q. Le, Shih-hsin Kan, Shida Banakar, Raymond Y. Wang, Mark E. 
Haskins, N. Matthew Ellinwood, and Patricia I. Dickson. 2013. "Features of Brain 
MRI in Dogs with Treated and Untreated Mucopolysaccharidosis Type I." 
Comparative Medicine 63 (2):163-173. 
Vite, Charles H., Ping Wang, Reema T. Patel, Raquel M. Walton, Steven U. Walkley, 
Rani S. Sellers, N. Matthew Ellinwood, Alphonsus S. Cheng, Joleen T. White, 
Charles A. O'Neill, and Mark Haskins. 2011. "Biodistribution and 
pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in 
mucopolysaccharidosis type I-affected cats following multiple intrathecal 
administrations." Molecular Genetics and Metabolism 103 (3):268-274. doi: 
10.1016/j.ymgme.2011.03.011. 
Walkley, S. U., M. E. Haskins, and R. M. Shull. 1988. "Alterations in neuron morphology 
in mucopolysaccharidosis type I." Acta Neuropathologica 75 (6):611-620. doi: 
10.1007/BF00686207. 
149 
 
Walkley, Steven U., and Marie T. Vanier. 2009. "Secondary lipid accumulation in 
lysosomal disease." Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research 1793 (4):726-736. doi: http://dx.doi.org/10.1016/j.bbamcr.2008.11.014. 
Wang, G., Y. Miyahara, Z. Guo, M. Khattar, S. M. Stepkowski, and W. Chen. 2010. 
""Default" generation of neonatal regulatory T cells." J Immunol 185 (1):71-8. doi: 
10.4049/jimmunol.0903806. 
Wang, L. L., R. Calcedo, P. Bell, J. P. Lin, R. L. Grant, D. L. Siegel, and J. M. Wilson. 
2011. "Impact of Pre-Existing Immunity on Gene Transfer to Nonhuman Primate 
Liver with Adeno-Associated Virus 8 Vectors." Human Gene Therapy 22 
(11):1389-1401. doi: 10.1089/hum.2011.031. 
Wang, L., H. Wang, P. Bell, D. McMenamin, and J. M. Wilson. 2012. "Hepatic gene 
transfer in neonatal mice by adeno-associated virus serotype 8 vector." Hum 
Gene Ther 23 (5):533-9. doi: 10.1089/hum.2011.183. 
Ward, E., W. W. Orrison, and C. B. Watridge. 1989. "Anatomic evaluation of cisternal 
puncture." Neurosurgery 25 (3):412-415. 
Wendeler, Michaela, and Konrad Sandhoff. 2009. "Hexosaminidase assays." 
Glycoconjugate Journal 26 (8):945-952. doi: 10.1007/s10719-008-9137-5. 
Whitley, C. B., K. G. Belani, P. N. Chang, C. G. Summers, B. R. Blazar, M. Y. Tsai, R. E. 
Latchaw, N. K. C. Ramsay, and J. H. Kersey. 1993. "Long-term outcome of hurler 
syndrome following bone-marrow transplantation." American Journal of Medical 
Genetics 46 (2):209-218. doi: 10.1002/ajmg.1320460222. 
Whitney, N., H. Sun, J. M. Pollock, and D. A. Ross. 2013. "The human foramen 
magnum--normal anatomy of the cisterna magna in adults." Neuroradiology 55 
(11):1333-9. doi: 10.1007/s00234-013-1269-z. 
Wolf, Daniel A., Andrew W. Lenander, Zhenhong Nan, Lalitha R. Belur, Chester B. 
Whitley, Pankaj Gupta, Walter C. Low, and R. Scott McLvor. 2011. "Direct gene 
transfer to the CNS prevents emergence of neurologic disease in a murine model 
of mucopolysaccharidosis type I." Neurobiology of Disease 43 (1):123-133. doi: 
10.1016/j.nbd.2011.02.015. 
Wraith, J. E., M. Beck, R. Lane, A. van der Ploeg, E. Shapiro, Y. Xue, E. D. Kakkis, and 
N. Guffon. 2007. "Enzyme replacement therapy in patients who have 
mucopolysaccharidosis I and are younger than 5 years: Results of a multinational 
study of recombinant human alpha-L-iduronidase (Laronidase)." Pediatrics 120 
(1):E37-E46. doi: 10.1542/peds.2006-2156. 
Wraith, James E., Lorne A. Clarke, Michael Beck, Edwin H. Kolodny, Gregory M. 
Pastores, Joseph Muenzer, David M. Rapoport, Kenneth I. Berger, Stuart J. 
Swiedler, Emil D. Kakkis, Tanja Braakman, Elenie Chadbourne, Karen Walton-
Bowen, and Gerald F. Cox. 2004. "Enzyme replacement therapy for 
mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, 
multinational study of recombinant human α-L-iduronidase (laronidase)." The 
Journal of Pediatrics 144 (5):581-588. doi: 
http://dx.doi.org/10.1016/j.jpeds.2004.01.046. 
Xiao, Weidong, Narendra Chirmule, Scott C Berta, Beth McCullough, Guangping Gao, 
and James M Wilson. 1999. "Gene therapy vectors based on adeno-associated 
virus type 1." Journal of virology 73 (5):3994-4003. 
Xing, M., E. I. Parker, A. Moreno-De-Luca, E. Harmouche, and M. R. Terk. 2014. 
"Radiological and clinical characterization of the lysosomal storage disorders: 
non-lipid disorders." British Journal of Radiology 87 (1033):14. doi: 
10.1259/bjr.20130467. 
150 
 
Xu, L., M. Mei, M. E. Haskins, T. C. Nichols, P. O'Donnell, K. Cullen, A. Dillow, D. 
Bellinger, and K. P. Ponder. 2007. "Immune response after neonatal transfer of a 
human factor IX-expressing retroviral vector in dogs, cats, and mice." Thromb 
Res 120 (2):269-80. doi: 10.1016/j.thromres.2006.09.010. 
Zafeiriou, D. I., and S. P. Batzios. 2013. "Brain and Spinal MR Imaging Findings in 
Mucopolysaccharidoses: A Review." American Journal of Neuroradiology 34 
(1):5-13. doi: 10.3174/ajnr.A2832. 
 
